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Abstract
Background—Approximately 600 million children of preschool and school age are anaemic 
worldwide. It is estimated that half of the cases are due to iron deficiency. Consequences of iron 
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deficiency anaemia during childhood include growth retardation, reduced school achievement, 
impaired motor and cognitive development, and increased morbidity and mortality. The provision 
of daily iron supplements is a widely used strategy for improving iron status in children but its 
effectiveness has been limited due to its side effects, which can include nausea, constipation or 
staining of the teeth. As a consequence, intermittent iron supplementation (one, two or three times 
a week on nonconsecutive days) has been proposed as an effective and safer alternative to daily 
supplementation.
Objectives—To assess the effects of intermittent iron supplementation, alone or in combination 
with other vitamins and minerals, on nutritional and developmental outcomes in children from 
birth to 12 years of age compared with a placebo, no intervention or daily supplementation.
Search methods—We searched the following databases on 24 May 2011: CENTRAL (2011, 
Issue 2), MEDLINE (1948 to May week 2, 2011), EMBASE (1980 to 2011 Week 20), CINAHL 
(1937 to current), POPLINE (all available years) and WHO International Clinical Trials Registry 
Platform (ICTRP). On 29 June 2011 we searched all available years in the following databases: 
SCIELO, LILACS, IBECS and IMBIOMED. We also contacted relevant organisations (on 3 July 
2011) to identify ongoing and unpublished studies.
Selection criteria—Randomised and quasi-randomised trials with either individual or cluster 
randomisation. Participants were children under the age of 12 years at the time of intervention 
with no specific health problems. The intervention assessed was intermittent iron supplementation 
compared with a placebo, no intervention or daily supplementation.
Data collection and analysis—Two authors independently assessed the eligibility of studies 
against the inclusion criteria, extracted data from included studies and assessed the risk of bias of 
the included studies.
Main results—We included 33 trials, involving 13,114 children (~49% females) from 20 
countries in Latin America, Africa and Asia. The methodological quality of the trials was mixed.
Nineteen trials evaluated intermittent iron supplementation versus no intervention or a placebo and 
21 studies evaluated intermittent versus daily iron supplementation. Some of these trials 
contributed data to both comparisons. Iron alone was provided in most of the trials.
Fifteen studies included children younger than 60 months; 11 trials included children 60 months 
and older, and seven studies included children in both age categories. One trial included 
exclusively females. Seven trials included only anaemic children; three studies assessed only non-
anaemic children, and in the rest the baseline prevalence of anaemia ranged from 15% to 90%.
In comparison with receiving no intervention or a placebo, children receiving iron supplements 
intermittently have a lower risk of anaemia (average risk ratio (RR) 0.51, 95% confidence interval 
(CI) 0.37 to 0.72, ten studies) and iron deficiency (RR 0.24, 95% CI 0.06 to 0.91, three studies) 
and have higher haemoglobin (mean difference (MD) 5.20 g/L, 95% CI 2.51 to 7.88, 19 studies) 
and ferritin concentrations (MD 14.17 μg/L, 95% CI 3.53 to 24.81, five studies).
Intermittent supplementation was as effective as daily supplementation in improving haemoglobin 
(MD −0.60 g/L, 95% CI −1.54 to 0.35, 19 studies) and ferritin concentrations (MD −4.19 μg/L, 
95% CI −9.42 to 1.05, 10 studies), but increased the risk of anaemia in comparison with daily iron 
supplementation (RR 1.23, 95% CI 1.04 to1.47, six studies). Data on adherence were scarce and it 
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tended to be higher among those children receiving intermittent supplementation, although this 
result was not statistically significant.
We did not identify any differential effect of the type of intermittent supplementation regimen 
(one, two or three times a week), the total weekly dose of elemental iron, the nutrient composition, 
whether recipients were male or female or the length of the intervention.
Authors’ conclusions—Intermittent iron supplementation is efficacious to improve 
haemoglobin concentrations and reduce the risk of having anaemia or iron deficiency in children 
younger than 12 years of age when compared with a placebo or no intervention, but it is less 
effective than daily supplementation to prevent or control anaemia. Intermittent supplementation 
may be a viable public health intervention in settings where daily supplementation has failed or 
has not been implemented. Information on mortality, morbidity, developmental outcomes and side 
effects, however, is still lacking.
PLAIN LANGUAGE SUMMARY
One, two or three times a week iron supplements for improving health and development 
among children under 12 years of age
Approximately 600 million preschool and school-age children are anaemic worldwide. It is 
estimated that half of these cases are due to a lack of iron. Iron deficiency anaemia during 
childhood may slow down growth, reduce motor and brain development, and increase illness 
and death. If anaemia is not treated promptly, these problems may persist later in life. 
Taking supplements containing iron (sometimes combined with folic acid and other vitamins 
and minerals) on a daily basis has shown to improve children’s health but its use has been 
limited because supplements may produce side effects such as nausea, constipation or 
staining of the teeth. It has been suggested that giving iron one, two or three times a week 
(known as ‘intermittent’ supplementation) may reduce these side effects and be easier to 
remember, and thus encourage children to continue taking the iron supplements.
We analysed 33 trials involving 13,314 children (49% females) from 20 countries in Latin 
America, Africa and Asia, to assess the effects of intermittent iron supplementation, alone or 
in combination with other vitamins and minerals, on nutritional and developmental 
outcomes in children from birth to 12 years of age compared with a placebo, no intervention. 
or daily supplementation.
The studies were of mixed quality. Overall, the results of this review show that giving 
children supplements with iron alone or in combination with other vitamins and minerals 
one, two or three times a week approximately halves their risk of having anaemia in 
comparison with receiving no iron supplements or a placebo. Giving children supplements 
on a intermittent basis was as effective as daily supplementation for improving haemoglobin 
and ferritin concentrations, although, children receiving iron supplements intermittently 
were at higher risk of having anaemia.
We aimed to examine the effects of intermittent supplementation on illness, death, and 
school and physical performance, as well as on other side effects, but there was insufficient 
information to draw firm conclusions.
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In summary, intermittent iron supplementation is efficacious to improve haemoglobin 
concentrations and reduce the risk of having anaemia or iron deficiency in children younger 
than 12 years of age when compared with a placebo or no intervention, but it is less effective 
than daily supplementation to prevent or control anaemia. Intermittent supplementation may 
be a viable public health intervention in settings where daily supplementation has failed or 
has not been implemented. Information on mortality, morbidity, developmental outcomes 
and side effects, however, is still lacking.
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [Explanation]
Patient or population: children under 12 years of age
Settings: community settings
Intervention: intermittent supplementation with iron alone or with other nutrients
Comparison: placebo or no intervention
Outcomes Relative effect (95% CI) No of Participants 
(studies)
Quality of the 
evidence (GRADE)
Anaemia (haemoglobin below a 
cut-off defined by trialists, taking 
into account the age and altitude)
RR 0.51 (0.37–0.72) 1824 (10 studies) ⊕⊕⊕○
moderate1
Haemoglobin (g/L) MD 5.20 (2.51–7.88) 3032 (19 studies) ⊕⊕○○
low2,3
Iron deficiency (using ferritin 
concentrations)
RR 0.24 (0.06–0.91) 431 (3 studies) ○○○○
very low2,3,4
Iron status (ferritin (μg/L) MD 14.17 (3.53–24.81) 550 (5 studies) ⊕⊕○○
low2,3
Iron deficiency anaemia Not estimable 0 (0 studies) None of the trials 
reported on this 
outcome
All-cause mortality Not estimable 0 (0 studies) None of the trials 
reported on this 
outcome
CI, confidence interval; RR, risk ratio; MD, mean difference
*
GRADE Working Group grades of evidence:
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We have moderate confidence in the effect estimate. The true effect is likely to be close to the 
estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited. The true effect may be substantially different from the 
estimate of the effect.
Very low quality: We have very little confidence in the effect estimate. The true effect is likely to be substantially 
different from the estimate of the effect
1
There was high statistical heterogeneity. Given the large and consistent effect (RR 0.51; 95% CI 0.37–0.72) we have 
refrained from downgrading even though three of the nine studies are at high risk of bias
2
High statistical heterogeneity but results were consistent.
3
Some studies lacked blinding and clear methods of allocation
4
Wide confidence intervals.
Note: For cluster-randomised trials the analyses only include the estimated effective sample size, after adjusting the data to 
account for the clustering effect
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Description of the condition
Iron is an essential nutrient for all body tissues and is present in the brain of the developing 
fetus, where it is needed for proper formation of neural tissue (Iannoti 2006) and 
development of brain cells (Beard 2008). Iron deficiency, a common form of nutritional 
deficiency, results from long-term imbalance caused by an inadequate dietary iron intake; 
poor iron absorption or utilisation; increased iron requirements for growth during childhood, 
adolescence or pregnancy; or chronic blood losses (Moy 2006). In the later stages of iron 
depletion, the haemoglobin concentration decreases, resulting in a condition known as iron 
deficiency anaemia.
Anaemia is characterised by a reduction in the oxygen-carrying capacity of blood such that 
the body’s needs can no longer be met. In addition to iron deficiency, other vitamin and 
mineral deficiencies (for example, folate, vitamin B12 and vitamin A), chronic 
inflammation, parasitic infections and inherited disorders of haemoglobin structure can 
result in all-cause anaemia (WHO 2001). Among females, anaemia is often exacerbated 
after beginning menstruation, especially if it occurs at an early age and the young females do 
not consume sufficient iron to offset menstrual losses (WHO 2001). Haemoglobin 
concentrations are used to diagnose anaemia, while serum ferritin, an iron storage protein, 
and serum transferrin, an iron transport protein, are commonly used as indicators of iron 
status in populations (WHO 2011a; WHO 2011b). Children, particularly those younger than 
five years, are vulnerable to iron deficiency anaemia because of their increased needs as a 
result of rapid growth. It is estimated that approximately 600 million preschool and school-
aged children are anaemic worldwide, and it is calculated that at least half of the cases are 
due to iron deficiency (WHO/CDC 2008). In general, low-income countries have a higher 
prevalence of anaemia (WHO/CDC 2008). This association is also true in high-income 
countries where people of low socioeconomic status are especially susceptible to iron and 
other vitamin and mineral deficiencies (Cole 2010).
Consequences of iron deficiency anaemia during childhood include growth retardation, 
reduced school achievement, impaired motor and cognitive development, and increased 
morbidity from a variety of causes including diarrhoea and acute respiratory infections 
(WHO 2001). Specifically, iron deficiency can lead to deficits in memory and behavioural 
regulation as iron is required to make neurotransmitters such as dopamine, epinephrine and 
serotonin (Iannoti 2006; Moy 2006; Beard 2008), while impaired myelination contributes to 
deficits in motor function. Long-term effects of early iron deficiency include decreased work 
capacity and impaired cognitive and behavioural development (Lozoff 2000; Lozoff 2007). 
Some of these impairments are thought to be irreversible if they occur at an early age and 
the consequences may continue even after treatment, reinforcing the importance of 
prevention (Siddiqui 2004; Iannoti 2006; Lozoff 2007).
Description of the intervention
Mass fortification of food staples with iron; dietary diversification to increase iron intake, 
absorption and utilisation; and iron supplementation have been used to prevent or treat iron 
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deficiency anaemia. Mass fortification of staple foods with iron is usually not aimed at 
meeting the needs of young children, with the exception of targeted complementary infant 
feeding programmes (WHO 2009a). Dietary diversification to improve iron status in 
populations at risk is also difficult because of limited food access among the most 
vulnerable populations, the limited quantity of food that children can consume, and the fact 
that the strategy requires multiple behavioural changes among children and their families. 
To date, there are few effective dietary diversification intervention programmes at scale 
(Davidsson 2003). Finally, iron supplementation, which is the provision of doses of iron 
alone or in combination with other micronutrients in the form of tablets, syrups or capsules, 
is the most widespread strategy for improving iron status in children worldwide.
The World Health Organization (WHO) recommends a supplemental provision of 2 mg of 
elemental iron per kilogram body weight per day for three months in children less than six 
years of age who were born at term. Children of school age and older should receive 30 mg 
of elemental iron and 250 μg (0.25 mg) of folic acid daily, particularly in populations where 
anaemia prevalence is greater than 40% (WHO 2001). Though the current recommendations 
include iron alone or with folic acid, it has been suggested that administration of additional 
vitamins and minerals may prevent or reverse anaemia derived from one or more nutritional 
deficiencies (Bhutta 2009). Daily iron supplementation has proven to be effective in 
increasing haemoglobin concentrations in children, especially in those who are anaemic 
(Gera 2007). In spite of this, in real world settings the long regimen duration, the low 
coverage rates and insufficient tablet distribution, and side effects associated with daily iron 
supplementation (for example, gastrointestinal discomfort, constipation and staining of teeth 
with drops or syrups) limit adherence, especially in young children (ACC/SCN 1991; 
Stoltzfus 2011). In older children these effects may partially be controlled with the use of 
slow-release iron tablets in which iron has similar bioavailability to regular iron compounds 
(for example, ferrous sulphate or ferrous fumarate) (Simmons 1993; Bothwell 2000), 
although their higher cost may be a limiting factor for wider use.
How the intervention might work
Oral iron supplementation on an intermittent basis (that is once, twice or three times a week 
on non-consecutive days) has been suggested as a more efficient preventive intervention in 
public health programmes than the more common daily iron supplementation scheme. The 
basis for this iron intermittent supplementation regimen is that the absorption is maximised 
by provision of iron in synchrony with the turnover of the mucosal cells (that is, intestinal 
cells are ‘fresh’ to take up iron) (Wright 1990; Berger 1997; Viteri 1997; Beaton 1999; Tavil 
2003). In addition, other minerals such as zinc and copper may be more readily absorbed 
because they are not regularly competing with iron for absorption channels, leading to an 
improved micronutrient status (Baqui 2005). It has been reported that intermittent 
supplementation may be safer than daily supplementation because intestinal cells are less 
exposed to an iron-rich environment, which may cause cell damage (Casanueva 2003; Viteri 
2005). Also, it has been suggested that additional iron may exacerbate malaria infection and 
so this reduced exposure to iron overall is particularly relevant in malaria settings as less 
iron is available for the parasite’s growth (Ekvall 2000; NIH 2011). Though side effects may 
still occur with intermittent regimens, they are experienced less frequently and may be 
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perceived as more acceptable as a result, increasing adherence to supplementation 
programmes (Thu 1999; Viteri 2005).
Despite the biological plausibility of this intervention to reduce anaemia, its success as a 
public health intervention will likely be determined by several factors such as the available 
resources; the existence of the appropriate policies and legislation; the production and 
supply of the supplements; the development of delivery systems; the development and 
implementation of external and internal quality control systems, and the development and 
implementation of strategies for information, education and communication for behaviour 
change among consumers. Figure 1 presents a generic logic model for micronutrient 
interventions that depicts the programme theory and the plausible relationships between 
inputs and expected changes in health and outcomes that can be adapted to the context of 
each setting (De-Regil 2011; WHO/CDC 2011).
Why it is important to do this review
There are currently no international recommendations on intermittent iron supplementation 
regimens in children. It has been reported that the provision of an iron supplement once a 
week is comparable to daily supplementation in improving anaemia status (Siddiqui 2004). 
Other authors suggest that this effect may be enhanced when iron is given twice a week 
(Schultink 1995; Tavil 2003; Olsen 2006).
Weekly iron and folic acid supplementation has recently been recommended by the WHO to 
prevent anaemia in women of reproductive age (WHO 2009b). This intervention is currently 
implemented at scale in many countries around the world as part of public health 
programmes. It could potentially be targeted to other age groups, such as young children and 
school-aged children, since the supplement can be provided at home and in schools or other 
institutional settings. However, to date, there has been no systematic assessment of the 
safety and effectiveness of weekly or any other intermittent iron supplementation regimen 
among children to inform policy makers.
This review complements the findings of two related Cochrane systematic reviews exploring 
the effects of intermittent regimens among menstruating women (Fernández-Gaxiola 2011) 
and pregnant women (Peña-Rosas 2009).
OBJECTIVES
To assess the effects of intermittent iron supplementation, alone or in combination with 
other vitamins and minerals, on nutritional and developmental outcomes in children less 
than 12 years of age compared with daily supplementation, a placebo or no supplementation.
METHODS
Criteria for considering studies for this review
Types of studies—We included randomised and quasi-randomised studies with 
randomisation at either an individual or cluster level. We defined quasi-randomised trials as 
trials which use systematic methods to allocate participants to treatment groups, such as 
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alternation, assignment based on date of birth or case record number (Higgins 2011). We did 
not include cross-over trials nor other types of evidence (for example, cohort or case-control 
studies) in the meta-analysis but we have considered such evidence in the discussion where 
relevant.
Types of participants—Children under the age of 12 years at the time of the trials. We 
did not include studies specifically targeting premature or low birth weight infants, or 
children with severe infectious diseases, such as HIV, as they may metabolise iron 
differently and have different health and disease indicators. These topics are subject to 
separate Cochrane reviews (Adetifa 2009; Mills 2009).
Types of interventions—Oral supplements of iron, alone or with other vitamins and 
minerals, given on an intermittent basis and compared with a placebo or no supplementation, 
or compared with the same supplements provided daily.
Oral iron supplementation refers to the delivery of iron compounds directly to the oral 
cavity, either as a tablet, capsule, dispersible tablet or liquid. For the purpose of this review, 
intermittent supplementation is defined as the provision of iron supplements one, two or 
three times a week on non-consecutive days.
We performed the following comparisons:
1. any intermittent iron supplementation versus no supplementation or placebo (0 to < 
12 years of age);
2. any intermittent iron supplementation versus any daily iron supplementation (0 to < 
12 years of age);
3. any intermittent iron supplementation versus no supplementation or placebo (0 to 
59 months of age);
4. any intermittent iron supplementation versus any daily iron supplementation (0 to 
59 months of age);
5. any intermittent iron supplementation versus no supplementation or placebo (5 to < 
12 years of age);
6. any intermittent iron supplementation versus any daily iron supplementation (5 to < 
12 years of age).
Any intermittent or daily supplementation with iron includes the provision of iron alone, 
iron plus folic acid or iron plus other vitamins and minerals.
We have included studies that examined interventions where iron supplementation was 
combined with co-interventions such as de-worming, education or other approaches only if 
the co-interventions were the same in both the intervention and comparison groups.
We excluded studies examining tube feeding, parenteral nutrition or supplementary food-
based interventions such as mass fortification of staple or complementary foods, home 
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fortification with micronutrient powders, lipid-based supplements or Foodlets tablets, or 
biofortification.
Types of outcome measures
Primary outcomes
1. Anaemia (haemoglobin below a cut-off defined by trialists, taking into account the 
age and altitude)*
2. Haemoglobin (g/L)*
3. Iron deficiency (as measured by trialists by using indicators of iron status, such as 
ferritin or transferrin)*
4. Iron status (ferritin in μg/L)*
5. Iron deficiency anaemia (defined by the presence of anaemia plus iron deficiency, 
diagnosed with an indicator of iron status selected by trialists)*
6. All-cause mortality (number of deaths during the trial)*
Secondary outcomes
1. All-cause morbidity (number of children with at least one reported illness during 
the trial)
2. Acute respiratory infection (as measured by trialists)
3. Diarrhoea (as measured by trialists)
4. Any other adverse side effects (as measured by trialists, such as stained teeth, 
headache, stomach ache, discomfort, constipation)
5. Adherence (percentage of children who consumed more than 70% of the expected 
doses)
6. Folate status (as measured by trialists)
7. Mental development and motor skill development (children 0 to 59 months) (as 
assessed by trialists, including Bayley Mental Development Index (MDI), Bayley 
Psychomotor Development Index (PDI), Stanford-Binet Test, DENVER II 
Developmental Screening Test)
8. School performance (children 60 months and older) (as measured by trialists)
9. Physical capacity (children 60 months and older) (as measured by trialists)
10. Height-for-age Z-scores and weight-for-age Z-scores
We planned to group the outcome time points as follows: immediately after the end of the 
intervention, one to six months after the end of intervention, and seven to 12 months after 
the end of the intervention. However, we limited our analyses to the end of the intervention 
as only two trials reported on continued follow-up after the end of the intervention. We have 
*Outcomes that were included in the ‘Summary of Findings’ tables.
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described this in Characteristics of included studies and plan to extract this information in 
future updates, if available.
Search methods for identification of studies
Electronic searches—We searched the following electronic databases:
Cochrane Central Register of Controlled Trials (CENTRAL) (2011, Issue 2), part of 
The Cochrane Library (searched 24 May 2011);
MEDLINE,1948 to May week 2, 2011 (searched 24 May 2011);
EMBASE, 1980 to 2011 Week 20 (searched 24 May 2011);
CINAHL, 1937 to current (searched 24 May 2011);
ICTRP (searched 24 May 2011);
POPLINE (searched 24 May 2011);
SCIELO (searched 29 June 2011);
LILACS (searched 29 June 2011);
IBECS (searched 29 June 2011);
IMBIOMED (searched 29 June 2011).
The search strategies are in Appendix 1.
We did not apply any language restrictions. For those articles written in a language other 
than English, we extracted the information or commissioned their translation into English.
Searching other resources—For assistance in identifying ongoing or unpublished 
studies, we contacted authors and known experts to identify any additional or unpublished 
data. We also contacted the Departments of Nutrition for Health and Development and 
regional offices of the World Health Organization (WHO), Centers for Disease Control and 
Prevention (CDC), the nutrition section of the United Nations Children’s Fund (UNICEF), 
the World Food Programme (WFP), the Micronutrient Initiative (MI) and Sight and Life 
Foundation (3 July 2011).
We searched the International Clinical Trials Registry Platform (ICTRP) (searched 24 May 
2011) for any ongoing or planned trials.
Data collection and analysis
Selection of studies—LMD screened all titles and abstracts for potential eligibility, 
while MEJ, TD and AS each assessed one-third of the abstracts. LMD contacted relevant 
institutions and searched for ongoing trials. All the authors independently assessed half of 
the full-text articles for inclusion according to the above mentioned criteria; each paper was 
therefore assessed by two review authors. We resolved any disagreement through 
discussion.
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If studies were published only as abstracts, or the study reports contained little information 
on methods, we contacted the authors to obtain further details of study design and results.
Data extraction and management—For eligible studies, two authors independently 
extracted data using a form designed for this review. LMD extracted data from all the 
studies and the remaining authors each extracted a third. LMD entered data into the Review 
Manager 5 software (RevMan 2011). The same review author who extracted one-third of the 
data in duplicate carried out checks for accuracy. We resolved any discrepancies through 
discussion and documented each stage of the process.
We completed the data collection form electronically and recorded information as follows.
(1) Trial methods
• Study design
• Unit and method of allocation
• Unit of analysis
• Masking of participants and outcome assessors
• Exclusion of participants after randomisation and proportion of losses at follow-up
• Study power
(2) Participants




• Socioeconomic status (as defined by trialists and where such information was 
available)
• Baseline status of anaemia




• Type of iron compound
• Supplementation regimen
• Duration of the intervention
• Co-intervention
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• Type of comparison (no intervention, placebo or daily supplementation with the 
same nutrients)
(5) Outcomes
• Primary and secondary outcomes outlined in the Types of outcome measures 
section
We recorded both prespecified and non-prespecified outcomes, although we did not use the 
latter to underpin the conclusions of the review.
When information regarding any of the studies was unclear, we contacted authors of the 
original reports to provide further details. If there was insufficient information for us to be 
able to assess risk of bias, studies were put into the awaiting assessment section of the 
review until further information is published or made available to us.
Assessment of risk of bias in included studies—One author (LMD) assessed the 
risk of bias for all the included studies and the remaining authors each assessed one-third of 
the studies so that all the trials were assessed by two authors independently, using the 
criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins 2011). We resolved any disagreement by discussion or by involving a third 
assessor. We reported this assessment in the ‘Description of studies’ and risk of bias tables. 
We explicitly mention when authors provided input on their trials.
(1) Sequence generation (checking for possible selection bias): We have described for 
each included study the method used to generate the allocation sequence.
We assessed the method as:
• low risk of bias (any truly random process, for example, random number table; 
computer random number generator);
• high risk of bias (any non-random process, for example, odd or even date of birth; 
hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias): We have described for 
each included study the method used to conceal the allocation sequence and have assessed 
whether intervention allocation could have been foreseen in advance of or during 
recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (for example, telephone or central randomisation; consecutively 
numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-opaque envelopes);
• unclear risk of bias.
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(3) Blinding (checking for possible performance and detection bias): We have described 
for each included study the methods used, if any, to blind study participants and personnel 
from knowledge of which intervention a participant received. For interventions involving 
the provision of iron supplements it may be possible to blind children, clinical staff and 
outcome assessors to group allocation by providing placebo preparations.
We assessed blinding separately for different classes of outcomes and have noted where 
there has been an attempt at partial blinding.
We assessed the risk of performance bias associated with blinding as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
We assessed the risk of detection bias associated with blinding as:
• low, high or unclear risk of bias for outcome assessors.
Whilst assessed separately, we combined the results into a single evaluation of risk of bias 
associated with blinding (Higgins 2011).
(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, 
dropouts, protocol deviations): We have described for each included study, and for each 
outcome or class of outcomes, the completeness of data including attrition and exclusions 
from the analysis. We have stated whether attrition and exclusions were reported, the 
numbers included in the analysis at each stage (compared with the total number of 
randomised participants), reasons for attrition or exclusion, where reported, and whether 
missing data were balanced across groups. We assessed methods as:
• low risk of bias (less than 20% of cases lost to follow-up and balanced in numbers 
across intervention groups);
• high risk of bias (20% or more cases lost to follow-up or outcome data imbalanced 
in numbers across intervention groups);
• unclear risk of bias.
(5) Selective reporting bias: We have described for each included study how we 
investigated the possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it was clear that all of the study’s prespecified outcomes 
and all expected outcomes of interest to the review have been reported);
• high risk of bias (where not all the study’s prespecified outcomes have been 
reported; one or more reported primary outcomes were not prespecified; outcomes 
of interest were reported incompletely and so cannot be used; study fails to include 
results of a key outcome that would have been expected to have been reported);
• unclear risk of bias.
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(6) Other sources of bias: We have described for each included study any important 
concerns we have about other possible sources of bias.
We assessed whether each study was free of other problems that could put it at risk of bias:
• high risk of other bias;
• low risk of other bias;
• unclear risk of other bias.
(7) Overall risk of bias: We summarised the risk of bias at two levels: within studies 
(across domains) and across studies.
For the first, we made explicit judgements about whether studies were at high risk of bias, 
according to the criteria given in the Cochrane Handbook for Systematic Reviews of 
Intervention (Higgins 2011). With reference to (1) to (6) above, we assessed the likely 
magnitude and direction of the bias and whether we considered it was likely to impact on the 
findings. Attrition, lack of blinding and losses to follow-up may be particular problems in 
studies looking at different regimens of iron supplementation and where children are 
followed up over time. We explored the impact of the level of bias by undertaking 
sensitivity analyses, see Sensitivity analysis below.
For the assessment across studies, the main findings of the review are set out in ‘Summary 
of findings for the main comparison and Summary of findings 2 (SoF) prepared using 
GRADE pro-filer software (GRADEpro 2008). The primary outcomes for each comparison 
have been listed with estimates of relative effects along with the number of participants and 
studies contributing data for those outcomes. For each individual outcome, the quality of the 
evidence has been assessed independently by two review authors using the GRADE 
approach (Balshem 2010), which involves consideration of within-study risk of bias 
(methodological quality), directness of evidence, heterogeneity, precision of effect estimates 
and risk of publication bias; this results in one out of four levels of quality (high, moderate, 
low or very low). This assessment was limited only to the trials included in this review and 
as we did not consider there was a serious risk of indirectness or publication bias we did not 
downgrade in these domains.
Measures of treatment effect
Dichotomous data: For dichotomous data, we have presented results as average risk ratios 
(RR) with 95% confidence intervals (CI).
Continuous data: We present the results as mean difference (MD) with 95% confidence 
intervals at the end of the intervention. If trials did not provide this information but reported 
the mean change, we included these data as suggested by Higgins 2011. There was no need 
to use the standardised mean difference to combine trials as these outcomes were measured 
with the same methods.
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Unit of analysis issues
Cluster-randomised trials: We included cluster-randomised trials in the analyses along 
with individually-randomised trials. Cluster-randomised trials are labelled with a (C). We 
obtained the intra-cluster correlation coefficient (ICC) from Hall 2002 (C) (ICC 0.0698; 
average cluster size (ACS): 18.55; design effect (DE) 2.22), Desai 2004 (C) (ICC 0.069; 
ACS: 1.5; DE 1.035) and Roschnik 2004 (C) (ICC 0.1123; ACS: 33.82; DE 4.35). We 
calculated the ACS from the reports and imputed the ICC from Roschnik 2004 (C) to 
Roschnik 2003 (C) as the study designs were very similar (ACS: 29); and from Hall 2002 
(C) to Liu 1995 (C) (ACS: 27.3), Sinisterra 1997 (C) (ACS: 199.5), Yang 2004 (C) (ACS: 
32), Sen 2009 (C) (ACS: 60) and Arcanjo 2011 (C) (ACS: 17.7) and then calculated each 
trial’s effective sample size. In the case of Yang 2004 (C), the number of classes was not 
clear so we assumed an average cluster size of 32 based on other reports (Okebe 2011). On 
the other hand, Awasthi 2005 (C) reported that the sample size was calculated including a 
design effect of 2.0. We used this value to calculate its effective sample size and also to 
conduct a sensitivity analysis to examine the potential effect of clustering on the CIs of the 
summary estimates. As the CIs did not change significantly (5% or more), we do not report 
the results of the sensitivity analysis. Desai 2004 (C) and Engstrom 2008 (C) were not 
adjusted as the trial authors reported that the analyses accounted for the effect of clustering.
Studies with more than two treatment groups: For studies with more than two 
intervention groups (multi-arm studies), we included the directly relevant arms only. When 
we identified studies with various relevant arms, we combined the groups into a single pair-
wise comparison (Higgins 2011) and included the disaggregated data in the corresponding 
subgroup category. When the control group was shared by two or more study arms, we 
divided the control group (events and total population) over the number of relevant subgroup 
categories to avoid double counting the participants. The details are described in the 
Characteristics of included studies tables.
Cross-over trials: We did not include cross-over trials.
Dealing with missing data—For included studies, we have noted levels of attrition in 
the Characteristics of included studies tables. We explored the impact of including studies 
with high levels of missing data in the overall assessment of treatment effect by carrying out 
sensitivity analysis (these same trials were assessed as being at high risk of bias, see 
Sensitivity analysis below).
We carried out analyses, as far as possible, on an intention-to-treat basis (ITT), that is, by 
attempting to include all participants randomised to each group in the analyses. If this was 
not possible, we performed an available case analysis in which data were analysed for every 
participant for whom the outcome was obtained.
Assessment of heterogeneity—We visually examined the forest plots from meta-
analyses to look for any obvious heterogeneity among studies in terms of the size or 
direction of treatment effect. We used the I2 statistic, Tau2 and Chi 2 test to quantify the 
level of heterogeneity among the trials in each analysis. If we identified moderate or 
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substantial heterogeneity, we explored it by prespecified Subgroup analysis and 
investigation of heterogeneity.
Assessment of reporting biases—Where we suspected reporting bias (see ‘Selective 
reporting bias’ above), we attempted to contact study authors asking them to provide 
missing outcome data. Where this was not possible, and the missing data were thought to 
introduce serious bias, we explored the impact of including such studies in the overall 
assessment of results by a sensitivity analysis.
We generated funnel plots (estimated differences in treatment effects against their standard 
error) only for haemoglobin in comparisons one and two, and ferritin in comparison two, as 
sufficient studies contributed data to these outcomes. Asymmetry could be due to 
publication bias but it can also be due to a real relationship between trial size and effect size, 
such as when larger trials have lower adherence and adherence is positively related to effect 
size.
Data synthesis—We carried out statistical analysis using the Review Manager 5 software 
(RevMan 2011). In this review we prespecified that we would use random-effects model 
analyses in view of anticipated heterogeneity in the interventions, populations and methods 
used in different trials.
Subgroup analysis and investigation of heterogeneity—Where data were 
available, we carried out the following subgroup analysis:
1. by dose of elemental iron per week in the intermittent group: 25 mg or less; greater 
than 25 mg to 75 mg; greater than 75 mg;
2. by duration of the supplementation: 0 to three months or less; more than three 
months;
3. by type of compound: ferrous sulphate; ferrous fumarate; other;
4. by anaemia status at baseline (haemoglobin < 110 g/L or < 115 g/L for children 6 
to 59 months or 5 to 11 years old, respectively, adjusted by altitude where 
appropriate): anaemic; non-anaemic; mixed or not reported;
5. by intermittent supplementation regimen: one supplement a week; other 
intermittent regimen;
6. by sex: males; females; mixed or not reported; and
7. by micronutrient composition: iron alone; iron + folic acid; iron + other 
micronutrient; iron + multiple micronutrients.
We used the primary outcomes in subgroup analysis.
Pragmatically, we decided not to conduct subgroup analyses for those outcomes with three 
trials or fewer. We examined differences between subgroups by visual inspection of the 
subgroups’ confidence intervals; non-overlapping confidence intervals suggesting a 
statistically significant difference in treatment effect between the subgroups. We also used 
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the Borenstein 2008 approach to formally investigate the differences between two or more 
subgroups. Analyses were conducted in Revman version 5.1.1 (RevMan 2011).
Sensitivity analysis—We carried out sensitivity analysis to examine the effects of 
removing studies at high risk of bias (studies with poor or unclear randomisation and 
allocation concealment, and either blinding or high or imbalanced losses to follow-up) from 
the analysis. We also examined the effect of different intra-cluster correlation co-efficients 
imputed to cluster-randomised trials on the summary estimates of primary outcomes.
RESULTS
Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics 
of studies awaiting classification; Characteristics of ongoing studies.
Results of the search—The search strategy identified 7784 references for possible 
inclusion, 2453 of which were duplicate references. We assessed 81 published articles in full 
text, three unpublished reports, one review that contained published and unpublished data, 
and one abstract that has not been published in full. Nine studies were published in 
languages other than English: Chinese (Yang 2004 (C)), Farsi (Kargarnovin 2010), French 
(Nguyen 2002) and Spanish (Sinisterra 1997 (C); Rivera 1998; Sotelo-Cruz 2002; 
Evangelista-Salazar 2004; UNICEF 2006; Avila-Jimenez 2011). Figure 2 depicts the process 
for assessing and selecting the studies. We included 33 trials (42 references); excluded 40 
(41 references); three trials are awaiting assessment (Husseini 1999; Reid 2001; 
Kargarnovin 2010), and we identified one ongoing study (Zeeba Zakaur-Rab 2010).
Included studies—We included 33 trials with 13,114 children; those studies which 
included more than two intervention arms may have been included in more than one 
comparison. All included trials contributed data to the review but some studies randomised 
participants to intervention arms that were not relevant to the comparisons we assessed. For 
these studies we did not include data from all groups in the analyses. We have indicated in 
the Characteristics of included studies tables if any randomised arms were not included.
Three of the trials had two arms providing different regimens of intermittent 
supplementation (Liu 1995 (C); Faqih 2006; Sen 2009 (C)). In these cases we combined the 
study arms for the overall comparison and included the disaggregated information in the 
subgroup analyses. Levels of supervision varied among trials but most of them were 
unsupervised. In addition, very few studies addressed the use of co-interventions such as 
health education to improve adherence or deworming prior to supplementation.
The sample size ranged between 60 and 1785 participants but overall tended to be small: 
75% of the studies included fewer than 500 children. However, for cluster-randomised trials 
the analyses only included the estimated effective sample size, after adjusting the data to 
account for the clustering effect.
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Settings—The studies included in the review were carried out over the last 16 years in 
low- and middle-income countries in Asia, Africa and Latin America: Bangladesh (Baqui 
2003), Bolivia (Berger 1997; Aguayo 2000), Brazil (Da Silva 2008; Engstrom 2008 (C); 
Arcanjo 2011 (C)), China (Liu 1995 (C); Yang 2004 (C)), India (Awasthi 2005 (C); Sen 
2009 (C)), Indonesia (Schultink 1995; Palupi 1997; Soemantri 1997), Iran (Khademloo 
2009), Jordan (Faqih 2006), Kenya (Olsen 2000; Verhoef 2002; Desai 2004 (C)), Malawi 
(Young 2001; Roschnik 2003 (C)), Mali (Hall 2002 (C)), Mexico (Evangelista-Salazar 
2004), Pakistan (Siddiqui 2004), Panama (Sinisterra 1997 (C)), Phillipines (Roschnik 2004 
(C)), South Africa (Taylor 2001), Tanzania (Ekvall 2000), Thailand (Sungthong 2002), 
Turkey (Ermis 2002; Tavil 2003; Yurdakok 2004) and Vietnam (Thu 1999; Nguyen 2002).
Participants—Participant ages ranged from newborn to 19 years old. While we did not 
include studies specifically recruiting postmenarchal females, as these are the subject of a 
separate review (Fernández-Gaxiola 2011), three included studies recruited adolescents and 
separate data were not available for younger children (Olsen 2000; Taylor 2001; Hall 2002 
(C)). Based on the age range reported in these studies, at least half of their participants 
fulfilled our inclusion criteria and thus we decided to retain them in the review. If the 
disaggregated data by age is made available to us, we will include it in future updates of the 
review.
In the analyses (comparisons three to six), we have set out our findings separately for studies 
recruiting children in these younger and older age groups. Fifteen studies included children 
from birth to 59 months of age only (Schultink 1995; Palupi 1997; Thu 1999; Ekvall 2000; 
Young 2001; Ermis 2002; Nguyen 2002; Verhoef 2002; Baqui 2003; Tavil 2003; 
Evangelista-Salazar 2004; Desai 2004 (C); Yurdakok 2004; Engstrom 2008 (C); Khademloo 
2009) and 11 trials included only older children 60 months of age and older (Sinisterra 1997 
(C); Soemantri 1997; Aguayo 2000; Taylor 2001; Sungthong 2002; Roschnik 2003 (C); 
Roschnik 2004 (C); Siddiqui 2004; Da Silva 2008; Sen 2009 (C); Arcanjo 2011 (C)). Seven 
studies included children in both age categories (Liu 1995 (C); Berger 1997; Olsen 2000; 
Hall 2002 (C); Yang 2004 (C); Awasthi 2005 (C); Faqih 2006). In those cases we took into 
account the reported average age in allocating the trial. For example, Faqih 2006 recruited 
children aged two to six years of age and was included in comparisons two and four 
(younger children), while Olsen 2000 assessed children aged four to 19 years and was 
included in comparisons one and five (older children).
On average, 49% of the participants were females, with a range from 37% (Tavil 2003) to 
100% (Sen 2009 (C)). Seven trials included only anaemic children (Schultink 1995; Berger 
1997; Verhoef 2002; Tavil 2003; Desai 2004 (C); Faqih 2006; Siddiqui 2004); three only 
non-anaemic (Aguayo 2000; Yang 2004 (C); Yurdakok 2004); and the rest of the trials had a 
baseline prevalence of anaemia ranging between 15% and 90%.
Participants socioeconomic status was not explicit in most of the studies although references 
to underprivileged populations were frequent.
Intermittent regimens, dose and type of iron compounds—Nine trials included 
arms where children were supplemented with iron twice a week (Liu 1995 (C); Schultink 
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1995; Olsen 2000; Verhoef 2002; Tavil 2003; Desai 2004 (C); Awasthi 2005 (C); Faqih 
2006; Sen 2009 (C)) and in two studies children were provided with iron every other day 
(three times a week) (Ekvall 2000; Ermis 2002). The rest of the studies provided iron 
supplements once weekly.
The total weekly iron dose given to the children ranged from 7.5 to 200 mg of elemental 
iron per week. Evangelista-Salazar 2004 provided 7.5 mg; Nguyen 2002 gave 15 mg; two 
trials provided 20 mg elemental iron (Thu 1999; Baqui 2003); in two trials children received 
a total weekly dose of 25 mg elemental iron (Da Silva 2008; Engstrom 2008 (C)); three 
trials gave 30 mg (Palupi 1997; Ekvall 2000; Yang 2004 (C)); one trial (Awasthi 2005 (C)) 
supplemented participants with 40 mg per week and another trial with 50 mg of iron per 
week (Arcanjo 2011 (C)). In five trials children received 60 mg of elemental iron per week 
(Schultink 1995; Sinisterra 1997 (C); Young 2001; Sungthong 2002; Siddiqui 2004); in 
three trials children received in total a weekly dose of 65 mg (Taylor 2001; Hall 2002 (C); 
Roschnik 2003 (C)); in one study the dose was 108 mg (Roschnik 2004 (C)); in another 
study the dose was 120 mg (Olsen 2000); and in Sen 2009 (C) the total weekly dose was 200 
mg of elemental iron.
Some studies reported the provision of 1 mg to 8 mg of elemental iron per kg per day (Liu 
1995 (C); Berger 1997; Soemantri 1997; Aguayo 2000; Ermis 2002; Verhoef 2002; Tavil 
2003; Desai 2004 (C); Yurdakok 2004; Faqih 2006). In these cases we calculated the weekly 
dose by using the median or average age reported in the trial and the corresponding weight 
according to the WHO growth charts, percentile 50.
In almost all the studies, ferrous sulphate was the source of supplemental iron. Other iron 
compounds tested were ferrous poly-maltose (Olsen 2000); ferrous dextran (Sen 2009 (C)) 
and ferrous fumarate (Taylor 2001; Verhoef 2002).
Most of the studies supplemented only with iron; one study gave iron in combination with 
30 mg of vitamin C (Evangelista-Salazar 2004) and five studies gave iron in combination 
with folic acid. In these trials the weekly dose of folic acid also varied: one trial gave 100 μg 
(0.1 mg) of folic acid per week (Taylor 2001; Awasthi 2005 (C)), in two the dose was 250 
μg (0.25 mg) (Hall 2002 (C); Roschnik 2003 (C)), while in Sen 2009 (C) the dose was 500 
μg (0.5 mg) folic acid per week. Four studies provided supplements containing multiple 
micronutrients (Thu 1999; Young 2001; Baqui 2003; Yang 2004 (C)).
Excluded studies—We excluded 40 trials (41 references) from the review. In 12 trials the 
evaluated population was out of the scope of this review (Beasley 2000; Kianfar 2000; 
Sharma 2000; Zavaleta 2000; Ahmed 2001; Februhartanty 2002; Shah 2002; Agarwal 2003; 
Shobha 2003; Jaleel 2004; Soekarjo 2004; Leenstra 2009). The second main reason for 
exclusion was that trials were not randomised (Rivera 1998; Jayatissa 1999; Perrin 2002; 
Sotelo-Cruz 2002; Jackson 2003; Kapur 2003; Kanal 2005; Lima 2006; UNICEF 2006; Vir 
2008; Mwanakasale 2009; Azeredo 2010). We excluded eight trials because the supplements 
were provided as Foodlets a (a crushable tablet that may be mixed with foods) and this 
intervention is outside the scope of this review (Briars 2003; Hop 2005; López de Romaña 
2005; Smuts 2005; Lechtig 2006; López de Romaña 2006; Wijaya-Erhardt 2007; Schümann 
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2009). Six trials were excluded because intermittent supplementation regimens were not 
compared with daily regimens or no treatment or placebo (Menendez 1997; Tee 1999; 
Tomashek 2001; Ahmed 2005; Risonar 2008; Avila-Jimenez 2011). We excluded Hafeez 
1998 because the intermittent supplements were given on consecutive days and Lin 2001 
because the nutrient tested was vitamin A. We have described these studies in the 
Characteristics of excluded studies tables.
Risk of bias in included studies
Overall, study methods were not well described in many of the included studies and this 
meant that assessing risk of bias was difficult (see Figure 3 and Figure 4). We attempted to 
contact the study authors for further clarifications and noted in the Characteristics of 
included studies when the information was provided by the authors.
Where we assessed methods of randomisation or allocation concealment as being at high 
risk of bias (or unclear), and trials were either not blinded or had high or imbalanced 
attrition rates, we assumed that they were at high risk of bias in the sensitivity analysis 
looking at the impact of study quality. Using these criteria, nine studies were assessed as 
being at low risk of bias (Thu 1999; Aguayo 2000; Ekvall 2000; Olsen 2000; Hall 2002 (C); 
Sungthong 2002; Verhoef 2002; Desai 2004 (C); Arcanjo 2011 (C)). The remaining studies 
were either assessed as being at high risk of bias or the methods were unclear.
Allocation—In 20 of the included trials, it was unclear how the randomisation sequence 
had been generated. In six studies investigators used random number tables (Thu 1999; 
Aguayo 2000; Verhoef 2002; Roschnik 2004 (C); Faqih 2006; Arcanjo 2011 (C)); in a 
further six studies computer-generated randomisation sequences were used (Ekvall 2000; 
Olsen 2000; Hall 2002 (C); Sungthong 2002; Desai 2004 (C); Da Silva 2008), and in two 
studies the groups were assigned to the treatments by drawing lots (Sinisterra 1997 (C); Sen 
2009 (C)).
Eleven of the included studies used methods of concealing group allocation that we judged 
were low risk of bias, for example, by providing coded supplements to treatment and control 
groups that appeared similar to participants and to those carrying out randomisation (Berger 
1997; Palupi 1997; Thu 1999; Aguayo 2000; Ekvall 2000; Olsen 2000; Taylor 2001; 
Nguyen 2002; Sungthong 2002; Verhoef 2002; Baqui 2003). In the remaining trials, 
methods were either not described or were unclear.
Eleven trials were randomised at cluster level (Liu 1995 (C); Sinisterra 1997 (C); Hall 2002 
(C); Roschnik 2003 (C); Desai 2004 (C); Roschnik 2004 (C); Yang 2004 (C); Awasthi 2005 
(C); Engstrom 2008 (C); Sen 2009 (C); Arcanjo 2011 (C)) and in these cases it was judged 
that selection bias at individual level was unlikely (low risk of bias).
Blinding—In 14 trials, we considered that there was low risk of bias related to blinding 
(Schultink 1995; Berger 1997; Palupi 1997; Thu 1999; Aguayo 2000; Ekvall 2000; Nguyen 
2002; Olsen 2000; Taylor 2001; Verhoef 2002; Sungthong 2002; Baqui 2003; Yang 2004 
(C); Arcanjo 2011 (C)). In the remaining trials, blinding was either not attempted or not 
mentioned.
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Incomplete outcome data—While we assessed that the majority of the included trials 
(20 out of 33) had acceptable levels of attrition (with loss to follow-up and missing data 
being less than 20% and balanced across groups), in the remaining trials the levels of 
attrition were high or not balanced across groups. In these studies high levels of attrition 
were likely to represent an important source of bias and thus results are difficult to interpret; 
this is the case particularly if we consider that reasons for attrition may have been related to 
outcomes (for example, when children with side effects or those who developed anaemia 
were excluded from the analysis). In one trial (Baqui 2003) the dropout rate was 
considerably higher in one of the intervention groups (those receiving multi-micronutrients 
lost 41% compared to a loss of 8% to 19% in other groups) and there were further missing 
data for some outcomes. High levels of loss to follow-up also occurred in the studies by 
Engstrom 2008 (C) (20.2% attrition); Faqih 2006 (53% attrition); Young 2001 (60% 
attrition); Schultink 1995 (75% attrition); Sen 2009 (C) (68% missing data for some 
outcomes); Roschnik 2003 (C) (41.2% attrition), and Taylor 2001 (36% attrition). In one 
study (Da Silva 2008), 16% of participants were lost to follow up and loss was not balanced 
across groups; the reasons given by the authors included children developing anaemia or 
side effects, with no clarity about the number of children lost in each group for these 
reasons. In four trials losses to follow-up were not clear as the denominators were not 
provided (Tavil 2003; Roschnik 2004 (C); Yang 2004 (C); Khademloo 2009).
Selective reporting—We were not able to fully assess outcome reporting bias as we only 
had access to published study reports. We assessed publication bias using funnel plots only 
for haemoglobin (in comparisons one and two) and for ferritin (comparison two), as more 
than 10 trials contributed data to those outcomes. We did not find clear asymmetry that may 
suggest publication bias (graphs not shown). In the analyses we have ordered studies by 
weight so that the effect of small studies is more apparent; we have drawn attention to any 
results where visual inspection of the forest plot seems to suggest a more pronounced 
treatment effect in small as compared with larger studies.
Other potential sources of bias—In a study (Awasthi 2005 (C)) some children 
received supervised intake of the supplement; it was not clear whether this varied depending 
on intervention group.
There was some baseline imbalance on outcomes or other potential confounders in terms of 
participant characteristics in some studies (Schultink 1995; Sinisterra 1997 (C); Taylor 
2001; Siddiqui 2004; Faqih 2006; Arcanjo 2011 (C)).
A potentially important source of bias was the impact of unit of randomisation; several of 
the included trials did not randomise at the individual level but used classes, schools or 
clinics as clusters for randomisation. The impact of the cluster-design effect was not clearly 
taken into account in most of the cluster-randomised trials (Liu 1995 (C); Sinisterra 1997 
(C); Hall 2002 (C); Roschnik 2003 (C); Roschnik 2004 (C); Yang 2004 (C); Awasthi 2005 
(C); Engstrom 2008 (C); Arcanjo 2011 (C)). In the Engstrom 2008 (C) trial, regression 
analysis was carried out to try to identify possible confounding factors but unit of analysis 
did not appear to be part of this analysis. We were able to obtain the ICCs for three trials 
(Desai 2004 (C); Roschnik 2003 (C) and Hall 2002 (C)) and we imputed the last two values 
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to other trials to obtain their effective sample size. The summary estimates obtained from 
cluster trials did not differ significantly from those obtained from studies randomised at an 
individual level.
There are three trials awaiting assessment (Husseini 1999; Reid 2001; Kargarnovin 2010). 
Based on the sample size of Kargarnovin 2010 and the findings reported in the abstract, we 
do not consider that its temporary exclusion from the analysis will bias the results of this 
review. Similarly, we did not consider that the omission of the data from Reid 2001 was 
likely to introduce serious bias due to the small sample size. On the other hand, the effect of 
excluding Husseini 1999 is uncertain as the only information available is published in 
Beaton 1999 who obtained it by personal communication. At the end of the intervention 
haemoglobin concentrations were higher and anaemia prevalence was lower among those 
children receiving daily supplements in comparison to those children receiving intermittent 
supplements. As we do not have access to the primary information, it is difficult to assess 
the quality of the study and to adjust data by the effect of clustering, which limits any 
assessment of its impact on our summary estimate.
Effects of interventions—See: Summary of findings for the main comparison 
Intermittent use of iron supplements versus placebo or no intervention in children younger 
than 12 years of age; Summary of findings 2 Intermittent versus daily use of iron 
supplements in children younger than 12 years of age
We have included data from 33 trials; overall, these trials involved 13,114 children. This 
figure represents the number of children recruited to studies, in some studies we have not 
included data for all arms of the trials in the review comparisons. The analyses include only 
the estimated effective sample size, after adjusting the data to account for the clustering 
effect.
We have organised the summary of results by comparing supplementation regimens and by 
primary and secondary outcomes. Most of the included studies focused on haematological 
outcomes and few reported on any of the other outcomes pre-specified in the review 
protocol. See the Data and analyses section for detailed results on primary and secondary 
outcomes.
Comparison 1. Intermittent iron supplementation versus no supplementation 
or placebo (19 trials)—Nineteen trials evaluated this comparison (Berger 1997; Palupi 
1997; Thu 1999; Aguayo 2000; Ekvall 2000; Olsen 2000; Taylor 2001; Ermis 2002; Hall 
2002 (C); Verhoef 2002; Sungthong 2002; Baqui 2003; Roschnik 2003 (C); Evangelista-
Salazar 2004; Roschnik 2004 (C); Yurdakok 2004; Yang 2004 (C); Sen 2009 (C); Arcanjo 
2011 (C)). Seven of the trials met the prespecified criteria mentioned above for being at 
lower risk of bias (Thu 1999; Aguayo 2000; Ekvall 2000; Olsen 2000; Hall 2002 (C); 
Verhoef 2002; Sungthong 2002). In sensitivity analyses these trials were retained in the 
analysis whilst trials at higher risk of bias were temporarily removed to examine whether 
this had any impact on the overall pattern of results.
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Anaemia: Ten trials with 1824 children provided data on anaemia following the 
interventions (Berger 1997; Palupi 1997; Thu 1999; Aguayo 2000; Hall 2002 (C); Verhoef 
2002; Roschnik 2003 (C); Evangelista-Salazar 2004; Roschnik 2004 (C); Arcanjo 2011 (C)). 
Those receiving intermittent iron supplementation were significantly less likely to have 
anaemia at follow-up compared with children receiving no intervention (average risk ratio 
(RR) 0.51, 95% confidence interval (CI) 0.37 to 0.72) (Analysis 1.1). There was variation 
among trials in terms of the size of the treatment effect (T2 = 0.18, I2 = 81% and Chi2 test 
for heterogeneity P < 0.00001). The large effect remained significant even after excluding 
the trials at higher risk of bias (RR 0.60; 95% CI 0.42 to 0.87).
Haemoglobin concentrations (g/L): Nineteen studies with 3032 participants provided data 
on mean haemoglobin levels following the intervention (Berger 1997; Palupi 1997; Thu 
1999; Aguayo 2000; Ekvall 2000; Olsen 2000; Taylor 2001; Ermis 2002; Hall 2002 (C); 
Verhoef 2002; Sungthong 2002; Baqui 2003; Roschnik 2003 (C); Evangelista-Salazar 2004; 
Roschnik 2004 (C); Yang 2004 (C); Yurdakok 2004; Sen 2009 (C); Arcanjo 2011 (C)). 
Those receiving intermittent iron supplements on average had higher haemoglobin (Hb) 
levels than those receiving no intervention or a placebo; the difference was statistically 
significant (mean difference (MD) 5.20, 95% CI 2.51 to 7.88) (Analysis 1.9). There were 
high levels of heterogeneity among trials (T2 = 32.45, I2 = 93% and Chi2 test for 
heterogeneity P < 0.00001). The effect remained significant after removing the trials at high 
risk of bias (RR 5.02, 95% CI 2.01 to 8.03).
Iron deficiency: Three trials with 431 children (Verhoef 2002; Evangelista-Salazar 2004; 
Yang 2004 (C)) reported on this outcome. Findings suggested that children receiving 
intermittent supplements were at lower risk of having iron deficiency at the end of the 
intervention as those receiving nothing or a placebo (RR 0.24, 95% CI 0.06 to 0.91) 
(Analysis 1.17). There were high levels of heterogeneity among trials (T2 = 1.01, I2 = 88% 
and Chi2 test for heterogeneity P < 0.0003).
Iron status measured by ferritin (μg/L): Five trials with follow-up data for 550 participants 
(Ermis 2002; Sungthong 2002; Baqui 2003; Yang 2004 (C); Yurdakok 2004) reported 
higher mean levels of ferritin among those receiving intermittent supplements compared 
with those receiving no treatment (MD 14.17, 95% CI 3.53 to 24.81) (Analysis 1.18). Only 
one trial (Sungthong 2002) was assessed as being at lower risk of bias.
Iron deficiency anaemia: No trials reported on this outcome.
All-cause mortality: No trials reported on mortality.
Secondary outcomes
All-cause morbidity: Information on all-cause morbidity was reported in one trial ( Palupi 
1997), with data for 194 children. There was no evidence of differences between groups 
(Analysis 1.26).
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Acute respiratory infection: No trials reported on this outcome.
Diarrhoea: No trials provided information on diarrhoea.
Any other adverse effects: One trial (Ermis 2002) reported no statistically significant 
difference in the total number of side effects reported by those children receiving 
supplements intermittently and those receiving no intervention or a placebo (Analysis 1.27). 
One trial (Aguayo 2000) reported on nausea and did not find differences between groups 
(Analysis 1.28).
Adherence: Baqui 2003 and Ekvall 2000 reported that children receiving intermittent iron 
supplements had similar levels of adherence to intermittent iron supplementation as those 
children receiving a placebo or no intervention (RR 1.04, 95% CI 0.98 to 1.09) (Analysis 
1.29).
Folate status (as measured by trialists): No trials reported on this outcome.
Mental development and motor skill development: Baqui 2003 reported on several 
measures of cognitive and physical development. There was no clear evidence of difference 
between groups for most of these outcomes (Analysis 1.30; Analysis 1.31; Analysis 1.32; 
Analysis 1.34).
School performance: One study (Sungthong 2002) examined intelligence quotient (IQ), 
language development and mathematics performance; there were no clear differences 
between those receiving intermittent iron and those on no supplementation (Analysis 1.35; 
Analysis 1.36; Analysis 1.37).
Physical capacity: One trial examined (Baqui 2003) the motor quality of children, which 
included seven items such as motor control and tone, and expressed the results in percentile 
scores. Authors found that children receiving intermittent supplementation had higher 
percentile scores although the clinical significance of this difference was not clear (MD 
15.60, 95% CI 7.66 to 23.54) (Analysis 1.33).
Height-for-age and weight-for-age Z-scores: Three trials (Palupi 1997; Thu 1999; Aguayo 
2000) reported results for weight-for-age and height-for-age Z-scores for school-aged 
children and did not find a statistically significant effect on these outcomes (Analysis 1.38; 
Analysis 1.39).
Comparison 2. Intermittent iron supplementation versus daily iron 
supplementation (21 trials)—Twenty-one trials evaluated this comparison (Liu 1995 
(C);, Schultink 1995; Berger 1997; Sinisterra 1997 (C); Soemantri 1997; Thu 1999; Young 
2001; Ermis 2002; Nguyen 2002; Sungthong 2002, Tavil 2003; Desai 2004 (C); Siddiqui 
2004; Yang 2004 (C); Yurdakok 2004; Awasthi 2005 (C); Faqih 2006; Da Silva 2008; 
Engstrom 2008 (C); Khademloo 2009; Sen 2009 (C)) and all of them contributed data to the 
analysis. Three of these trials were assessed as being at lower risk of bias and, where they 
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contributed data, they were retained in the analysis when we conducted sensitivity analyses 
(Thu 1999; Sungthong 2002; Desai 2004 (C)).
Primary outcomes
Anaemia: Six trials with 980 participants provided data on the number of children with 
anaemia following the interventions (Schultink 1995; Berger 1997; Sinisterra 1997 (C); Thu 
1999; Awasthi 2005 (C); Engstrom 2008 (C)). Children receiving intermittent iron 
supplementation had a higher risk of being anaemic at the end of the study period compared 
to those receiving daily iron supplementation (RR 1.23, 95% CI 1.04 to 1.47) (Analysis 2.1). 
Only one trial was considered at low risk of bias (Thu 1999) and found similar results (RR 
1.31, 95% CI 0.31 to 5.57).
Haemoglobin concentrations (g/L): Nineteen trials with 2851 participants provided data on 
mean haemoglobin levels following the intervention (Liu 1995 (C); Schultink 1995; Berger 
1997; Soemantri 1997; Thu 1999; Young 2001; Ermis 2002; Nguyen 2002; Sungthong 
2002; Tavil 2003; Desai 2004 (C); Siddiqui 2004; Yang 2004 (C); Yurdakok 2004; Awasthi 
2005 (C); Faqih 2006; Engstrom 2008 (C); Khademloo 2009; Sen 2009 (C)). The groups 
receiving intermittent iron supplements on average had 0.60 less grams of haemoglobin per 
litre than those receiving daily supplementation but the difference between groups was not 
statistically significant (95% CI −1.54 to 0.35) (Analysis 2.9). There were high levels of 
heterogeneity for this outcome (T2 = 2.26, I2 = 56%, and Chi2 test for heterogeneity P = 
0.001). When only those trials at lower risk of bias (Sungthong 2002; Desai 2004 (C)) were 
retained in the analysis, the difference between groups remained statistically non-significant 
(MD −0.87, 95% CI −2.77 to 1.02) (data for sensitivity analysis not shown).
Iron deficiency: Only one trial (Yang 2004 (C)) reported on iron deficiency and found that 
at the end of the intervention the number of children with iron deficiency was higher among 
those who received iron supplements intermittently compared to daily (RR 4.00, 95% CI 
1.23 to 13.05) (Analysis 2.17).
Iron status measured by ferritin (ng/L): Ten trials with data for 902 participants (Liu 1995 
(C); Schultink 1995; Ermis 2002; Sungthong 2002; Tavil 2003; Siddiqui 2004; Yang 2004 
(C); Yurdakok 2004; Faqih 2006; Khademloo 2009) reported that ferritin values were not 
statistically different between those receiving iron intermittently and those receiving daily 
iron (MD −4.19, 95% CI −9.42 to 1.05) (Analysis 2.18). Only one trial was at low risk of 
bias (Sungthong 2002) and found no differences between these two interventions. There was 
high heterogeneity for this outcome with considerable variation in mean values between 
trials; in addition, one of the studies reported exceptionally low standard errors for mean 
ferritin values (from which we calculated SDs) (Siddiqui 2004). We carried out a sensitivity 
analysis temporarily excluding this study from the meta-analysis; removing this study did 
not change the interpretation of results (MD - 5.20, 95% CI −10.76 to 0.35).
Iron deficiency anaemia: No trials reported data on iron deficiency anaemia.
All-cause mortality: No trials reported mortality by any cause.
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All-cause morbidity: Information on all-cause morbidity was reported in two trials (Desai 
2004 (C); Da Silva 2008), with data for 601 children. There was no evidence of a difference 
between groups (RR 0.96, 95% CI 83 to 1.12) (Analysis 2.27).
Acute respiratory infection: No trials reported on this outcome.
Diarrhoea: Two trials (Yurdakok 2004; Da Silva 2008) had data on diarrhoea and did not 
find differences between groups (Analysis 2.28).
Any other adverse effects: Four trials (Liu 1995 (C); Ermis 2002; Desai 2004 (C); 
Yurdakok 2004) reported side effects among 895 children. There was no evidence of 
differences between intermittent and daily iron supplementation (RR 0.60, 96% CI 0.19 to 
1.87) (Analysis 2.29).
Adherence: Five trials involving 1130 participants reported on this outcome (Berger 1997; 
Desai 2004 (C); Awasthi 2005 (C); Engstrom 2008 (C); Sen 2009 (C)). There was no 
statistically significant difference in adherence to the interventions between groups although 
it tended to be higher among those children receiving intermittent iron supplements (RR 
1.23, 95% CI 0.98 to 1.54) (Analysis 2.30).
Folate status (as measured by trialists): No trials reported on this outcome.
Mental development and motor skill development: No trials reported on this outcome.
School performance: One study (Sungthong 2002) examined IQ, Thai language 
development and mathematics performance; there were no clear differences between groups 
receiving intermittent iron versus no supplementation (Analysis 2.31; Analysis 2.32; 
Analysis 2.33).
Physical capacity: One trial that provided weekly and twice-a-week supplementation (Sen 
2009 (C)) did not find statistically significant differences in the increment of steps climbed 
by children receiving either intermittent or daily supplementation (Analysis 2.26).
Height-for-age and weight-for-age Z-scores: Three trials reported results for height-for-age 
Z-scores for school-aged children and did not find an effect on this outcome (Analysis 2.34).
Subgroup comparisons: There was considerable variation among trials in terms of the 
populations examined and the way studies were conducted, which very likely resulted in the 
high statistical heterogeneity observed in some outcomes. For primary outcomes, we 
examined subgroups to look for possible differences between studies in terms of the duration 
of the intervention; children’s anaemia status at baseline; higher and lower weekly doses of 
iron; type of iron compound provided; and supplementation regimen.
For most of the outcomes very few studies contributed data, so we limited the subgroup 
analysis to anaemia and haemoglobin and ferritin concentrations. In the analyses we have 
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provided overall totals along with subtotals for subgroups, and the statistics for subgroup 
differences.
Intermittent iron dose per week (25 mg or less; greater than 25 mg to 75 mg; greater than 
75 mg): Most of the trials provided between 25 and 75 mg of iron per week. There was 
some within subgroup heterogeneity and no consistent and clear differences between 
subgroup categories (Analysis 1.10; Analysis 1.19; Analysis 2.2; Analysis 2.10; Analysis 
2.19). It seemed that the effect of intermittent supplementation on anaemia was lost among 
those children receiving iron doses greater than 75 mg per week, although only two trials 
contributed to this subgroup (Analysis 1.2).
Duration of the intervention (0 to three months; more than three months): An almost even 
number of trials provided iron supplements for three months or less, or for more than three 
months. There was no statistical evidence that the response of haematological outcomes to 
intermittent supplementation differed by duration of the intervention (Analysis 1.3; Analysis 
1.11; Analysis 1.20; Analysis 2.3; Analysis 2.11; Analysis 2.20).
Type of compound (ferrous sulphate; ferrous fumarate; other): Most of the trials provided 
iron in the form of ferrous sulphate, but when other compounds were given there was no 
clear statistical evidence that they produced different results on haematological outcomes 
from those observed with ferrous sulphate (Analysis 1.4; Analysis 2.4; Analysis 2.12; 
Analysis 2.21). In one case haemoglobin responded better to supplementation with fumarate, 
but only one study contributed to this subgroup category and findings should be cautiously 
interpreted (Analysis 1.21).
Anaemia status at baseline (anaemic; non-anaemic; mixed or not reported): Intermittent 
supplementation appeared to be as efficacious in trials that included only anaemic children 
as in those studies that included populations with different degrees of anaemia (Analysis 1.5; 
Analysis 1.13; Analysis 1.22; Analysis 2.5; Analysis 2.13; Analysis 2.22). One study 
conducted in anaemic Bolivian children (Berger 1997) reported a very pronounced 
therapeutic effect on haematological outcomes and this trial contributed to the observed 
statistical heterogeneity; its results were consistent in terms of direction with the rest of the 
trials.
Intermittent regimen (one supplement a week; other intermittent regimen): Most of the 
trials supplemented children on a weekly basis and in some cases only one study was 
included in each subgroup, which impeded the interpretation of the analyses (Analysis 1.6; 
Analysis 1.23). For the rest of the subgroup comparisons, there was no statistical evidence 
that the results of haematological outcomes differed when the supplements were given once, 
twice or three times a week (Analysis 1.14; Analysis 2.6; Analysis 2.14; Analysis 2.23).
Sex (males; females; mixed or not reported): All but one trial included males and females, 
although it was possible to extract the results by sex only from Hall 2002 (C). There was no 
statistical evidence that in this population the positive effect of intermittent supplementation 
on haematological outcomes differed by sex (Analysis 1.7; Analysis 1.15; Analysis 1.24; 
Analysis 2.7; Analysis 2.15; Analysis 2.24).
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Supplement’s nutrient composition (iron alone; iron + folic acid; iron+other nutrient; 
iron + multiple micronutrients): Most of the trials provided only iron. In the majority of the 
subgroup analyses there was no evidence that the provision of other nutrients in addition to 
iron altered the effects of intermittent supplementation on haematological outcomes 
(Analysis 1.16; Analysis 1.25; Analysis 2.8; Analysis 2.16; Analysis 2.25). However, it 
seemed that the effect of intermittent supplementation on anaemia was higher among those 
children receiving iron + vitamin C (Analysis 1.8), although this result should be interpreted 
cautiously as only one trial assessed the joint effect of these micronutrients.
Comparisons 3 to 6. Analysis by age group: children younger than 60 months 
versus 60 months and older—We have summarised the results of comparisons 3 to 6 in 
Table 1 and Table 2.
The visual examination of the confidence intervals suggests that the haematological effects 
produced by intermittent supplementation are similar between young (0 to 59 months) and 
older children (60 months and older), although the statistical power may be an issue in 
assessing the consistency among results.
ADDITIONAL SUMMARY OF FINDINGS [Explanation]
Patient or population: children under 12 years of age
Settings: community settings
Intervention: intermittent supplementation with iron alone or with other micronutrients
Comparison: daily supplementation with iron alone or with other micronutrients
Outcomes Relative effect (95% CI) No of Participants 
(studies)
Quality of the 
evidence (GRADE)
Anaemia (haemoglobin below a 
cut-off defined by trialists, taking 
into account the age and altitude)
RR 1.23 (1.04–1.47) 980 (6 studies) ⊕⊕○○
low1,2
Haemoglobin (g/L) MD −0.60 (−1.54–0.35) 2851 (19 studies) ⊕⊕○○
low1,3
Iron deficiency (using ferritin 
concentrations)
RR 4.00 (1.23–13.05) 76 (1 study) ○○○○
very low4
Iron status (ferritin (μg/L) MD −4.19 (−9.42–1.05) 902 (10 studies) ⊕⊕○○
low13
Iron deficiency anaemia Not estimable 0 (0 studies) None of the trials 
reported on this 
outcome
Mortality Not estimable 0 (0 studies) None of the trials 
reported on this 
outcome
CI, confidence interval; RR, risk ratio; MD, mean difference
*
GRADE Working Group grades of evidence:
High quality: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: We have moderate confidence in the effect estimate. The true effect is likely to be close to the 
estimate of the effect, but there is a possibility that it is substantially different.
Low quality: Our confidence in the effect estimate is limited. The true effect may be substantially different from the 
estimate of the effect.
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Very low quality: We have very little confidence in the effect estimate. The true effect is likely to be substantially 
different from the estimate of the effect
1




High heterogeneity but results were mostly consistent.
4
Only one trial with unclear methods to generate the random sequence and conceal the allocation. Wide confidence 
intervals
Note: For cluster-randomised trials the analyses only include the estimated effective sample size, after adjusting the data to 
account for the clustering effect
DISCUSSION
Summary of main results
Available data indicate that among children less than 12 years of age, intermittent 
supplementation with iron (alone or in combination with other nutrients) effectively 
increases haemoglobin and ferritin concentrations and reduces the prevalence of anaemia 
compared to placebo or no intervention. Overall, this positive response does not differ 
between once, biweekly or three times weekly supplementation; nor does it depend on 
child’s sex or age or the duration of the intervention.
In comparison to daily iron supplementation, children receiving intermittent iron 
supplementation are more likely to develop anaemia but their haemoglobin and ferritin 
concentrations are similar.
Adherence tends to be higher in children receiving intermittent iron supplementation 
compared with those receiving daily iron supplements, although the results were not 
statistically significant. Information on morbidity, mortality, adverse side effects, 
neurocognitive and motor outcomes is scarce and therefore no clear conclusions can be 
drawn.
Overall completeness and applicability of evidence
A total of 33 randomised trials were included in this review, with data for 13,114 children 
included in the analysis. Seventy-five per cent of the included trials had a sample size of less 
than 500 children and the trials often lacked blinding and a clear description of 
randomisation methods. The trials were published in a wide variety of journals (and the level 
of quality of the journals might vary) and were mostly written in English. The diversity of 
publications may also reflect the range of settings in which studies were carried out: Latin 
America, Africa and Asia.
No studies were conducted in high-income countries and it is uncertain whether the results 
would be similar in those settings. On the one hand, the prevalences of anaemia and iron 
deficiency are lower in high income countries and there is an inverse relationship between 
initial iron status and response to iron supplementation. On the other hand, intermittent 
supplementation for children in high income countries could, however, be successful 
because of potentially strong institutional infrastructure and high attendance rates at schools 
that could support sustained high coverage and use of this intervention.
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We decided to include only randomised and quasi-randomised trials in this review. Whilst 
randomisation reduces the risk of bias, this approach also limited the inclusion of large scale 
pre-post trials with no comparison groups. Such studies are more likely to be affected by 
external circumstances, such as famines, and it is possible that the magnitude of the effect of 
intermittent iron supplementation might be different under programmatic conditions. The 
baseline anaemia and iron deficiency status varied across studies; most were conducted in 
settings with a high prevalence of anaemia. The studies included in this review largely 
examined this intervention for prevention as a public health strategy and not treatment of 
anaemia and iron deficiency as part of clinical practice. However, seven of the 33 trials 
included only anaemic children and subgroup analysis suggested that weekly 
supplementation was efficacious compared with daily supplementation. The efficacy of the 
intermittent supplementation schemes on haematological outcomes also seemed similar 
across different age groups, with few inconsistencies.
There were insufficient studies to allow us to evaluate in detail all the outcomes of interest, 
and by subgroups. Particularly, there were insufficient trials and a lack of comparable 
measures to examine mortality, morbidity, cognitive and developmental outcomes. In 
addition, there was a lack of data to meaningfully examine adherence and adverse effects 
specifically related to intensity and frequency of dosing. These last two are critical 
limitations considering that these are primary justifications for the use of weekly over daily 
supplementation.
Quality of the evidence
1. Quality of the evidence across within studies—Less than one third of the trials 
were assessed as having a low risk of bias after considering the methods for allocating the 
treatment, the blinding and the attrition rates, with many studies being at high risk of bias 
(see Risk of bias in included studies). In most of the included trials, the methods used to 
randomly assign participants and conceal allocation were not described. Blinding of 
participants, care providers and outcome assessors was not generally attempted, although in 
some studies technical staff carrying out laboratory investigations were reported to be 
unaware of group allocation. The lack of blinding may represent a potentially serious source 
of bias. Attrition was also a problem in many of these studies.
2. Quality of the evidence across studies—We used the GRADE methodology for 
this assessment and set out the results for primary outcomes in the Summary of findings for 
the main comparison and the Summary of findings 2. We considered that indirectness or 
publication bias was unlikely but the quality of the trials and inconsistency (or the lack of 
studies) were potentially important factors in the overall assessment of the evidence. When 
intermittent supplementation was compared with a placebo or no intervention, the overall 
quality of the available evidence was found to be moderate for anaemia, whereas for 
haemoglobin and ferritin concentrations it was low and very low for iron deficiency. When 
compared with daily supplementation, the quality of the available evidence with regard to 
anaemia, haemoglobin and ferritin concentrations was found to be low and for iron 
deficiency it was very low.
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Potential biases in the review process
There were a number of potential biases in the review process. We attempted to be as 
inclusive as possible in the search strategy and found publications in different languages in 
journals from all the continents, although the literature identified was predominantly written 
in English. We were also able to obtain unpublished information.
We attempted to minimise bias in several ways: two review authors independently assessed 
eligibility for inclusion and two review authors checked data extraction, assessments of risk 
of bias and data entry. However, carrying out reviews is not an exact science and may 
require a number of subjective judgements; it is possible that a different review team may 
have reached different decisions regarding assessments of eligibility and risk of bias. We 
would encourage readers to examine the Characteristics of included studies tables to assist in 
the interpretation of results.
In addition to the individual assessments of the study risk of bias, we included ’Summary of 
findings’ tables to assess the overall quality of the evidence for primary outcomes. We 
attempted to produce the tables using a transparent process with two review authors 
independently assessing the evidence for each outcome for each quality domain and 
discussing any disagreements.
Agreements and disagreements with other studies or reviews
To our knowledge, only one meta-analysis of randomised controlled trials has been 
conducted on the efficacy of intermittent iron supplementation in the control of iron 
deficiency anaemia (Beaton 1999). It includes the results of 22 trials completed before 1999 
in different age groups. In some cases authors were able to obtain the full data sets but in the 
rest of the cases summary statistics were collected from abstracts, final reports or directly 
supplied by investigators. Of the included studies, four were carried out among preschool-
aged children (age range five months to five years), 10 among school-aged children and 
adolescents (age range three years to 21 years) and eight among pregnant women. All of the 
preschool and school children or adolescent trials compared once or twice a week versus 
daily supplementation, and most included control groups. All the studies reported results for 
haemoglobin; two studies in preschool children and three in schoolchildren or adolescents 
also measured ferritin. All the studies that Beaton 1999 included involving preschool and 
school-aged children were also included in this review.
The authors found that intermittent supplementation was efficacious compared to no 
treatment and that it increased haemoglobin and ferritin levels and reduced anaemia. In 
contrast to the present review, they found that daily supplementation was more efficacious 
than intermittent supplementation in improving haemoglobin and ferritin levels. The authors 
concluded that weekly supplementation should be considered for preschool and school-aged 
children only in situations where there is strong assurance of supervision and high 
adherence.
The larger number of trials included in this Cochrane review, conducted in different settings 
and with different levels of supervision, suggest that intermittent supplementation is an 
efficacious public health intervention in children younger than 12 years of age that may be 
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implemented in a various contexts. It may be a viable approach to consider, particularly 
where daily supplementation has failed, is operationally complex or unfeasible or in settings 
where it has not been implemented yet.
The results of the present review are only applicable to children 12 years and younger. 
However, other systematic review assessing the benefits and safety of this intervention in 
menstruating women (Fernández-Gaxiola 2011) concur with our findings. From the 
programme implementation perspective, a recent narrative review reports that weekly iron 
and folic acid supplementation has been successfully implemented in Cambodia, Egypt, 




The findings from this review show that intermittent supplementation with iron (alone or in 
combination with other nutrients) is efficacious in improving haemoglobin concentrations 
and ferritin levels and reducing anaemia among children younger than 12 years of age in 
settings with moderate to high prevalence of anaemia. The effects of intermittent 
supplementation on haemoglobin and ferritin outcomes were similar to those achieved with 
daily supplementation although children receiving intermittent supplements were at higher 
risk of anaemia.
Most of the evidence in this review is derived from trials providing weekly doses between 
25 and 75 mg of elemental iron, either alone, with folic acid or with other micronutrients. 
The positive effect of intermittent supplementation was observed in populations of males 
and females, with different anaemia backgrounds, and seemed not to be affected by the 
duration of the intervention, although a minimum of three months seems reasonable to 
trigger the haematological response and build some iron stores. Very few trials reported on 
the level of supervision or the use of a communication or education strategy to improve the 
use of supplements. An integrated approach with a strong behaviour change communication 
component that targets different audiences may be necessary to adequately support 
adherence and appropriate use for any supplementation regimen. Intermittent 
supplementation for children might be an option for countries with strong institutional 
infrastructures for delivery that facilitate wide and sustained coverage, for example, where 
school attendance is high; although it is clear that efforts should be made to also reach those 
children not covered by the school or health systems.
This review attempted to examine several of the primary justifications for choosing 
intermittent over daily supplementation, including improved adherence, reduced side effects 
and improved efficiency in absorption. Surprisingly, very few trials reported on these 
outcomes and they did not show that the children receiving supplements intermittently 
adhere better to the intervention or have fewer side effects that those receiving daily 
supplements. Clearly, more research is needed in this area. Other rationales for intermittent 
supplementation include diminished exposure to an iron-rich environment, which may 
exacerbate oxidative stress in the gut lumen and intestinal mucosal cells, as well as 
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decreased competition with other minerals such as zinc and copper for absorption channels. 
Unfortunately, few trials reported on other indicators of vitamin and mineral status and 
therefore no conclusions can be drawn.
In summary, intermittent supplementation is efficacious at improving haemoglobin and 
ferritin concentrations and reducing anaemia prevalence, although children receiving daily 
supplements were less likely to present anaemia compared to those receiving intermittent 
supplements. These results suggest that in settings where daily supplementation is likely to 
be unsuccessful or not feasible, intermittent supplementation could be an effective public 
health strategy to improve iron status and reduce anaemia in children under 12 years of age.
Implications for research
Important research is needed at different levels before we can fully assess the effects and 
safety of intermittent iron supplementation regimens on anaemia, iron status and 
development in children less than 12 years of age. Future research should focus on the 
following.
● Clinical research
1. Examining the efficacy of intermittent iron regimens on neurocognitive and 
developmental outcomes and growth. In addition, attempts should be made to use 
comparable measures across studies, when possible.
2. Reporting the side effects in greater detail to acknowledge not only the presence of 
a side effect but also its intensity and frequency.
3. Expanding the evidence on the provision of multiple micronutrients on an 
intermittent basis and their effect on iron status and other indicators of vitamin and 
mineral status, such as retinol or zinc.
4. Reporting comprehensively the effects of the intermittent supplementation on 
anaemia, haemoglobin concentrations or ferritin to better understand the clinical 
significance of haemoglobin changes.
● Programme implementation
1. Establishing the periodicity of this intervention over a year, taking into account 
both its biological and programmatic feasibility.
2. Improving reporting of adherence and addressing the relevance of direct and 
continued supervision.
3. Exploring the factors which may influence adherence (such as behaviour change 
communication (BCC)) and the types of support needed to improve adherence in 
supplementation interventions. BCC and supporting adherence may be important 
components of an effective supplementation programme but trials rarely provide 
detailed information about them. This limits the ability to understand the intensity 
of these activities needed to achieve the effects found in the trials.
De-Regil et al. Page 33













4. Examining the cost effectiveness of intermittent compared with daily 
supplementation, taking into account more than just the differential cost of pills.
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APPENDICES
Appendix 1. Search strategies
CENTRAL
#1 MeSH descriptor Iron, this term only
#2 MeSH descriptor Iron, Dietary, this term only
#3 MeSH descriptor Anemia, Iron-Deficiency, this term only
#4 MeSH descriptor Folic Acid, this term only
#5 MeSH descriptor Dietary Supplements, this term only
#6 MeSH descriptor Trace Elements, this term only
#7 iron*
#8 folic* or folate* or folvite* or folacin* or pteroylglutamic*
#9 diet* NEAR/3 supplement*
#10 micro-nutrient* or micronutrient* or multi-nutrient* or multinutrient*
#11 MeSH descriptor Ferric Compounds, this term only
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#12 MeSH descriptor Ferrous Compounds, this term only
#13 ferrous* or ferric* or fe
#14 MeSH descriptor Micronutrients, this term only
#15 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 
OR #12 OR #13 OR #14)
#16 MeSH descriptor Drug Administration Schedule, this term only
#17 MeSH descriptor Dose-Response Relationship, Drug explode all trees
#18 MeSH descriptor Time Factors, this term only
#19 week* or biweek* or bi NEXT week* or intermittent* or alternat*
#20 (#16 OR #17 OR #18 OR #19)
#21 (#15 AND #20)
#22 (iron NEAR/3 (dose* or dosage or administer* or administration or frequency))
#23 (#21 OR #22)
#24 (baby or babies or newborn* or neonat* or toddler* or child* or preschool* or 
schoolchild* or boy* or girl* or pre-school* or teen* or adolescen* or preteen* 
or youth* or young person* or young people)
#25 (#23 AND #24)
MEDLINE





6. (folic$ or folate$ or folvite$ or folacin$ or pteroylglutamic$).tw.
7. Trace Elements/
8. (diet$ adj3 supplement$).tw.
9. (micro-nutrient$ or micronutrient$ or multi-nutrient$ or multinutrient$).tw.
10. Ferric Compounds/
11. Ferrous Compounds/
12. (ferrous$ or ferric$ or fe).tw.
13. or/1–12
14. Drug Administration Schedule/
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15. Dose-Response Relationship, Drug/
16. Time Factors/
17. (week$ or biweek$ or bi-week$ or intermittent$ or alternat$).tw.
18. or/14–17
19. 13 and 18
20. (iron adj3 (dose$ or dosage or administer$ or administration or frequency)).tw.




25. (baby or babies or newborn$ or neonat$ or toddler$ or child$ or preschool$ or 
schoolchild$ or boy$ or girl$ or pre-school$ or teen$ or adolescen$ or preteen$ or 
youth$ or young person$ or young people).tw.
26. or/22–25
27. randomized controlled trial.pt.








36. exp animals/ not humans.sh.
37. 35 not 36




3. iron deficiency anemia/
4. folic acid/
5. exp trace element/
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8. (folic$ or folate$ or folvite$ or folacin$ or pteroylglutamic$).tw.
9. (diet$ adj3 supplement$).tw.





15. drug dose regimen/
16. time/
17. (week$ or biweek$ or bi-week$ or intermittent$ or alternat$).tw.
18. or/14–17
19. 13 and 18
20. (iron adj3 (dose$ or dosage or administer$ or administration or frequency)).tw.




25. (baby or babies or newborn$ or neonat$ or toddler$ or child$ or preschool$ or 
schoolchild$ or boy$ or girl$ or pre-school$ or teen$ or adolescen$ or preteen$ or 
youth$ or young person$ or young people).tw.
26. or/22–25
27. 21 and 26
28. exp Clinical trial/
29. Randomization/
30. Single blind procedure/
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40. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
41. Placebo$.tw.
42. prospective study/
43. (crossover or cross-over).tw.
44. prospective.tw.
45. or/28–44
46. 27 and 45
CINAHL
S43 S24 and S42
S42 S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 
or S37 or S38 or S39 or S40 or S41
S41 (MH “Evaluation Research”) OR (MH “Summative Evaluation Research”) OR 
(MH “Program Evaluation”)
S40 (MH “Treatment Outcomes”)
S39 (MH “Comparative Studies”)
S38 TI (evaluat* study or evaluat* research) or AB (evaluat* study or evaluat* 
research) or TI (effectiv* study or effectiv* research) or AB (effectiv* study or 
effectiv* research) OR TI (prospectiv* study or prospectiv* research) or AB 
(prospectiv* study or prospectiv* research) or TI (follow-up study or follow-up 
research) or AB (follow-up study or follow-up research)
S37 placebo*
S36 crossover* or “cross over*”
S35 (MH “Crossover Design”)
S34 (tripl* N3 mask*) or (tripl* N3 blind*)
S33 (trebl* N3 mask*) or (trebl* N3 blind*)
S32 (doubl* N3 mask*) or (doubl* N3 blind*)
S31 (singl* N3 mask*) or (singl* N3 blind*)
S30 (clinic* N3 trial*) or (control* N3 trial*)
S29 (random* N3 allocat*) or (random* N3 assign*)
De-Regil et al. Page 46













S28 randomis* or randomiz*
S27 (MH “Meta Analysis”)
S26 (MH “Clinical Trials+”)
S25 MH random assignment
S24 S19 and S23
S23 S20 or S21 or S22
S22 baby or babies or newborn* or neonat* or toddler* or child or preschool* or 
schoolchild* or boy* or girl* or pre-school* or teen* or adolescen* or preteen* or 
youth* or young person* or young people
S21 AG adolescent
S20 AG infant or child
S19 S17 or S18
S18 (iron N3 dose*) or (iron N3 dosage) or (iron N3 administer*) or (iron N3 
administration) or (iron N3 frequency)
S17 S11 and S16
S16 S12 or S13 or S14 or S15
S15 (week* or biweek* or bi-week*or bi week* or intermittent* or alternat*)
S14 (MH “Time Factors”)
S13 (MH “Dose-Response Relationship, Drug”)
S12 (MH “Drug Administration Schedule”)
S11 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10
S10 micro-nutrient* or micronutrient* or micro nutrient* multi-nutrient* or 
multinutrient* or multi nutrient*
S9 ferrous* or ferric* or “fe”
S8 diet* N3 supplement*
S7 folic* or folate* or folvite* or folacin* or pteroylglutamic*
S6 iron*
S5 (MH “Micronutrients”)
S4 (MH “Trace Elements”)
S3 (MH “Dietary Supplements”)
S2 (MH “Folic Acid”)
S1 (MH “Iron”) OR (MH “Anemia, Iron Deficiency”) OR (MH “Iron Compounds”) OR 
(MH “Ferric Compounds”) OR (MH “Ferrous Compounds”)
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(iron* /folic* / folate* /supplement*/micronutrient*/micro-nutrient*) & (week* /bi-week* / 
bi week* / biweek* / intermittent / alternat*)
ICTRP
Intervention: iron or folic or folate or micronutrient*










Comparison 1. Intermittent iron supplementation versus placebo or no 
intervention: children 0 – 12 years
Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
1 Anaemia (ALL) 10 1824 Risk Ratio (M-H, 
Random, 95% CI)
0.51 [0.37, 0.72]
2 Anaemia (by dose of 
elemental iron in the 
intermittent group)
10 1824 Risk Ratio (M-H, 
Random, 95% CI)
0.51 [0.37, 0.72]
 2.1 25 mg or less/week 2 157 Risk Ratio (M-H, 
Random, 95% CI)
0.15 [0.06, 0.37]
 2.2 Greater than 25 mg 
to 75 mg/week
6 1256 Risk Ratio (M-H, 
Random, 95% CI)
0.54 [0.37, 0.80]
 2.3 Greater than 75 mg/
week
2 411 Risk Ratio (M-H, 
Random, 95% CI)
0.71 [0.48, 1.04]
3 Anaemia (by duration of 
the intervention)
10 1824 Risk Ratio (M-H, 
Random, 95% CI)
0.51 [0.37, 0.72]
 3.1 0 to three months 5 1456 Risk Ratio (M-H, 
Random, 95% CI)
0.63 [0.49, 0.82]
 3.2 More than three 
months
5 368 Risk Ratio (M-H, 
Random, 95% CI)
0.37 [0.14, 1.02]
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Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
4 Anaemia (by type of 
compound)
10 1824 Risk Ratio (M-H, 
Random, 95% CI)
0.51 [0.37, 0.72]
 4.1 Ferrous sulphate 9 1517 Risk Ratio (M-H, 
Random, 95% CI)
0.47 [0.30, 0.75]
 4.2 Ferrous fumarate 1 307 Risk Ratio (M-H, 
Random, 95% CI)
0.61 [0.49, 0.74]
 4.3 Other 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
5 Anaemia (by anaemia 
status at baseline)
10 1824 Risk Ratio (M-H, 
Random, 95% CI)
0.51 [0.37, 0.72]
 5.1 Anaemic 2 424 Risk Ratio (M-H, 
Random, 95% CI)
0.30 [0.07, 1.38]
 5.2 Non-anaemic 1 64 Risk Ratio (M-H, 
Random, 95% CI)
0.78 [0.27, 2.31]
 5.3 Mixed/unknown 7 1336 Risk Ratio (M-H, 
Random, 95% CI)
0.59 [0.41, 0.85]
6 Anaemia (by intermittent 
regimen)
10 1824 Risk Ratio (M-H, 
Random, 95% CI)
0.51 [0.37, 0.72]
 6.1 One supplement a 
week
9 1517 Risk Ratio (M-H, 
Random, 95% CI)
0.47 [0.30, 0.75]
 6.2 Other intermittent 
regimen
1 307 Risk Ratio (M-H, 
Random, 95% CI)
0.61 [0.49, 0.74]
7 Anaemia (by sex) 10 1824 Risk Ratio (M-H, 
Random, 95% CI)
0.55 [0.41, 0.73]
 7.1 Girls 1 248 Risk Ratio (M-H, 
Random, 95% CI)
0.75 [0.59, 0.95]
 7.2 Boys 1 253 Risk Ratio (M-H, 
Random, 95% CI)
0.81 [0.66, 1.00]
 7.3 Mixed/unknown 9 1323 Risk Ratio (M-H, 
Random, 95% CI)
0.46 [0.30, 0.70]
8 Anaemia (by nutrient) 10 1824 Risk Ratio (M-H, 
Random, 95% CI)
0.51 [0.37, 0.72]
 8.1 Iron alone 6 1074 Risk Ratio (M-H, 
Random, 95% CI)
0.48 [0.31, 0.74]
 8.2 Iron + folic acid 2 593 Risk Ratio (M-H, 
Random, 95% CI)
0.83 [0.66, 1.03]
 8.3 iron + vitamin C 1 50 Risk Ratio (M-H, 
Random, 95% CI)
0.06 [0.00, 0.97]
 8.4 Iron + multiple 
micronutrients
1 107 Risk Ratio (M-H, 
Random, 95% CI)
0.16 [0.06, 0.44]
9 Haemoglobin (ALL) 19 3032 Mean Difference (IV, 
Random, 95% CI)
5.20 [2.51, 7.88]
10 Haemoglobin (by by 
dose of elemental iron in 
the intermittent group)
19 3032 Mean Difference (IV, 
Random, 95% CI)
5.20 [2.51, 7.88]
 10.1 25 mg or less/week 3 324 Mean Difference (IV, 
Random, 95% CI)
8.19 [−4.01, 20.38]
 10.2 Greater than 25 mg 
to 75 mg/week
12 2059 Mean Difference (IV, 
Random, 95% CI)
5.45 [2.31, 8.58]
 10.3 Greater than 75 mg/
week
4 649 Mean Difference (IV, 
Random, 95% CI)
1.84 [0.25, 3.44]
De-Regil et al. Page 49













Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
11 Haemoglobin (by 
duration of the 
intervention)
19 3032 Mean Difference (IV, 
Random, 95% CI)
5.20 [2.51, 7.88]
 11.1 0 to three months 7 1616 Mean Difference (IV, 
Random, 95% CI)
5.16 [2.82, 7.51]
 11.2 More than three 
months
12 1416 Mean Difference (IV, 
Random, 95% CI)
5.13 [0.90, 9.36]
12 Haemoglobin (by type 
of compound)
19 3032 Mean Difference (IV, 
Random, 95% CI)
5.20 [2.51, 7.88]
 12.1 Ferrous sulphate 14 2288 Mean Difference (IV, 
Random, 95% CI)
5.57 [2.21, 8.92]
 12.2 Ferrous fumarate 2 432 Mean Difference (IV, 
Random, 95% CI)
7.03 [3.36, 10.71]
 12.3 Other 3 312 Mean Difference (IV, 
Random, 95% CI)
2.03 [−0.26, 4.33]
13 Haemoglobin (by 
anaemia status at baseline)
19 3032 Mean Difference (IV, 
Random, 95% CI)
5.20 [2.51, 7.88]
 13.1 Anaemic 2 422 Mean Difference (IV, 
Random, 95% CI)
13.17 [3.07, 23.26]
 13.2 Non-anaemic 1 64 Mean Difference (IV, 
Random, 95% CI)
2.0 [−2.46, 6.46]
 13.3 Mixed/unknown 16 2546 Mean Difference (IV, 
Random, 95% CI)
4.35 [1.88, 6.82]
14 Haemoglobin (by 
intermittent regimen)
19 3032 Mean Difference (IV, 
Random, 95% CI)
5.15 [2.52, 7.79]
 14.1 One supplement a 
week
15 2256 Mean Difference (IV, 
Random, 95% CI)
5.61 [2.13, 9.09]
 14.2 Other intermittent 
regimen
5 776 Mean Difference (IV, 
Random, 95% CI)
3.67 [1.05, 6.28]
15 Haemoglobin (by sex) 19 3032 Mean Difference (IV, 
Random, 95% CI)
5.17 [2.56, 7.77]
 15.1 Girls 1 248 Mean Difference (IV, 
Random, 95% CI)
4.0 [0.83, 7.17]
 15.2 Boys 1 253 Mean Difference (IV, 
Random, 95% CI)
3.70 [0.58, 6.82]
 15.3 Mixed/unknown 18 2531 Mean Difference (IV, 
Random, 95% CI)
5.31 [2.40, 8.22]
16 Haemoglobin (by 
nutrient)
19 3032 Mean Difference (IV, 
Random, 95% CI)
4.83 [2.25, 7.41]
 16.1 Iron alone 11 1699 Mean Difference (IV, 
Random, 95% CI)
4.41 [1.32, 7.50]
 16.2 Iron + folic acid 4 756 Mean Difference (IV, 
Random, 95% CI)
3.36 [1.51, 5.21]
 16.3 iron + zinc 1 77 Mean Difference (IV, 
Random, 95% CI)
−1.60 [−8.09, 4.89]
 16.4 Iron + vitamin C 1 50 Mean Difference (IV, 
Random, 95% CI)
20.70 [17.51, 23.89]
 16.5 Iron + multiple 
micronutrients
4 450 Mean Difference (IV, 
Random, 95% CI)
5.47 [0.32, 10.61]
17 Iron deficiency (ALL) 3 431 Risk Ratio (M-H, 
Random, 95% CI)
0.24 [0.06, 0.91]
18 Ferritin (ALL) 5 550 Mean Difference (IV, 
Random, 95% CI)
14.17 [3.53, 24.81]
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Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
19 Ferritin (by dose of 
elemental iron in the 
intermittent group)
5 550 Mean Difference (IV, 
Random, 95% CI)
14.17 [3.53, 24.81]
 19.1 25 mg or less/week 1 148 Mean Difference (IV, 
Random, 95% CI)
4.60 [−0.89, 10.09]
 19.2 Greater than 25 mg 
to 75 mg/week
4 402 Mean Difference (IV, 
Random, 95% CI)
17.77 [8.21, 27.34]
 19.3 Greater than 75 mg/
week
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
20 Ferritin (by duration of 
the supplementation)
5 550 Mean Difference (IV, 
Random, 95% CI)
14.17 [3.53, 24.81]
 20.1 0 to three months 1 35 Mean Difference (IV, 
Random, 95% CI)
15.80 [−1.23, 32.83]
 20.2 More than three 
months
4 515 Mean Difference (IV, 
Random, 95% CI)
13.82 [1.84, 25.81]
21 Ferritin (by type of 
compound)
5 550 Mean Difference (IV, 
Random, 95% CI)
14.17 [3.53, 24.81]
 21.1 Ferrous sulphate 4 476 Mean Difference (IV, 
Random, 95% CI)
16.28 [4.68, 27.87]
 21.2 Ferrous fumarate 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 21.3 Other 1 74 Mean Difference (IV, 
Random, 95% CI)
2.46 [−14.37, 19.29]
22 Ferritin (by anaemia 
status at baseline)
5 550 Mean Difference (IV, 
Random, 95% CI)
14.17 [3.53, 24.81]
 22.1 Anaemic 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 22.2 Non-anaemic 1 74 Mean Difference (IV, 
Random, 95% CI)
2.46 [−14.37, 19.29]
 22.3 Mixed/unknown 4 476 Mean Difference (IV, 
Random, 95% CI)
16.28 [4.68, 27.87]
23 Ferritin (by 
supplementation regimen)
5 550 Mean Difference (IV, 
Random, 95% CI)
14.17 [3.53, 24.81]
 23.1 One supplement a 
week
4 497 Mean Difference (IV, 
Random, 95% CI)
10.14 [1.74, 18.53]
 23.2 Other intermittent 
regimen
1 53 Mean Difference (IV, 
Random, 95% CI)
27.80 [22.88, 32.72]
24 Ferritin (by sex) 5 550 Mean Difference (IV, 
Random, 95% CI)
14.17 [3.53, 24.81]
 24.1 Girls 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 24.2 Boys 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 24.3 Mixed/unknown 5 550 Mean Difference (IV, 
Random, 95% CI)
14.17 [3.53, 24.81]
25 Ferritin (by nutrient) 5 550 Mean Difference (IV, 
Random, 95% CI)
11.41 [2.71, 20.11]
 25.1 Iron alone 4 379 Mean Difference (IV, 
Random, 95% CI)
16.25 [5.41, 27.09]
 25.2 Iron + folic acid 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 25.3 Iron + zinc 1 53 Mean Difference (IV, 
Random, 95% CI)
5.50 [−3.91, 14.91]
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Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
 25.4 Iron + multiple 
micronutrients
2 118 Mean Difference (IV, 
Random, 95% CI)
3.80 [−4.96, 12.56]
26 All cause morbidity 
(ALL)
1 194 Risk Ratio (M-H, 
Random, 95% CI)
0.26 [0.03, 2.24]
27 Any side effects (ALL) 1 53 Risk Ratio (M-H, 
Fixed, 95% CI)
3.87 [0.19, 76.92]
28 Nausea 1 64 Risk Ratio (M-H, 
Random, 95% CI)
2.82 [0.12, 66.82]
29 Adherence (ALL) 2 289 Risk Ratio (M-H, 
Random, 95% CI)
1.04 [0.98, 1.09]
30 Mental development 
scale (ALL)
1 172 Mean Difference (IV, 
Random, 95% CI)
2.0 [−2.40, 6.40]
31 Orientation engagement 
(ALL)
1 172 Mean Difference (IV, 
Random, 95% CI)
8.40 [−1.79, 18.59]
32 Emotional regulation 
(ALL)
1 172 Mean Difference (IV, 
Random, 95% CI)
−2.5 [−11.58, 6.58]





1 172 Mean Difference (IV, 
Random, 95% CI)
6.90 [1.35, 12.45]
35 IQ (ALL) 1 252 Mean Difference (IV, 
Random, 95% CI)
−3.00 [−5.96, −0.04]
36 Thai language (ALL) 1 208 Mean Difference (IV, 
Random, 95% CI)
−0.30 [−0.50, −0.09]
37 Mathematics (ALL) 1 233 Mean Difference (IV, 
Random, 95% CI)
−0.27 [−0.44, −0.10]
38 WAZ 3 366 Std. Mean Difference 
(IV, Random, 95% CI)
−0.03 [−0.33, 0.27]
39 HAZ 3 366 Mean Difference (IV, 
Random, 95% CI)
0.03 [−0.04, 0.10]
Comparison 2. Intermittent iron supplementation versus daily iron 
supplementation: children 0 – 12 years
Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Anaemia (ALL) 6 980 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [1.04, 1.47]
2 Anaemia (by dose of 
elemental iron in the 
intermittent group)
6 980 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [1.04, 1.47]
 2.1 25 mg or less/week 2 404 Risk Ratio (M-H, 
Random, 95% CI)
1.20 [0.98, 1.47]
 2.2 Greater than 25 mg to 
75 mg/week
4 576 Risk Ratio (M-H, 
Random, 95% CI)
1.34 [0.96, 1.88]
 2.3 Intermittent group: 
greater than 75 mg/week
0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
3 Anaemia (by duration of 
the supplementation)
6 980 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [1.04, 1.47]
 3.1 0 to three months 2 172 Risk Ratio (M-H, 
Random, 95% CI)
1.24 [0.55, 2.77]
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 3.2 More than three 
months
4 808 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [1.03, 1.47]
4 Anaemia (by type of 
compound)
6 980 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [1.04, 1.47]
 4.1 Ferrous sulphate 6 980 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [1.04, 1.47]
 4.2 Ferrous fumarate 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
 4.3 Other 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
5 Anaemia (by anaemia 
status at baseline)
6 980 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [1.04, 1.47]
 5.1 Anaemic 2 183 Risk Ratio (M-H, 
Random, 95% CI)
0.96 [0.50, 1.82]
 5.2 Non-anaemic 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
 5.3 Mixed/unknown 4 797 Risk Ratio (M-H, 
Random, 95% CI)
1.26 [1.05, 1.51]
6 Anaemia (by 
supplementation regimen)
6 980 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [1.04, 1.47]
 6.1 One supplement a 
week
4 549 Risk Ratio (M-H, 
Random, 95% CI)
1.18 [0.97, 1.43]
 6.2 Other intermittent 
regimen
2 431 Risk Ratio (M-H, 
Random, 95% CI)
1.49 [1.02, 2.19]
7 Anaemia (by sex) 6 980 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [1.04, 1.47]
 7.1 Girls 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
 7.2 Boys 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
 7.3 Mixed/unknown 6 980 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [1.04, 1.47]
8 Anaemia (by nutrient) 6 980 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [1.04, 1.47]
 8.1 Iron alone 4 507 Risk Ratio (M-H, 
Random, 95% CI)
1.17 [0.97, 1.42]
 8.2 Iron + folic acid 1 366 Risk Ratio (M-H, 
Random, 95% CI)
1.55 [1.02, 2.36]
 8.3 Iron + multiple 
micronutrients
1 107 Risk Ratio (M-H, 
Random, 95% CI)
1.31 [0.31, 5.57]
9 Haemoglobin (ALL) 19 2851 Mean Difference (IV, 
Random, 95% CI)
−0.60 [−1.54, 0.35]
10 Haemoglobin (by dose 
of elemental iron in the 
intermittent group)
18 2751 Mean Difference (IV, 
Random, 95% CI)
−0.62 [−1.60, 0.37]
 10.1 25 mg or less/week 3 536 Mean Difference (IV, 
Random, 95% CI)
−2.42 [−4.18, −0.66]
 10.2 Greater than 25 mg 
to 75 mg/week
13 2078 Mean Difference (IV, 
Random, 95% CI)
−0.58 [−1.62, 0.45]
 10.3 Greater than 75 mg/
week
2 137 Mean Difference (IV, 
Random, 95% CI)
1.00 [−4.68, 6.68]
11 Haemoglobin (by 
duration of the 
supplementation)
19 2842 Mean Difference (IV, 
Random, 95% CI)
−0.38 [−1.26, 0.50]
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 11.1 0 to three months 11 1455 Mean Difference (IV, 
Random, 95% CI)
0.47 [−0.91, 1.84]
 11.2 More than three 
months
8 1387 Mean Difference (IV, 
Random, 95% CI)
−1.14 [−2.07, −0.22]
12 Haemoglobin (by type of 
compound)
19 2851 Mean Difference (IV, 
Random, 95% CI)
−0.60 [−1.54, 0.35]
 12.1 Ferrous sulphate 17 2733 Mean Difference (IV, 
Random, 95% CI)
−0.60 [−1.60, 0.40]
 12.2 Ferrous fumarate 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 12.3 Other 2 118 Mean Difference (IV, 
Random, 95% CI)
−0.46 [−4.24, 3.32]
13 Haemoglobin (by 
anaemia status at baseline)
19 2851 Mean Difference (IV, 
Random, 95% CI)
−0.61 [−1.54, 0.32]
 13.1 Anaemic 7 957 Mean Difference (IV, 
Random, 95% CI)
−0.76 [−2.59, 1.07]
 13.2 Non-anaemic 3 166 Mean Difference (IV, 
Random, 95% CI)
0.79 [−1.42, 2.99]
 13.3 Mixed/unknown 10 1728 Mean Difference (IV, 
Random, 95% CI)
−0.76 [−2.00, 0.48]
14 Haemoglobin (by 
supplementation regimen)
19 2851 Mean Difference (IV, 
Random, 95% CI)
−0.70 [−1.70, 0.30]
 14.1 One supplement a 
week
14 1612 Mean Difference (IV, 
Random, 95% CI)
−0.25 [−1.57, 1.07]
 14.2 Other intermittent 
regimen
8 1239 Mean Difference (IV, 
Random, 95% CI)
−1.42 [−3.02, 0.19]
15 Haemoglobin (by sex) 19 2851 Mean Difference (IV, 
Random, 95% CI)
−0.60 [−1.54, 0.35]
 15.1 Girls 1 42 Mean Difference (IV, 
Random, 95% CI)
−2.0 [−5.43, 1.43]
 15.2 Boys 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 15.3 Mixed/unknown 18 2809 Mean Difference (IV, 
Random, 95% CI)
−0.53 [−1.51, 0.46]
16 Haemoglobin (by 
nutrient)
19 2851 Mean Difference (IV, 
Random, 95% CI)
−0.59 [−1.52, 0.35]
 16.1 Iron alone 15 2144 Mean Difference (IV, 
Random, 95% CI)
−0.51 [−1.61, 0.59]
 16.2 Iron + folic acid 2 408 Mean Difference (IV, 
Random, 95% CI)
−2.26 [−4.30, −0.22]
 16.3 Iron + multiple 
micronutrients
3 299 Mean Difference (IV, 
Random, 95% CI)
0.61 [−2.04, 3.26]
17 Iron deficiency (ALL) 1 76 Risk Ratio (M-H, 
Random, 95% CI)
4.0 [1.23, 13.05]
18 Ferritin (ALL) 10 902 Mean Difference (IV, 
Random, 95% CI)
−4.19 [−9.42, 1.05]
19 Ferritin (by dose of 
elemental iron in the 
intermittent group)
9 802 Mean Difference (IV, 
Random, 95% CI)
−4.34 [−10.20, 1.53]
 19.1 by dose of elemental 
iron in the intermittent 
group: 25 mg or less/week
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 19.2 by dose of elemental 
iron in the intermittent 
9 802 Mean Difference (IV, 
Random, 95% CI)
−4.34 [−10.20, 1.53]
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group: greater than 25 mg 
to 75 mg/week
 19.3 by dose of elemental 
iron in the intermittent 
group: greater than 75 mg/
week
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
20 Ferritin (by duration of 
the supplementation)
10 902 Mean Difference (IV, 
Random, 95% CI)
−4.19 [−9.42, 1.05]
 20.1 by duration of the 
supplementation: 0 to three 
months
6 442 Mean Difference (IV, 
Random, 95% CI)
−1.06 [−6.62, 4.51]
 20.2 by duration of the 
supplementation: more than 
three months
4 460 Mean Difference (IV, 
Random, 95% CI)
−9.58 [−23.08, 3.93]
21 Ferritin (by type of 
compound)
10 902 Mean Difference (IV, 
Random, 95% CI)
−4.19 [−9.42, 1.05]
 21.1 by type of 
compound: ferrous sulphate
9 826 Mean Difference (IV, 
Random, 95% CI)
−3.85 [−9.28, 1.59]
 21.2 by type of 
compound: ferrous 
fumarate
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 21.3 by type of 
compound: other
1 76 Mean Difference (IV, 
Random, 95% CI)
−9.03 [−23.95, 5.89]
22 Ferritin (by anaemia 
status at baseline)
10 902 Mean Difference (IV, 
Random, 95% CI)
−4.93 [−9.98, 0.12]
 22.1 by anaemia status at 
baseline: anaemic
5 285 Mean Difference (IV, 
Random, 95% CI)
−2.94 [−12.23, 6.34]
 22.2 by anaemia status at 
baseline: non-anaemic
3 167 Mean Difference (IV, 
Random, 95% CI)
−2.67 [−5.89, 0.54]
 22.3 by anaemia status at 
baseline: mixed/unknown
3 450 Mean Difference (IV, 
Random, 95% CI)
−9.42 [−23.19, 4.35]
23 Ferritin (by 
supplementation regimen)
10 902 Mean Difference (IV, 
Random, 95% CI)
−4.48 [−9.68, 0.71]
 23.1 by supplementation 
regimen: one supplement a 
week
7 595 Mean Difference (IV, 
Random, 95% CI)
−7.34 [−16.12, 1.44]
 23.2 by supplementation 
regimen: other intermittent 
regimen
5 307 Mean Difference (IV, 
Random, 95% CI)
−0.93 [−3.94, 2.08]
24 Ferritin (by sex) 10 902 Mean Difference (IV, 
Random, 95% CI)
−4.19 [−9.42, 1.05]
 24.1 by sex: girls 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 24.2 by sex: boys 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 24.3 by sex: mixed/
unknown
10 902 Mean Difference (IV, 
Random, 95% CI)
−4.19 [−9.42, 1.05]
25 Ferritin (by nutrient) 10 902 Mean Difference (IV, 
Random, 95% CI)
−4.19 [−9.42, 1.05]
 25.1 By nutrient: iron 
alone
9 826 Mean Difference (IV, 
Random, 95% CI)
−3.85 [−9.28, 1.59]
 25.2 By nutrient: iron + 
folic acid
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 25.3 By nutrient: iron + 
multiple micronutrients
1 76 Mean Difference (IV, 
Random, 95% CI)
−9.03 [−23.95, 5.89]
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26 Increase in steps climbed 
(ALL)
1 65 Mean Difference (IV, 
Random, 95% CI)
−5.0 [−13.34, 3.34]
27 All cause morbidity 
(ALL)
2 599 Risk Ratio (M-H, 
Random, 95% CI)
0.96 [0.83, 1.12]
28 Diarrhoea (ALL) 2 122 Risk Ratio (M-H, 
Random, 95% CI)
1.17 [0.60, 2.28]
29 Any side effects (ALL) 4 895 Risk Ratio (M-H, 
Random, 95% CI)
0.60 [0.19, 1.87]
30 Adherence (ALL) 5 1130 Risk Ratio (M-H, 
Random, 95% CI)
1.23 [0.98, 1.54]
31 IQ (ALL) 1 252 Mean Difference (IV, 
Random, 95% CI)
−3.00 [−5.96, −0.04]
32 Thai language (ALL) 1 208 Mean Difference (IV, 
Random, 95% CI)
−0.30 [−0.50, −0.09]
33 Mathematics (ALL) 1 233 Mean Difference (IV, 
Random, 95% CI)
−0.27 [−0.44, −0.10]
34 HAZ 3 279 Std. Mean Difference 
(IV, Random, 95% CI)
−0.26 [−0.80, 0.28]
Comparison 3. Intermittent iron supplementation versus placebo or no 
intervention: children 0 – 59 months
Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
1 Anaemia (ALL) 4 658 Risk Ratio (M-H, 
Random, 95% CI)
0.43 [0.23, 0.80]
2 Anaemia (by dose of 
elemental iron in the 
intermittent group)
4 658 Risk Ratio (M-H, 
Random, 95% CI)
0.43 [0.23, 0.80]
 2.1 25 mg or less/week 2 157 Risk Ratio (M-H, 
Random, 95% CI)
0.15 [0.06, 0.37]
 2.2 Greater than 25 mg to 
75 mg/week
2 501 Risk Ratio (M-H, 
Random, 95% CI)
0.61 [0.51, 0.74]
 2.3 Greater than 75 mg/
week
0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
3 Anaemia (by duration of 
the supplementation)
4 658 Risk Ratio (M-H, 
Random, 95% CI)
0.43 [0.23, 0.80]
 3.1 0 to three months 3 608 Risk Ratio (M-H, 
Random, 95% CI)
0.48 [0.27, 0.85]
 3.2 More than three 
months
1 50 Risk Ratio (M-H, 
Random, 95% CI)
0.06 [0.00, 0.97]
4 Anaemia (by type of 
compound)
4 658 Risk Ratio (M-H, 
Random, 95% CI)
0.43 [0.23, 0.80]
 4.1 Ferrous sulphate 3 351 Risk Ratio (M-H, 
Random, 95% CI)
0.26 [0.07, 1.03]
 4.2 Ferrous fumarate 1 307 Risk Ratio (M-H, 
Random, 95% CI)
0.61 [0.49, 0.74]
 4.3 Other 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
5 Anaemia (by anaemia 
status at baseline)
4 658 Risk Ratio (M-H, 
Random, 95% CI)
0.43 [0.23, 0.80]
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 5.1 Anaemic 1 307 Risk Ratio (M-H, 
Random, 95% CI)
0.61 [0.49, 0.74]
 5.2 Non-anaemic 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
 5.3 Mixed/unknown 3 351 Risk Ratio (M-H, 
Random, 95% CI)
0.26 [0.07, 1.03]
6 Anaemia (by intermittent 
regimen)
4 658 Risk Ratio (M-H, 
Random, 95% CI)
0.43 [0.23, 0.80]
 6.1 One supplement a 
week
3 351 Risk Ratio (M-H, 
Random, 95% CI)
0.26 [0.07, 1.03]
 6.2 Other intermittent 
regimen
1 307 Risk Ratio (M-H, 
Random, 95% CI)
0.61 [0.49, 0.74]
7 Anaemia (by sex) 4 658 Risk Ratio (M-H, 
Random, 95% CI)
0.43 [0.23, 0.80]
 7.1 Girls 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
 7.2 Boys 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
 7.3 Mixed/unknown 4 658 Risk Ratio (M-H, 
Random, 95% CI)
0.43 [0.23, 0.80]
8 Anaemia (by nutrient) 4 658 Risk Ratio (M-H, 
Random, 95% CI)
0.43 [0.23, 0.80]
 8.1 Iron alone 2 501 Risk Ratio (M-H, 
Random, 95% CI)
0.61 [0.51, 0.74]
 8.2 Iron + folic acid 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
 8.3 iron + vitamin C 1 50 Risk Ratio (M-H, 
Random, 95% CI)
0.06 [0.00, 0.97]
 8.4 Iron + multiple 
micronutrients
1 107 Risk Ratio (M-H, 
Random, 95% CI)
0.16 [0.06, 0.44]
9 Haemoglobin (ALL) 9 1254 Mean Difference (IV, 
Random, 95% CI)
6.45 [2.36, 10.55]
10 Haemoglobin (by dose 
of elemental iron in the 
intermittent group)
9 1254 Mean Difference (IV, 
Random, 95% CI)
6.45 [2.36, 10.55]
 10.1 25 mg or less/week 3 324 Mean Difference (IV, 
Random, 95% CI)
8.19 [−4.01, 20.38]
 10.2 Greater than 25 mg 
to 75 mg/week
6 930 Mean Difference (IV, 
Random, 95% CI)
5.50 [2.64, 8.36]
 10.3 Greater than 75 mg/
week
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
11 Haemoglobin (by 
duration of the 
supplementation)
9 1254 Mean Difference (IV, 
Random, 95% CI)
6.45 [2.36, 10.55]
 11.1 0 to three months 4 643 Mean Difference (IV, 
Random, 95% CI)
6.64 [3.01, 10.27]
 11.2 More than three 
months
5 611 Mean Difference (IV, 
Random, 95% CI)
6.16 [−1.55, 13.87]
12 Haemoglobin (by type 
of iron compound)
9 1254 Mean Difference (IV, 
Random, 95% CI)
6.45 [2.36, 10.55]
 12.1 Ferrous sulphate 7 873 Mean Difference (IV, 
Random, 95% CI)
6.54 [1.44, 11.63]
De-Regil et al. Page 57













Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
 12.2 Ferrous fumarate 1 307 Mean Difference (IV, 
Random, 95% CI)
8.0 [5.00, 11.00]
 12.3 Other 1 74 Mean Difference (IV, 
Random, 95% CI)
4.06 [−1.32, 9.44]
13 Haemoglobin (by 
anaemia status at baseline)
9 1254 Mean Difference (IV, 
Random, 95% CI)
6.45 [2.36, 10.55]
 13.1 Anaemic 1 307 Mean Difference (IV, 
Random, 95% CI)
8.0 [5.00, 11.00]
 13.2 Non-anaemic 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 13.3 Mixed/unknown 8 947 Mean Difference (IV, 
Random, 95% CI)
6.25 [1.60, 10.90]
14 Haemoglobin (by 
supplementation regimen)
9 1254 Mean Difference (IV, 
Random, 95% CI)
6.45 [2.36, 10.55]
 14.1 One supplement a 
week
6 699 Mean Difference (IV, 
Random, 95% CI)
7.35 [0.92, 13.77]
 14.2 Other intermittent 
regimen
3 555 Mean Difference (IV, 
Random, 95% CI)
4.68 [1.28, 8.08]
15 Haemoglobin (by sex) 9 1254 Mean Difference (IV, 
Random, 95% CI)
6.45 [2.36, 10.55]
 15.1 Girls 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 15.2 Boys 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 15.3 Mixed/unknown 9 1254 Mean Difference (IV, 
Random, 95% CI)
6.45 [2.36, 10.55]
16 Haemoglobin (by 
nutrient)
9 1254 Mean Difference (IV, 
Random, 95% CI)
6.01 [2.13, 9.89]
 16.1 Iron alone 5 744 Mean Difference (IV, 
Random, 95% CI)
3.81 [1.61, 6.01]
 16.2 Iron + folic acid 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 16.3 Iron + multiple 
micronutrients
5 510 Mean Difference (IV, 
Random, 95% CI)
8.46 [0.60, 16.32]
17 Iron deficiency (ALL) 3 431 Risk Ratio (M-H, 
Random, 95% CI)
0.24 [0.06, 0.91]
18 Ferritin (ALL) 4 310 Mean Difference (IV, 
Random, 95% CI)
13.15 [−2.28, 28.59]
19 Ferritin (by dose of iron 
in the intermittent group)
4 310 Mean Difference (IV, 
Random, 95% CI)
13.15 [−2.28, 28.59]
 19.1 25 mg or less/week 1 148 Mean Difference (IV, 
Random, 95% CI)
4.60 [−0.89, 10.09]
 19.2 Greater than 25 mg 
to 75 mg/week
3 162 Mean Difference (IV, 
Random, 95% CI)
16.91 [0.99, 32.82]
 19.3 Greater than 75 mg/
week
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
20 Ferritin (by duration of 
the supplementation)
4 310 Mean Difference (IV, 
Random, 95% CI)
13.15 [−2.28, 28.59]
 20.1 0 to three months 1 35 Mean Difference (IV, 
Random, 95% CI)
15.80 [−1.23, 32.83]
 20.2 More than three 
months
3 275 Mean Difference (IV, 
Random, 95% CI)
12.34 [−6.19, 30.87]
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21 Ferritin (by type of iron 
compound)
4 310 Mean Difference (IV, 
Random, 95% CI)
13.15 [−2.28, 28.59]
 21.1 Ferrous sulphate 3 236 Mean Difference (IV, 
Random, 95% CI)
16.12 [−1.81, 34.05]
 21.2 Ferrous fumarate 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 21.3 Other 1 74 Mean Difference (IV, 
Random, 95% CI)
2.46 [−14.37, 19.29]
22 Ferritin (by anaemia 
status at baseline)
4 310 Mean Difference (IV, 
Random, 95% CI)
13.15 [−2.28, 28.59]
 22.1 by anaemia status at 
baseline: anaemic
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 22.2 by anaemia status at 
baseline: non-anaemic
1 74 Mean Difference (IV, 
Random, 95% CI)
2.46 [−14.37, 19.29]
 22.3 by anaemia status at 
baseline: mixed/unknown
3 236 Mean Difference (IV, 
Random, 95% CI)
16.12 [−1.81, 34.05]
23 Ferritin (by 
supplementation regimen)
4 310 Mean Difference (IV, 
Random, 95% CI)
13.15 [−2.28, 28.59]
 23.1 One supplement a 
week
3 257 Mean Difference (IV, 
Random, 95% CI)
5.37 [0.39, 10.36]
 23.2 Other intermittent 
regimen
1 53 Mean Difference (IV, 
Random, 95% CI)
27.80 [22.88, 32.72]
24 Ferritin (by sex) 4 310 Mean Difference (IV, 
Random, 95% CI)
13.15 [−2.28, 28.59]
 24.1 Girls 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 24.2 Boys 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 24.3 Mixed/unknown 4 310 Mean Difference (IV, 
Random, 95% CI)
13.15 [−2.28, 28.59]
25 Ferritin (by nutrient) 4 310 Mean Difference (IV, 
Random, 95% CI)
11.15 [−1.92, 24.22]
 25.1 Iron alone 3 144 Mean Difference (IV, 
Random, 95% CI)
15.70 [−2.68, 34.08]
 25.2 Iron + folic acid 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 25.3 Iron + multiple 
micronutrients
2 166 Mean Difference (IV, 
Random, 95% CI)
4.58 [−2.27, 11.43]
26 All cause morbidity 
(ALL)
1 194 Risk Ratio (M-H, 
Random, 95% CI)
0.26 [0.03, 2.24]
27 Any side effects (ALL) 1 53 Risk Ratio (M-H, 
Random, 95% CI)
3.87 [0.19, 76.92]
28 Adherence (ALL) 2 289 Risk Ratio (M-H, 
Random, 95% CI)
1.04 [0.98, 1.09]
29 Mental development 
scale (ALL)
1 172 Mean Difference (IV, 
Random, 95% CI)
2.0 [−2.40, 6.40]
30 Orientation engagement 
(ALL)
1 172 Mean Difference (IV, 
Random, 95% CI)
8.40 [−1.79, 18.59]
31 Emotional regulation 
(ALL)
1 172 Mean Difference (IV, 
Random, 95% CI)
−2.5 [−11.58, 6.58]
32 Motor quality (ALL) 1 172 Mean Difference (IV, 
Random, 95% CI)
15.60 [7.66, 23.54]
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33 Psychomotor 
development index (ALL)
1 172 Mean Difference (IV, 
Random, 95% CI)
6.90 [1.35, 12.45]
34 HAZ 2 302 Mean Difference (IV, 
Random, 95% CI)
0.04 [−0.03, 0.11]
Comparison 4. Intermittent iron supplementation versus daily iron 
supplementation: children 0 – 59 months
Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
1 Anaemia (ALL) 3 770 Risk Ratio (M-H, 
Random, 95% CI)
1.26 [1.05, 1.51]
2 Haemoglobin (ALL) 14 2270 Mean Difference (IV, 
Random, 95% CI)
−0.75 [−1.80, 0.29]
3 Haemoglobin (by dose of 
elemental iron in the 
intermittent group)
14 2438 Mean Difference (IV, 
Random, 95% CI)
−0.82 [−1.82, 0.18]
 3.1 25 mg or less/week 3 536 Mean Difference (IV, 
Random, 95% CI)
−2.42 [−4.18, −0.66]
 3.2 Greater than 25 mg 
to 75 mg/week
11 1902 Mean Difference (IV, 
Random, 95% CI)
−0.45 [−1.59, 0.68]
 3.3 Greater than 75 mg/
week
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
4 Haemoglobin (by 
duration of 
supplementation)
14 2270 Mean Difference (IV, 
Random, 95% CI)
−0.75 [−1.80, 0.29]
 4.1 0 to three months 9 1309 Mean Difference (IV, 
Random, 95% CI)
−0.15 [−1.66, 1.36]
 4.2 More than three 
months
5 961 Mean Difference (IV, 
Random, 95% CI)
−1.53 [−2.95, −0.11]
5 Haemoglobin (by type of 
compound)
14 2270 Mean Difference (IV, 
Random, 95% CI)
−0.75 [−1.80, 0.29]
 5.1 Ferrous sulphate 13 2194 Mean Difference (IV, 
Random, 95% CI)
−0.85 [−1.91, 0.21]
 5.2 Ferrous fumarate 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 5.3 Other 1 76 Mean Difference (IV, 
Random, 95% CI)
1.96 [−3.05, 6.97]
6 Haemoglobin (by 
anaemia status at baseline)
14 2270 Mean Difference (IV, 
Random, 95% CI)
−0.75 [−1.80, 0.29]
 6.1 Anaemic 5 834 Mean Difference (IV, 
Random, 95% CI)
−0.57 [−2.81, 1.68]
 6.2 Non-anaemic 2 113 Mean Difference (IV, 
Random, 95% CI)
1.99 [−0.72, 4.70]
 6.3 Mixed/unknown 7 1323 Mean Difference (IV, 
Random, 95% CI)
−1.20 [−2.22, −0.19]
7 Haemoglobin (by 
supplementation regimen)
14 2270 Mean Difference (IV, 
Random, 95% CI)
−0.72 [−1.71, 0.27]
 7.1 One supplement a 
week
9 1054 Mean Difference (IV, 
Random, 95% CI)
−0.23 [−1.67, 1.21]
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Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
 7.2 Other intermittent 
regimen
7 1216 Mean Difference (IV, 
Random, 95% CI)
−1.14 [−2.57, 0.29]
8 Haemoglobin (by sex) 14 2270 Mean Difference (IV, 
Random, 95% CI)
−0.75 [−1.80, 0.29]
 8.1 Girls 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 8.2 Boys 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 8.3 Mixed/unknown 14 2270 Mean Difference (IV, 
Random, 95% CI)
−0.75 [−1.80, 0.29]
9 Haemoglobin (by 
nutrient)
14 2270 Mean Difference (IV, 
Random, 95% CI)
−0.75 [−1.80, 0.29]
 9.1 Iron alone 10 1490 Mean Difference (IV, 
Random, 95% CI)
−0.80 [−2.05, 0.46]
 9.2 Iron + folic acid 1 366 Mean Difference (IV, 
Random, 95% CI)
−2.40 [−4.94, 0.14]
 9.3 Iron + multiple 
micronutrients
3 414 Mean Difference (IV, 
Random, 95% CI)
0.57 [−1.84, 2.98]
10 Iron deficiency (ALL) 1 76 Risk Ratio (M-H, 
Random, 95% CI)
4.0 [1.23, 13.05]
11 Ferritin (ALL) 8 582 Mean Difference (IV, 
Random, 95% CI)
−3.10 [−6.59, 0.39]
12 Ferritin (by dose of 
elemental iron in the 
intermittent subgroup)
8 582 Mean Difference (IV, 
Random, 95% CI)
−2.22 [−6.03, 1.59]
 12.1 25 mg or less/week 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 12.2 Greater than 25 mg 
to 75 mg/week
8 582 Mean Difference (IV, 
Random, 95% CI)
−2.22 [−6.03, 1.59]
 12.3 Greater than 75 mg/
week
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
13 Ferritin (by duration of 
supplementation)
8 582 Mean Difference (IV, 
Random, 95% CI)
−3.10 [−6.59, 0.39]
 13.1 0 to three months 5 382 Mean Difference (IV, 
Random, 95% CI)
−3.02 [−7.91, 1.87]
 13.2 More than three 
months
3 200 Mean Difference (IV, 
Random, 95% CI)
−1.63 [−5.88, 2.62]
14 Ferritin (by type of 
compound)
8 582 Mean Difference (IV, 
Random, 95% CI)
−3.10 [−6.59, 0.39]
 14.1 Ferrous sulphate 7 506 Mean Difference (IV, 
Random, 95% CI)
−2.69 [−6.42, 1.05]
 14.2 Ferrous fumarate 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 14.3 Other 1 76 Mean Difference (IV, 
Random, 95% CI)
−9.03 [−23.95, 5.89]
15 Ferritin (by anaemia 
status at baseline)
8 582 Mean Difference (IV, 
Random, 95% CI)
−3.70 [−8.25, 0.86]
 15.1 Anaemic 4 225 Mean Difference (IV, 
Random, 95% CI)
−4.47 [−15.45, 6.52]
 15.2 Non-anaemic 3 167 Mean Difference (IV, 
Random, 95% CI)
−2.67 [−5.89, 0.54]
 15.3 Mixed/unknown 2 190 Mean Difference (IV, 
Random, 95% CI)
−1.53 [−5.23, 2.17]
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Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
16 Ferritin (by 
supplementation regimen)
8 582 Mean Difference (IV, 
Random, 95% CI)
−3.27 [−7.87, 1.33]
 16.1 One supplement a 
week
5 291 Mean Difference (IV, 
Random, 95% CI)
−6.21 [−12.98, 0.55]
 16.2 Other intermittent 
regimen
4 291 Mean Difference (IV, 
Random, 95% CI)
−0.81 [−3.89, 2.27]
17 Ferritin (by sex) 8 582 Mean Difference (IV, 
Random, 95% CI)
−3.10 [−6.58, 0.39]
 17.1 Girls 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 17.2 Boys 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 17.3 Mixed/unknown 8 582 Mean Difference (IV, 
Random, 95% CI)
−3.10 [−6.58, 0.39]
18 Ferritin (by nutrient) 8 582 Mean Difference (IV, 
Random, 95% CI)
−3.10 [−6.59, 0.39]
 18.1 Iron alone 7 506 Mean Difference (IV, 
Random, 95% CI)
−2.69 [−6.42, 1.05]
 18.2 Iron + folic acid 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 18.3 Iron + multiple 
micronutrients
1 76 Mean Difference (IV, 
Random, 95% CI)
−9.03 [−23.95, 5.89]
19 All cause morbidity 
(ALL)
1 522 Risk Ratio (M-H, 
Random, 95% CI)
0.98 [0.82, 1.16]
20 Diarrhoea (ALL) 1 45 Risk Ratio (M-H, 
Random, 95% CI)
2.88 [0.12, 67.03]
21 Any side effects (ALL) 4 895 Risk Ratio (M-H, 
Random, 95% CI)
0.60 [0.19, 1.87]
22 Adherence (ALL) 3 1185 Risk Ratio (M-H, 
Random, 95% CI)
1.29 [1.15, 1.45]
23 HAZ 1 109 Std. Mean Difference 
(IV, Random, 95% CI)
−0.15 [−0.52, 0.23]
24 WAZ 1 109 Std. Mean Difference 
(IV, Random, 95% CI)
−0.44 [−0.82, −0.06]
Comparison 5. Intermittent iron supplementation versus placebo or no 
intervention: children 5 – 12 years
Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
1 Anaemia (ALL) 6 1166 Risk Ratio (M-H, 
Random, 95% CI)
0.54 [0.33, 0.90]
2 Anaemia (by dose) 6 1166 Risk Ratio (M-H, 
Random, 95% CI)
0.54 [0.33, 0.90]
 2.1 25 mg or less/week 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
 2.2 Greater than 25 mg 
to 75 mg/week
4 755 Risk Ratio (M-H, 
Random, 95% CI)
0.47 [0.21, 1.02]
 2.3 Greater than 75 mg/
week
2 411 Risk Ratio (M-H, 
Random, 95% CI)
0.71 [0.48, 1.04]
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Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
3 Anaemia (by duration) 6 1166 Risk Ratio (M-H, 
Random, 95% CI)
0.54 [0.33, 0.90]
 3.1 0 to three months 2 848 Risk Ratio (M-H, 
Random, 95% CI)
0.77 [0.67, 0.89]
 3.2 More than three 
months
4 318 Risk Ratio (M-H, 
Random, 95% CI)
0.44 [0.16, 1.24]
4 Anaemia (by type of 
compound)
6 1166 Risk Ratio (M-H, 
Random, 95% CI)
0.54 [0.33, 0.90]
 4.1 Ferrous sulphate 6 1166 Risk Ratio (M-H, 
Random, 95% CI)
0.54 [0.33, 0.90]
 4.2 Ferrous fumarate 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
 4.3 Other 0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
5 Anaemia (by anaemia 
status at baseline)
6 1166 Risk Ratio (M-H, 
Random, 95% CI)
0.54 [0.33, 0.90]
 5.1 Anaemic 1 117 Risk Ratio (M-H, 
Random, 95% CI)
0.14 [0.07, 0.27]
 5.2 Non-anaemic 1 64 Risk Ratio (M-H, 
Random, 95% CI)
0.78 [0.27, 2.31]
 5.3 Mixed/unknown 4 985 Risk Ratio (M-H, 
Random, 95% CI)
0.73 [0.54, 0.98]
6 Anaemia (by intermittent 
regimen)
6 1166 Risk Ratio (M-H, 
Random, 95% CI)
0.54 [0.33, 0.90]
 6.1 One supplement a 
week
6 1166 Risk Ratio (M-H, 
Random, 95% CI)
0.54 [0.33, 0.90]
 6.2 Other intermittent 
regimen
0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
7 Anaemia (by sex) 6 1166 Risk Ratio (M-H, 
Random, 95% CI)
0.59 [0.40, 0.86]
 7.1 Girls 1 248 Risk Ratio (M-H, 
Random, 95% CI)
0.75 [0.59, 0.95]
 7.2 Boys 1 253 Risk Ratio (M-H, 
Random, 95% CI)
0.81 [0.66, 1.00]
 7.3 Mixed/unknown 5 665 Risk Ratio (M-H, 
Random, 95% CI)
0.49 [0.24, 1.01]
8 Anaemia (by nutrient) 6 1166 Risk Ratio (M-H, 
Random, 95% CI)
0.54 [0.33, 0.90]
 8.1 Iron alone 4 573 Risk Ratio (M-H, 
Random, 95% CI)
0.39 [0.17, 0.90]
 8.2 Iron + folic acid 2 593 Risk Ratio (M-H, 
Random, 95% CI)
0.83 [0.66, 1.03]
 8.3 Iron + multiple 
micronutrients
0 0 Risk Ratio (M-H, 
Random, 95% CI)
0.0 [0.0, 0.0]
9 Haemoglobin (ALL) 10 1778 Mean Difference (IV, 
Random, 95% CI)
4.04 [0.30, 7.78]
10 Haemoglobin (by dose 
of elemental iron in the 
intermittent group)
10 1778 Mean Difference (IV, 
Random, 95% CI)
4.04 [0.30, 7.78]
 10.1 25 mg or less/week 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 10.2 Greater than 25 mg 
to 75 mg/week
6 1129 Mean Difference (IV, 
Random, 95% CI)
5.24 [−0.78, 11.26]
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Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
 10.3 Group: greater than 
75 mg/week
4 649 Mean Difference (IV, 
Random, 95% CI)
1.84 [0.25, 3.44]
11 Haemoglobin (by 
duration of the 
supplementation)
10 1778 Mean Difference (IV, 
Random, 95% CI)
4.04 [0.30, 7.78]
 11.1 0 to three months 3 973 Mean Difference (IV, 
Random, 95% CI)
3.13 [1.49, 4.77]
 11.2 More than three 
months
7 805 Mean Difference (IV, 
Random, 95% CI)
4.38 [−1.20, 9.96]
12 Haemoglobin (by type 
of iron compound)
10 1778 Mean Difference (IV, 
Random, 95% CI)
4.04 [0.30, 7.78]
 12.1 Ferrous sulphate 7 1415 Mean Difference (IV, 
Random, 95% CI)
4.59 [−0.30, 9.47]
 12.2 Ferrous fumarate 1 125 Mean Difference (IV, 
Random, 95% CI)
3.4 [−4.09, 10.89]
 12.3 Other 2 238 Mean Difference (IV, 
Random, 95% CI)
1.79 [−1.25, 4.84]
13 Haemoglobin (by 
anaemia status at baseline)
10 1778 Mean Difference (IV, 
Random, 95% CI)
4.04 [0.30, 7.78]
 13.1 Anaemic 1 115 Mean Difference (IV, 
Random, 95% CI)
18.30 [15.55, 21.05]
 13.2 Non-anaemic 1 64 Mean Difference (IV, 
Random, 95% CI)
2.0 [−2.46, 6.46]
 13.3 Mixed/unknown 8 1599 Mean Difference (IV, 
Random, 95% CI)
2.37 [1.17, 3.57]
14 Haemoglobin (by 
supplementation regimen)
10 1868 Mean Difference (IV, 
Random, 95% CI)
4.04 [0.45, 7.62]
 14.1 One supplement a 
week
9 1647 Mean Difference (IV, 
Random, 95% CI)
4.43 [0.21, 8.65]
 14.2 Other intermittent 
regimen
2 221 Mean Difference (IV, 
Random, 95% CI)
1.17 [−1.27, 3.61]
15 Haemoglobin (by sex) 10 1778 Mean Difference (IV, 
Random, 95% CI)
4.03 [0.51, 7.55]
 15.1 Girls 1 248 Mean Difference (IV, 
Random, 95% CI)
4.0 [0.83, 7.17]
 15.2 Boys 1 253 Mean Difference (IV, 
Random, 95% CI)
3.70 [0.58, 6.82]
 15.3 Mixed/unknown 9 1277 Mean Difference (IV, 
Random, 95% CI)
4.05 [−0.37, 8.46]
16 Haemoglobin (by 
nutrient)
10 1778 Mean Difference (IV, 
Random, 95% CI)
4.04 [0.30, 7.78]
 16.1 Iron alone 6 1022 Mean Difference (IV, 
Random, 95% CI)
4.98 [−0.71, 10.68]
 16.2 Iron + folic acid 4 756 Mean Difference (IV, 
Random, 95% CI)
2.91 [0.65, 5.16]
 16.3 Iron + multiple 
micronutrients
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
17 Ferritin (ALL) 1 240 Mean Difference (IV, 
Random, 95% CI)
16.6 [11.12, 22.08]
18 All cause morbidity 
(ALL)
1 194 Risk Ratio (M-H, 
Random, 95% CI)
0.26 [0.03, 2.24]
19 Any side effects (ALL) 1 53 Risk Ratio (M-H, 
Random, 95% CI)
3.87 [0.19, 76.92]
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Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
20 Nausea 1 64 Risk Ratio (M-H, 
Random, 95% CI)
2.82 [0.12, 66.82]
21 IQ (ALL) 1 252 Mean Difference (IV, 
Random, 95% CI)
−3.00 [−5.96, −0.04]
22 Thai language (ALL) 1 208 Mean Difference (IV, 
Random, 95% CI)
−0.30 [−0.50, −0.09]
23 Mathematics (ALL) 1 233 Mean Difference (IV, 
Random, 95% CI)
−0.27 [−0.44, −0.10]
24 Increase in steps 
climbed (ALL)
1 60 Mean Difference (IV, 
Random, 95% CI)
8.0 [−0.72, 16.72]
25 WAZ 1 64 Std. Mean Difference 
(IV, Random, 95% CI)
−0.24 [−0.74, 0.25]
26 HAZ 1 64 Mean Difference (IV, 
Fixed, 95% CI)
−0.24 [−0.69, 0.21]
Comparison 6. Intermittent iron supplementation versus daily iron 
supplementation: children 5 – 12 years
Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
1 Anaemia (ALL) 2 145 Risk Ratio (M-H, 
Random, 95% CI)
0.95 [0.47, 1.91]
2 Haemoglobin (ALL) 5 581 Mean Difference (IV, 
Random, 95% CI)
−0.31 [−2.59, 1.97]
3 Haemoglobin (by dose 
of elemental iron)
5 581 Mean Difference (IV, 
Random, 95% CI)
−0.31 [−2.59, 1.97]
 3.1 25 mg or less/week 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 3.2 Greater than 25 mg 
to 75 mg/week
3 444 Mean Difference (IV, 
Random, 95% CI)
−1.10 [−3.01, 0.80]
 3.3 Intermittent group: 
greater than 75 mg/week
2 137 Mean Difference (IV, 
Random, 95% CI)
1.00 [−4.68, 6.68]
4 Haemoglobin (by 
duration of the 
supplementation)
5 581 Mean Difference (IV, 
Random, 95% CI)
−0.31 [−2.59, 1.97]
 4.1 0 to three months 2 155 Mean Difference (IV, 
Random, 95% CI)
0.32 [−6.54, 7.18]
 4.2 More than three 
months
3 426 Mean Difference (IV, 
Random, 95% CI)
−0.64 [−2.12, 0.84]
5 Haemoglobin (by type 
of compound)
5 581 Mean Difference (IV, 
Random, 95% CI)
−0.31 [−2.59, 1.97]
 5.1 Ferrous sulphate 4 539 Mean Difference (IV, 
Random, 95% CI)
0.04 [−2.63, 2.71]
 5.2 Ferrous fumarate 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 5.3 Other 1 42 Mean Difference (IV, 
Random, 95% CI)
−2.0 [−5.43, 1.43]
6 Haemoglobin (by 
baseline prevalence of 
anaemia)
5 581 Mean Difference (IV, 
Random, 95% CI)
−0.31 [−2.59, 1.97]
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Outcome or subgroup 
title No. of studies No. of participants Statistical method Effect size
 6.1 Anaemic 3 271 Mean Difference (IV, 
Random, 95% CI)
0.37 [−3.44, 4.17]
 6.2 Non-anaemic 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 6.3 Mixed/unknown 2 310 Mean Difference (IV, 
Random, 95% CI)
−1.22 [−3.08, 0.63]
7 Haemoglobin (by 
supplementation 
regimen)
5 581 Mean Difference (IV, 
Random, 95% CI)
−0.31 [−2.59, 1.97]
 7.1 by supplementation 
regimen: one supplement 
a week
5 581 Mean Difference (IV, 
Random, 95% CI)
−0.31 [−2.59, 1.97]
 7.2 by supplementation 
regimen: other 
intermittent regimen
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
8 Haemoglobin (by sex) 5 581 Mean Difference (IV, 
Random, 95% CI)
−0.31 [−2.59, 1.97]
 8.1 Girls 1 42 Mean Difference (IV, 
Random, 95% CI)
−2.0 [−5.43, 1.43]
 8.2 Boys 0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
 8.3 Mixed/unknown 4 539 Mean Difference (IV, 
Random, 95% CI)
0.04 [−2.63, 2.71]
9 Haemoglobin (by 
nutrient)
5 581 Mean Difference (IV, 
Random, 95% CI)
−0.31 [−2.59, 1.97]
 9.1 Iron alone 4 539 Mean Difference (IV, 
Random, 95% CI)
0.04 [−2.63, 2.71]
 9.2 Iron + folic acid 1 42 Mean Difference (IV, 
Random, 95% CI)
−2.0 [−5.43, 1.43]
 9.3 By nutrient: iron + 
multiple micronutrients
0 0 Mean Difference (IV, 
Random, 95% CI)
0.0 [0.0, 0.0]
10 Ferritin (ALL) 2 320 Mean Difference (IV, 
Random, 95% CI)
−11.57 [−38.75, 15.61]
11 All cause morbidity 
(ALL)
1 77 Risk Ratio (M-H, 
Random, 95% CI)
0.92 [0.68, 1.24]
12 Diarrhoea (ALL) 1 77 Risk Ratio (M-H, 
Random, 95% CI)
1.12 [0.56, 2.22]
13 Adherence (ALL) 2 245 Risk Ratio (M-H, 
Random, 95% CI)
1.29 [0.44, 3.75]
14 IQ (ALL) 1 252 Mean Difference (IV, 
Random, 95% CI)
−3.00 [−5.96, −0.04]
15 Thai language (ALL) 1 208 Mean Difference (IV, 
Random, 95% CI)
−0.30 [−0.50, −0.09]
16 Mathematics (ALL) 1 233 Mean Difference (IV, 
Random, 95% CI)
−0.27 [−0.44, −0.10]
17 Increase in steps 
climbed (ALL)
1 65 Mean Difference (IV, 
Random, 95% CI)
−5.0 [−13.34, 3.34]
18 HAZ 2 170 Std. Mean Difference 
(IV, Random, 95% CI)
−0.32 [−1.26, 0.63]
19 WAZ 2 170 Std. Mean Difference 
(IV, Random, 95% CI)
0.09 [−0.21, 0.39]
20 WAZ 2 302 Std. Mean Difference 
(IV, Random, 95% CI)
0.04 [−0.34, 0.41]
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 1 Anaemia (ALL).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 2 Anaemia (by dose of elemental iron in the intermittent group).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 3 Anaemia (by duration of the intervention).
De-Regil et al. Page 69














Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 4 Anaemia (by type of compound).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 5 Anaemia (by anaemia status at baseline).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 6 Anaemia (by intermittent regimen).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 7 Anaemia (by sex).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 8 Anaemia (by nutrient).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 9 Haemoglobin (ALL).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 10 Haemoglobin (by by dose of elemental iron in the intermittent 
group).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 11 Haemoglobin (by duration of the intervention).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 12 Haemoglobin (by type of compound).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 13 Haemoglobin (by anaemia status at baseline).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 14 Haemoglobin (by intermittent regimen).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 15 Haemoglobin (by sex).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 16 Haemoglobin (by nutrient).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 17 Iron deficiency (ALL).
Analysis 1.18. 
Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 18 Ferritin (ALL).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 19 Ferritin (by dose of elemental iron in the intermittent group).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 20 Ferritin (by duration of the supplementation).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 21 Ferritin (by type of compound).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 22 Ferritin (by anaemia status at baseline).
Analysis 1.23. 
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 23 Ferritin (by supplementation regimen).
Analysis 1.24. 
Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 24 Ferritin (by sex).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 25 Ferritin (by nutrient).
Analysis 1.26. 
Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 26 All cause morbidity (ALL).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 27 Any side effects (ALL).
Analysis 1.28. 
Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 28 Nausea.
Analysis 1.29. 
Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 29 Adherence (ALL).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 30 Mental development scale (ALL).
Analysis 1.31. 
Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 31 Orientation engagement (ALL).
Analysis 1.32. 
Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 32 Emotional regulation (ALL).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 33 Motor quality (ALL).
Analysis 1.34. 
Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 34 Psychomotor development index (ALL).
Analysis 1.35. 
Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 35 IQ (ALL).
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 36 Thai language (ALL).
Analysis 1.37. 
Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 37 Mathematics (ALL).
Analysis 1.38. 
Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 38 WAZ.
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Comparison 1 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 12 years, Outcome 39 HAZ.
Analysis 2.1. 
Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 1 Anaemia (ALL).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 2 Anaemia (by dose of elemental iron in the intermittent group).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 3 Anaemia (by duration of the supplementation).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 4 Anaemia (by type of compound).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 5 Anaemia (by anaemia status at baseline).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 6 Anaemia (by supplementation regimen).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 7 Anaemia (by sex).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 8 Anaemia (by nutrient).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 9 Haemoglobin (ALL).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 10 Haemoglobin (by dose of elemental iron in the intermittent 
group).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 11 Haemoglobin (by duration of the supplementation).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 12 Haemoglobin (by type of compound).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 13 Haemoglobin (by anaemia status at baseline).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 14 Haemoglobin (by supplementation regimen).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 15 Haemoglobin (by sex).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 16 Haemoglobin (by nutrient).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 17 Iron deficiency (ALL).
Analysis 2.18. 
Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 18 Ferritin (ALL).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 19 Ferritin (by dose of elemental iron in the intermittent group).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 20 Ferritin (by duration of the supplementation).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 21 Ferritin (by type of compound).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 22 Ferritin (by anaemia status at baseline).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 23 Ferritin (by supplementation regimen).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 24 Ferritin (by sex).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 25 Ferritin (by nutrient).
Analysis 2.26. 
Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 26 Increase in steps climbed (ALL).
De-Regil et al. Page 117














Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 27 All cause morbidity (ALL).
Analysis 2.28. 
Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 28 Diarrhoea (ALL).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 29 Any side effects (ALL).
Analysis 2.30. 
Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 30 Adherence (ALL).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 31 IQ (ALL).
Analysis 2.32. 
Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 32 Thai language (ALL).
Analysis 2.33. 
Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 33 Mathematics (ALL).
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Comparison 2 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 12 years, Outcome 34 HAZ.
Analysis 3.1. 
Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 1 Anaemia (ALL).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 2 Anaemia (by dose of elemental iron in the intermittent group).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 3 Anaemia (by duration of the supplementation).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 4 Anaemia (by type of compound).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 5 Anaemia (by anaemia status at baseline).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 6 Anaemia (by intermittent regimen).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 7 Anaemia (by sex).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 8 Anaemia (by nutrient).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 9 Haemoglobin (ALL).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 10 Haemoglobin (by dose of elemental iron in the intermittent 
group).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 11 Haemoglobin (by duration of the supplementation).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 12 Haemoglobin (by type of iron compound).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 13 Haemoglobin (by anaemia status at baseline).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 14 Haemoglobin (by supplementation regimen).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 15 Haemoglobin (by sex).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 16 Haemoglobin (by nutrient).
Analysis 3.17. 
Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 17 Iron deficiency (ALL).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 18 Ferritin (ALL).
Analysis 3.19. 
Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 19 Ferritin (by dose of iron in the intermittent group).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 20 Ferritin (by duration of the supplementation).
Analysis 3.21. 
Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 21 Ferritin (by type of iron compound).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 22 Ferritin (by anaemia status at baseline).
Analysis 3.23. 
Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 23 Ferritin (by supplementation regimen).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 24 Ferritin (by sex).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 25 Ferritin (by nutrient).
Analysis 3.26. 
Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 26 All cause morbidity (ALL).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 27 Any side effects (ALL).
Analysis 3.28. 
Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 28 Adherence (ALL).
Analysis 3.29. 
Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 29 Mental development scale (ALL).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 30 Orientation engagement (ALL).
Analysis 3.31. 
Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 31 Emotional regulation (ALL).
Analysis 3.32. 
Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 32 Motor quality (ALL).
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Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 33 Psychomotor development index (ALL).
Analysis 3.34. 
Comparison 3 Intermittent iron supplementation versus placebo or no intervention: children 
0 – 59 months, Outcome 34 HAZ.
Analysis 4.1. 
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 1 Anaemia (ALL).
Analysis 4.2. 
Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 2 Haemoglobin (ALL).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 3 Haemoglobin (by dose of elemental iron in the intermittent 
group).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 4 Haemoglobin (by duration of supplementation).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 5 Haemoglobin (by type of compound).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 6 Haemoglobin (by anaemia status at baseline).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 7 Haemoglobin (by supplementation regimen).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 8 Haemoglobin (by sex).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 9 Haemoglobin (by nutrient).
Analysis 4.10. 
Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 10 Iron deficiency (ALL).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 11 Ferritin (ALL).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 12 Ferritin (by dose of elemental iron in the intermittent subgroup).
Analysis 4.13. 
Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 13 Ferritin (by duration of supplementation).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 14 Ferritin (by type of compound).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 15 Ferritin (by anaemia status at baseline).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 16 Ferritin (by supplementation regimen).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 17 Ferritin (by sex).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 18 Ferritin (by nutrient).
Analysis 4.19. 
Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 19 All cause morbidity (ALL).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 20 Diarrhoea (ALL).
Analysis 4.21. 
Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 21 Any side effects (ALL).
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Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 22 Adherence (ALL).
Analysis 4.23. 
Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 23 HAZ.
Analysis 4.24. 
De-Regil et al. Page 161













Comparison 4 Intermittent iron supplementation versus daily iron supplementation: children 
0 – 59 months, Outcome 24 WAZ.
Analysis 5.1. 
Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 1 Anaemia (ALL).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 2 Anaemia (by dose).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 3 Anaemia (by duration).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 4 Anaemia (by type of compound).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 5 Anaemia (by anaemia status at baseline).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 6 Anaemia (by intermittent regimen).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 7 Anaemia (by sex).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 8 Anaemia (by nutrient).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 9 Haemoglobin (ALL).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 10 Haemoglobin (by dose of elemental iron in the intermittent 
group).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 11 Haemoglobin (by duration of the supplementation).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 12 Haemoglobin (by type of iron compound).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 13 Haemoglobin (by anaemia status at baseline).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 14 Haemoglobin (by supplementation regimen).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 15 Haemoglobin (by sex).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 16 Haemoglobin (by nutrient).
Analysis 5.17. 
Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 17 Ferritin (ALL).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 18 All cause morbidity (ALL).
Analysis 5.19. 
Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 19 Any side effects (ALL).
Analysis 5.20. 
Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 20 Nausea.
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 21 IQ (ALL).
Analysis 5.22. 
Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 22 Thai language (ALL).
Analysis 5.23. 
Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 23 Mathematics (ALL).
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Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 24 Increase in steps climbed (ALL).
Analysis 5.25. 
Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 25 WAZ.
Analysis 5.26. 
Comparison 5 Intermittent iron supplementation versus placebo or no intervention: children 
5 – 12 years, Outcome 26 HAZ.
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Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 1 Anaemia (ALL).
Analysis 6.2. 
Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 2 Haemoglobin (ALL).
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Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 3 Haemoglobin (by dose of elemental iron).
Analysis 6.4. 
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Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 4 Haemoglobin (by duration of the supplementation).
Analysis 6.5. 
Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 5 Haemoglobin (by type of compound).
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Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 6 Haemoglobin (by baseline prevalence of anaemia).
Analysis 6.7. 
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Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 7 Haemoglobin (by supplementation regimen).
Analysis 6.8. 
Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 8 Haemoglobin (by sex).
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Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 9 Haemoglobin (by nutrient).
Analysis 6.10. 
Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 10 Ferritin (ALL).
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Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 11 All cause morbidity (ALL).
Analysis 6.12. 
Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 12 Diarrhoea (ALL).
Analysis 6.13. 
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Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 13 Adherence (ALL).
Analysis 6.14. 
Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 14 IQ (ALL).
Analysis 6.15. 
Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 15 Thai language (ALL).
Analysis 6.16. 
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Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 16 Mathematics (ALL).
Analysis 6.17. 
Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 17 Increase in steps climbed (ALL).
Analysis 6.18. 
Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 18 HAZ.
Analysis 6.19. 
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Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 19 WAZ.
Analysis 6.20. 
Comparison 6 Intermittent iron supplementation versus daily iron supplementation: children 
5 – 12 years, Outcome 20 WAZ.
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WHO/CDC logic model for micronutrients interventions in public health (with permission 
from WHO)
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Risk of bias graph: review authors’ judgements about each risk of bias item presented as 
percentages across all included studies.
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Risk of bias summary: review authors’ judgements about each risk of bias item for each 
included study.
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Table 1
Intermittent iron supplementation versus placebo or no intervention by age group
Outcome Comparison 3
Children 0 to 59 months
Relative effect
(95% CI)
Number of trials and effective sample size
Comparison 5
Children 60 months and older
Relative effect
(95% CI)
Number of trials and effective sample size
Anaemia RR 0.43
(0.23 to 0.80)
4 trials, 658 children
RR 0.54,
(0.33 to 0.90)
6 trials, 1166 children
Haemoglobin (g/L) MD 6.45
(2.36 to 10.55)
9 trials, 1254 children
MD 4.04
(0.30 to 7.78)
10 trials, 1778 children
4.04 [0.30, 7.78]




3 trials, 431 children
None of the trials reported on this outcome
Ferritin (μg/L) MD 13.15
(−2.28 to 28.59)
4 trials, 310 children
MD 16.60
(11.12 to 22.08)
1 trial, 240 children
Adherence RR 1.04
(0.98 to 1.09)
2 trials, 289 children
None of the trials reported on this outcome
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Table 2
Intermittent versus daily iron supplementation by age group
Outcome Comparison 4
Children 0 to 59 months
Relative effect
(95% CI)
Number of trials and effective sample size
Comparison 6
Children 60 months and older
Relative effect
(95% CI)
Number of trials and effective sample size
Anaemia RR 1.26
(1.05 to 1.51)
3 trials, 770 children
RR 0.95
(0.47 to 1.91)
2 trials, 145 children
Haemoglobin (g/L) MD −0.75
(−1.80 to 0.29)
14 trials, 2270 children
MD −0.31
(−2.59 to 1.97)
5 trials, 581 children
Iron deficiency RR 4.00
(1.23 to 13.05)
1 trial, 76 children
None of the trials reported on this outcome
Ferritin (μg/L) MD −3.10
(−6.59 to 0.39)
8 trials, 582 children
MD −11.57
(−38.75 to 15.61)
2 trials, 320 children
Adherence RR 1.29
(1.15 to 1.45)
3 trials, 1185 children
RR 1.29
(0.44 to 3.75)
2 trials, 245 children
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Table 3
Characteristics of included studies [ordered by study ID]
Aguayo 2000
Methods Randomised double-blind placebo-controlled trial. 2-arm design with individual randomisation
Participants 73 children (64 children followed up), both sexes (30 females (47%)), aged 6–11.9 years (9 years in average), from 
outskirts of La Paz, Bolivia (4000 m above sea level). Inclusion criterion: non-anaemic. Socioeconomic status not reported
Interventions Participants were allocated to one of the following groups:
Group 1 (n = 37): children received weekly tablets containing iron. The iron dose was calculated to provide children with 3 
mg of elemental iron per kg of body weight (approximately 85 mg of iron per week). The supplement consisted of two 
types of tablets containing either 20 mg or 36 mg of elemental iron (as ferrous sulphate). These tablets were used in 
combination to adjust the dose to the child’s weight;
Group 2 (n = 36): children received a placebo similar in colour and appearance to the iron supplement
Length of the intervention: 18 weeks
Outcomes Haemoglobin, mean haemoglobin change, anaemia, anthropometric measurements (weight for age Z-score, height for age 
Z-score and mid-upper arm circumference), and side effects
Notes A teacher trained by the principal investigator was responsible for delivering the iron tablets in the classrooms. All children 
completed at least 17 doses. Pills were administered on Wednesday and students who were not in school on Wednesday 
were administered the supplements on Thursday
Z-scores used the National Center for Health Statistics data as a reference
Non-malaria area.
Risk of bias





Low risk Children were randomly assigned to the treatment or the control 




Low risk A teacher trained by the principal investigator was responsible for 
the delivery of the iron tablets in the classrooms. The teacher was 
provided with a list of the names of the children and the number and 
kind of pills (colour coded) each child should take every week. 
Neither the teacher nor the assistant were aware of the composition 







Low risk Tablets were similar in appearance.
Participants:Children were not aware of the treatment.
Personnel: Neither the teacher nor his assistant were aware of the 
composition of the tablets delivered to the children





Low risk A complete set of data was obtained for 33 children in the treatment 




Unclear risk There is insufficient information to permit judgement.
Other bias Low risk No significant differences at baseline in the variables studied, and 
females/males ratio.
No differences at baseline between those that completed the study 
and those who dropped out
Arcanjo 2011 (C)
Methods Cluster-randomised, placebo-controlled double-blind trial. 2 arm design with randomisation at classroom level
Participants 106 preschool children, both sexes (56 females (52.8%), aged 5 years. The study was conducted in a public school located 
in the City of Sobral, in the northeast of Brazil between September and December 2009. Exclusion criteria: current 
supplement intake. Baseline prevalence of anaemia: 58.5%. Forty per cent of the families had an income <300 USD
Interventions Classrooms were allocated to one of the following groups:
Group 1 (3 classrooms, 52 children): children received once a week 50 mg of elemental iron (as ferrous sulphate 
heptahydrate) once a week;
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Group 2 (3 classrooms, 54 children): children received once a week a placebo (on Wednesdays). The placebo contained 2 
ml of natural colour additive, annatto, which is odourless and tasteless, providing a yellow-orange colour similar to that of 
the elemental iron used in the study
Length of the intervention: 14 weeks.
Outcomes Haemoglobin, hematocrit and anaemia (Hb less than 115 g/L)
Notes The supplements were administered on Wednesdays. The supplement was administered by a teacher using a plastic medical 
syringe with scale to squirt the composition into the child’s mouth. The syringes were prepared on an individual basis by 
medical staff
We adjusted the results of this study to account for the effect of clustering in data; the estimated effective sample size was 
used in the analyses.
Malaria endemicity not reported.
Risk of bias





Low risk An allocation code was generated with a table of random numbers 




Low risk The study used a placebo. Since randomisation occurred at 






Low risk Participants: were not aware of different interventions.
Personnel: the teacher was not aware of the treatment nor involved 
in data collection
Ouctome assessors: the staff involved in data collection was blinded 





Low risk During the study, there were 2 (3.8%) dropouts in group 1, and 5 




Unclear risk There is insufficient information to permit judgement.
Other bias Unclear risk The data was not adjusted by the effect of clustering.
Anaemia prevalence at baseline was not balanced between groups: 
48% in group 1 and 69% in group 2 (but similar concentrations of 
haemoglobin)
Awasthi 2005 (C)
Methods Cluster-randomised community effectiveness trial. 2 arm design with randomisation at subcentre level
Participants 803 children, both sexes (730 females (45.4%)), aged 3–6 years, living in sub centres of Shahpur Baxolia and Sipa 
Hidayatpur from Nindura Block, Barabanki district, North India. Exclusion criteria: those without written informed 
consent, or those likely to move within the next three months. Children identified as severely anaemic were given iron and 
folic acid in therapeutic doses under close supervision (but does not say they were excluded). Baseline prevalence of 
anaemia in children was 53.79 %. Socioeconomic status not reported
Interventions Sub centres were allocated to one of the following groups:
Group 1 (n = 403): children in Shahpur Baxolia sub centre received tablets containing 20 mg elemental iron (presumably in 
form of ferrous sulphate) iron and 100 μg (0.1 mg) folic acid twice a week, on fixed days (Wednesday and Saturday);
Group 2 (n = 400): children in Sipa Hidayatpur sub centre received one tablet daily
Length of the intervention: one year.
Outcomes Haemoglobin, haemoglobin mean change, anaemia, and adherence
Notes Iron and folic acid was given to the children either by the Anganwadi worker, if they were registered and used the informal 
education services of the Integrated Child Health Development Services, or by the mother for non-registered children. 
Mothers could pick up monthly supplies for their children one day a month from an Anganwadi centre
A monitoring in-charge was responsible for each intervention type. He visited each Anganwadi centre every 15 days to take 
an account of the IFA distributed to registered children. The monitor in-charge also visited 20 randomly selected houses of 
non-registered children and collected information about the IFA tablet intake, including the number of pills consumed
Sample size was calculated taking into consideration a design effect of 2. We adjusted the results of this study to account 
for the effect of clustering in data; the estimated effective sample size was used in the analyses.
Malaria endemicity not reported.
Risk of bias
Bias Authors’ judgement Support for judgement


















Unclear risk For this study all sub centres were listed alphabetically, serially 
numbered, and two were selected by random for assessment of the 
interventional strategies, one per subcentre. It is unclear whether the 




Low risk Since the intervention was allocated at sub-centre level, it is unlikely 






High risk Participants: Not reported.
Personnel: Not reported.





Low risk Loss to follow up 8.34% at one year with no difference between 




Unclear risk There is insufficient information to permit judgement.
Other bias High risk Some children had directly observed intake and others were given 
the pills by the mother. About 1/3 of the children are registered to 
obtain services of the Anganwadi centre (under the ICDS services) 
and this had a differential effect on supplementation (favouring 
registered children)
Results did not account for the cluster effect.
Baqui 2003
Methods Randomised, double-blinded community-based trial. 5-arm design with individual randomisation
Participants 799 Bangladeshi children, both sexes (406 females (50.8%)), enrolled at 5–6 months of age for a 6 month study (12 mo old 
when completed). Potential families were identified through ongoing health and demographic surveillance system. 
Participants were eligible if did not receive infant formula, were not severely malnourished (mid-upper arm circumference 
>110mm), not severely anaemic (haemoglobin >90 g/L), with no obvious neurologic disorders, physical disabilities, or 
chronic illnesses that might affect feeding, activity, and cognitive development. There were no differences in monthly 
income, household size or father’s education across the arms. Approximately two-thirds of the children were mildly 
anaemic at recruitment
Interventions Infants were randomly allocated to one of the following groups:
Group 1 (n = 154): Infants received once a week multiple micronutrients in a dose that doubled the recommended dietary 
allowance (WHO standards) of thiamine, niacin, folic acid, pantothenic acid, iodine, copper, manganese, selenium, and 
vitamins C, D, E, B6 and B12. It contained 20 mg elemental iron (as ferrous sulphate), 20 mg elemental zinc (as zinc 
acetate), and 1 mg riboflavin
Group 2 (n = 161): Infants received once a week 20 mg elemental iron and 1 mg riboflavin
Group 3 (n = 161): Infants received once a week 20 mg of elemental zinc and 1 mg riboflavin
Group 4 (n = 162): Infants received once a week 20 mg of elemental zinc, 20 mg elemental iron and 1 mg riboflavin
Group 5 (n = 157): Infants received riboflavin (control).
For the purpose of this review, groups 1, 2 & 4 were merged and compared with group 5
Length of the intervention: 6 months.
Outcomes Ferritin, diarrhoea, ALRI, physical growth, mental, motor, behavioral development from 6 to 12 month (measured using 
Bayley II scales of infant development), adherence. Data on diarrhoea and ALRI was not combined as it is reported in 
incidence rate/(child-y)
Notes Supplements were prepared as capsules, which were mixed with flavoured syrup and fed to infants by community health 
workers
All supplements had similar taste and appearance and all groups also received 100,000 IU of vitamin A at the beginning of 
the study, in line with national policy in Bangladesh Trial with sub-studies with different sample sizes.
Risk of bias





Unclear risk Participants were randomly allocated to the study groups. Method of 




Low risk Each study infant received the assigned supplement in the same type 
of capsules and labelled in such a way that the various types of 
supplements could not be differentiated



















Low risk Described as doubled-blinded clinical trial. Each study infant 
received the assigned supplement in the same type of capsules and 






High risk Drop out rate much higher (41%) in the MM group than in other 
groups (8–19%). Motor/Cognitive outcomes: 125 kids (36%) did not 
complete 12 mo-assessment, leaving 221 children in final sample. 
There were no differences among arms or major sociodemographic 
variables for dropouts. 16.3% did not undergo evaluation with 
HOME scale
5% did not have haemoglobin data at 12 mo, 1.8% did not have 




High risk Trial with sub studies with different sample sizes.
Other bias Unclear risk No discussion of adjustment or exclusion for inflammation for iron 
status analysis
Berger 1997
Methods Double-blind randomised controlled trial. 3-arm design with individual randomisation
Participants 176 children, both sexes (91 females (52%)), aged 3.3–8.3 years (69 months old in average), attending the schools 
administered by the non-governmental organization “Fe y Alegria” located in a socioeconomically disadvantaged district of 
La Paz, Bolivia (altitude of 4000 m above sea level). Inclusion criterion: anaemia (haemoglobin concentration equal to or 
lower than 144 g/L). No additional exclusion criteria listed. Socioeconomic status not reported
Interventions Participants were allocated to one of the following groups:
Group 1 (n = 59): children received every Tuesday 3–4 mg of iron per kg of body weight (approximately 60–80 mg per 
week);
Group 2 (n = 59): children received a daily dose of 3–4 mg of iron per kg of body weight, 5 days per week, Monday to Fri. 
Daily group received 5 times as much iron as weekly;
Group 3 (n = 58): children received a placebo, once a week, every Tuesday. Placebo consisted of same tablets without iron
Supplements given to groups 1 and 2 consisted of two types of tablets containing either 20 mg or 36 mg of elemental iron 
in form of ferrous sulphate. These tablets were used in combination to adjust the dose to the child’s weight
Length of the intervention: 16 weeks
Outcomes Haemoglobin, change in haemoglobin, anaemia, zinc erythrocyte protoporphyrin, adherence
Notes Tablets were given to children at school, with clean, boiled water, at mid morning, by trained school assistants, under the 
supervision of a member of the research team. Same tablets were used for weekly, daily, and same tablets without iron 
were used for placebo
Non malaria area.
Risk of bias





Unclear risk Children were randomly assigned to one of three groups. Method of 











Low risk Described as double-blind trial. Same tablets were used for weekly, 
daily, and same tablets without iron were used for placebo
Participants: children were not aware of the treatment
Personnel: personnel were not aware of the treatment





Low risk Only one person lost to follow-up in each group, 3 people total. 





Unclear risk There is insufficient information to permit judgement.
Other bias Low risk The study appears to be free of other sources of bias.
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Da Silva 2008
Methods Randomised controlled trial. 3-arm design with randomisation at individual level
Participants 135 children (114 followed up, 54 female (47%)), both sexes, aged 5 to 6.9 months, from Vicosa, the Southeast of Brazil. 
Children were identified from live birth forms and parents were interviewed; parents who were interested in participating 
were recruited (213 children were screened, 78 infants with anaemia were excluded and treated). Inclusion criteria: non-
anaemic infants (Hb equal to or greater than 110 g/L), living in urban area; full term, singleton births; birth weight > 2500 
g; mother aged > 19 years old; no neonatal abnormalities or chronic disease; no previous iron supplements; non-exclusive 
breastfeeding. Maternal years of education ranged between 4 and 11 years (mean approximately 8 years)
Interventions Participants were allocated to one of the following groups:
Group 1 (n = 51): infants received 1 mg of elemental iron/kg/day (as liquid ferrous sulphate);
Group 2 (n = 42): infants received 2 mg of elemental iron/kg/day (as liquid ferrous sulphate);
Group 3 (n = 42): infants received 25 mg elemental iron once a week (as liquid ferrous sulphate)
Length of the intervention: 16 weeks
For the purpose of this review only groups 2 and 3 were compared as the overall dose of iron given to the children was 
similar between them
Outcomes Height, weight and change scores for height and weight (with Z-scores), morbidity (diarrhoea, fever, cough, nasal 
congestion, wheezing)
Notes Supplements were provided free to all groups and participants were advised to take 1 hour before meals
Z scores used the World Health Organization data as a reference
Malaria endemicity not reported.
Risk of bias










High risk Open random allocation schedule. Children were enrolled to the 
study in a row; there was a list showing the sequence in which 







High risk Participants: Not reported.
Personnel: Not reported.





High risk 135 children were randomised. 114 completed the intervention 
(84%). Loss was not balanced across groups: 12/51 lost from group 
1, 6/42 from group 2, 3/42 from group 3
Reasons for loss included patient withdrawal (7) supplement 
intolerance (6) anaemia (2) and other reasons. It was not clear how 
many withdrew from each group for these reasons
It was stated that analysis was based on an intention to treat 
principle, irrespective of adherence, but those lost to follow up did 
not appear to be included in the analysis, although denominators 




Unclear risk There is insufficient information to permit judgement.
Other bias Low risk The study appears to be free of other sources of bias.
Desai 2004 (C)
Methods Cluster-randomised trial. 2×2 factorial design in which housing compounds were the unit of randomisation
Participants 1049 children, both sexes (519 females (49.5%)), aged 2–59 months (27 months in average), living in 14 villages in 
Asembo, Bondo district, Nyanza Province, western Kenya. Inclusion criteria: haemoglobin 50–109 g/L (anaemic); asexual 
parasite count <20,000/mm; no history of intake of iron, sulphadoxine-pyrimethamine or amodiaquine use, or blood 
transfusion within the last 2 weeks, no known sickle cell disease
Baseline prevalence of anaemia in children was 74%. Caretakers had a median of 6 or more years of education across all 
arms and 48.6% of households had a wealth score above the median
Interventions Compounds were allocated to one of the following groups at baseline:
Group 1 (n = 266): children received two doses of 3–6 mg/kg each, separated by 3–4 days (total dose per week: 6–12 
mg/kg; approximately 36–72 mg of iron per week). Supervised;
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Group 2 (n = 271): children received two doses of 3–6 mg/kg each, separated by 3–4 days (total dose per week: 6–12 mg/
kg). Unsupervised;
Group 3 (n = 261): children received one daily dose of 3–6 mg/(kg per day). Supervised;
Group 4 (n = 251): children received one daily dose of 3–6 mg/(kg per day). Unsupervised
Target iron dose was ferrous sulphate syrup 40 g/L, 27.5% elemental iron. Iron doses were based on body weight (<5 kg: 
1.25 mL/d, 5–10 kg: 2.5 mL/d, >10 kg: 5.0 mL/d).
No folic acid was given
Supervised arms (Groups 1 and 3) were used to assess the haematological response while unsupervised groups (2 and 4) 
provided data on adherence and side effects
Length of the intervention: 6 weeks.
Outcomes Haemoglobin, haemoglobin mean change, hematological recovery, microcytosis, all-cause morbidity, clinical malaria, 
malaria parasitaemia, adherence
Notes All parents received the 6-week supply of oral iron and received identical instructions in the local language about use, 
expected side effects, safety and correct dose of iron supplementation
To determine differences in the duration of any treatment effect on Hb levels, children were seen again at 12 wk (1 d)
The mean cluster size was 1.5 children per compound, and the reported design effect was 1.035. Standard errors were 
adjusted for clustering at the compound level
Malaria-endemic area.
All arms were given single treatment dose of sulfadoxine-pyrimethamine (SP)
Risk of bias





Low risk A computer-generated random number listing was used to 
sequentially assign eligible children to 1 of 4 treatment groups, 




Low risk Plastic screw top bottles used, labelled with personal identifiers and 
dosing instructions. Since the intervention was allocated at 







High risk Participants:were aware of the treatment assigned.
Personnel: no blinding









Unclear risk There is insufficient information to permit judgement.
Other bias Unclear risk Children lost to follow up had lower (P= 0.01) haemoglobin 
concentrations at enrolment than those successfully followed for 6 
wk, but were not different for other characteristics. None of the 
characteristics differed among the groups after excluding children 
lost to follow up. 6 children (4 compounds) excluded from analyses 
at 6 wk follow up due to missing haemoglobin values. No discussion 
on adjustment/exclusion for inflammation
Ekvall 2000
Methods Randomised trial. 2-arm design with individual randomisation
Participants 207 children, both sexes (sex distribution unknown), 5 months-3 years of age, living in Fukayosi village, Bagamoyo district 
of coastal Tanzania, from June to November 1995, during the seasonal peak of perennial malaria transmission. Exclusion 
criteria: migration plans, the presence of congenital malformations and Hb concentration, 50 g/L at baseline, requiring 
immediate treatment. Baseline prevalence of anaemia in children was 89% (Hb lower than 110 g/L). Socioeconomic status 
not reported
Interventions Participants were allocated to one of the following groups:
Group 1 (n = 104): children received three times a week 1 mL of a micronutrient preparation containing 10 mg iron (as 
ferrous sulphate), 1500 IU vitamin A, 400 IU vitamin D, 5 IU vitamin E, 35 mg vitamin C, 0.5 mg vitamin B1, 0.6 mg 
vitamin B2, 8 mg niacin and 0.4 mg vitamin B6;
Group 2 (n = 103): children received three times a week 1 mL of a placebo (1 mg of promethazine hydrochloride)
Iron compound and weekly dose: 30 mg of elemental iron (as ferrous sulphate) per week
Length of the intervention: 5 months.
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Outcomes Haemoglobin, mean cell volume as an indicator of iron status, clinical malaria, fever, adherence
Notes All children were to receive a total of 56 doses over 5 months administered during home visits by six research assistants 
who were assigned 30–35 children each
Malaria holoendemic area. For active case detection of clinical malaria episodes, all children were seen fortnightly by the 
research team at the village dispensary for axillary temperature measurement. Children with malaria received chloroquine 
syrup (25 mg/kg over three days), and additional treatment with sulphadoxine pyrimethamine (SP) was given if a child 
showed clinical signs of treatment failure
Risk of bias





Low risk The children were randomly allocated to the supplement group or 




Low risk The supplement and placebo had different colours to facilitate 
correct administration. However, neither the research assistants 







Low risk The supplement and placebo had different colours to facilitate 
correct administration
Participants: mothers did not know the treatment code
Personnel: research assistants did not know the treatment code









Unclear risk There is insufficient information to permit judgement.
Other bias Low risk The study appears to be free of other sources of bias.
Engstrom 2008 (C)
Methods Cluster-randomised trial. 3 arm design in which health facilities were the unit of randomisation
Participants 391 children, both sexes (184 females (47%)), 6 months old. Study carried out through primary healthcare units in Rio de 
Janeiro, Brazil. 15 health care centres (6 intervention, 9 control). Inclusion criteria: absence of iron supplementation in the 
month preceding recruitment and negative for sickle cell anaemia
Baseline prevalence of anaemia (taken from the control group): 60.4%. Socioeconomic status:approximately 30% of the 
mothers worked outside the home; most families (>90%) had access to radio and television, but < 20% had access to a car
Interventions Health facilities were allocated to one of the following groups:
Group 1 (n = 188): children received weekly supplementation with 25 mg of elemental iron (as oral ferrous sulphate) per 
week in syrup and education on anaemia and diet;
Group 2 (n = 188): children received daily supplements containing 12.5 mg elemental iron daily and education on anaemia 
and diet;
Group 3 (n = 94): children received received no intervention and was recruited retrospectively
Length of the intervention: 24 weeks.
For the purposes of this review we only compared groups 1 and 2
Outcomes Haemoglobin, anaemia (Hb <110 g/L) and adherence.
Notes Analyses were performed taking into account cluster sampling
Non-malaria area.
Risk of bias










Low risk Not reported. Since the intervention was allocated at health care unit 
level, it is unlikely there was a selection bias at the individual level



















High risk Participants: Mothers were aware of supplements
Personnel: Clinic staff were aware of supplements
Outcome assessors: Unlikely
Control group identified retrospectively so they were not aware of 





High risk 38/188 (20.2%) were lost to follow up the daily group and 41/188 




Unclear risk There is insufficient information to permit judgement.
Other bias Unclear risk Baseline characteristics were similar for most variables. Regression 
analysis was carried out to identify possible confounders and where 
possible confounders accounted for at least 10% of variation they 
were entered into the final model. However for anaemia no 
confounders were maintained in the final regression analysis
Ermis 2002
Methods Randomised placebo-controlled trial. 4-arm design with individual randomisation
Participants 113 infants, both sexes (56 females (50%)), 5-month old, receiving routine paediatric care at the Research hospital of 
Karaelmas University in Zonguldak, Turkey. Inclusion criteria: no gestational problems (hypertension, preeclampsia, 
infection), no congenital anomalies, no neonatal complications, no emergency caesarian delivery, no jaundice requiring 
phototherapy, no hospitalisation, no chronic illness, no iron therapy, no formula feeding. Must have been exclusively 
breasted, birthweight > 3.0 kg and gestational age of > 37 weeks. Exclusion: Hb < 95 g/L, serum ferritin <12 ng/mL, MCV 
< 74 fl or infection during iron supplementation. Children were eliminated from the study if compliance was lower than 
75%. 58.6%–74. Baseline prevalence of anaemia not reported. One percent of the mothers of participants included in the 
study graduated from high school or university
Interventions Infants were allocated to one of the following groups:
Group 1 (n = 30): infants were given a supplement containing 1 mg iron/kg (as ferrous sulphate) daily;
Group 2 (n = 30): infants were given a supplement of 2 mg iron/kg (as ferrous sulphate) daily;
Group 3 (n = 30): infants were given a supplement of 2 mg iron/kg (as ferrous sulphate)) every other day (approximately 
42 mg of iron per week);
Group 4 (n = 23): infants received a placebo.
Length of the intervention: 4 months.
Groups 1 and 2 were combined and compared with group 3.
Outcomes Haemoglobin, MCV, ferritin, side effects.
Notes Supplements were given by mothers just before or just after breastfeeding and at least one hour before or after any other 
food intake
Malaria endemicity not reported.
Risk of bias





Unclear risk Children were randomised to the different groups. Method of 










High risk Participants: Not reported.
Personnel: Not reported.





Low risk Two, three and one cases were eliminated because of low 
compliance(<75%), in group 1, 2 and 3, respectively. The causes of 
non-compliance were infection during iron usage, refusing iron 





Unclear risk Cases with less than 75% of adherence were excluded.
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Other bias Unclear risk Cases with less than 75% of adherence were excluded. It is unclear 
why the control group has 25% less participants
Evangelista-Salazar 2004
Methods Randomised controlled trial. 4-arm design with individual randomisation
Participants 100 newborns, both sexes (50 females), living in Urban areas in Colima, Mexico. Incluson criteria: healthy, term, single-
born babies during their first year of life. Exclusion criteria: low birth weight, unknown date of last menses to calculate 
term pregnancy, twins, bleeding disorder or other medical conditions that may be associated with anaemia (i.e., 
malabsorption). Baseline prevalence of anaemia: unknown. Socioeconomic status not reported but children were born to 
parents that were receiving a salary
Interventions Neonates were randomly allocated at one of the following groups:
Group 1 (n = 25): infants were given weekly a supplement of 7.5 mg elemental iron (as ferrous sulphate), and 30 mg 
vitamin C;
Group 2 (n = 25): infants were given fortnightly a supplement of 7.5 mg elemental iron (as ferrous sulphate), and 30 mg 
vitamin C;
Group 3 (n = 25): infants were given monthly a supplement of 7.5 mg elemental iron (as ferrous sulphate) and 30 mg 
vitamin C;
Group 4 (n = 25): received no intervention.
Length of the intervention: 12 months. During the first 6 months children received 7.5 mg and after that the dose was 
double. We only included the first period of evaluation in our analysis
For the purposes of this review we only compared groups 1 and 4
Outcomes Anaemia, iron deficiency, haemoglobin, ferritin. Neurocognitive development (Brazelton score at birth, Bayley mental and 
motor assessment) and growth. The latter data were not extracted as no measures of dispersion are reported
Notes Trained personnel visited families to assess illness incidence and adherence
Ferritin data for the group receiving intermittent supplementation was 201.2 ± 51.08 and 120.0 ± 56.63 ng/mL (or μg/L). 
Although the results are consistent in terms of direction, these concentrations are much higher than those observed in the 
rest of the trials included in this review. The corresponding author was contacted to verify this information and we decided 
not include this information while we await for the response
Malaria-free area.
Risk of bias





Unclear risk Children randomly allocated to the study groups. Method of 










Unclear risk Participants: unclear
Personnel: unclear
Outcome assessors: Not reported.
Trial reported as single blind but the use of placebos is not 









Unclear risk There is insufficient information to permit judgement.
Other bias Low risk The study appears to be free of other sources of bias.
Faqih 2006
Methods Randomised clinical effectiveness trial. 3-arm design with randomisation at individual level
Participants 134 children, both sexes (38.1% female at follow up), aged 2 to 6 years (in average 43 months), attending Prince Hashim 
Military Hospital of the Royal Medical Services in Zarqa, Jordan. This clinic is open to children from families affiliated 
with the army who are not medically insured and have generally low income. Inclusion criteria: Iron deficiency anaemia at 
baseline (Hb ≤ 105 g/L and mean corpuscular volume ≤ 75), born at full term with birthweight equal or higher than 2.5 kg 
and exhibited normal growth with no signs of thalassaemia, chronic illness, congential abnormalities, or chronic and 
repeated infections. Baseline prevalence of anaemia not reported. Socioeconomic status not reported
Interventions Children were allocated to one of the following groups:
Group 1 (n = 45): children received a daily dose of 5 mg elemental iron per kilogram of body weight;
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Group 2 (n = 45): children received once a week 5 mg of elemental iron per kg of body weight on Fridays (approximately 
45 mg of iron per week);
Group 3 (n = 44): children received 5 mg of elemental iron per kilogram of body weight twice a week, Friday and Monday 
(approximately 90 mg of iron per week)
Parents were instructed to give the ferrous sulphate supplement in 2 portions between 30 to 60 minutes before breakfast and 
dinner. Parents were advised to mix the supplement with water, orange juice or lemonade if the child refused the 
supplement
Length of the intervention: three months.
All the groups were analysed in this review. Groups 2 and 3 were combined and only reported separately for the subgroup 
analysis by regimen
Outcomes Weight, height, haemoglobin, mean corpuscular value, hematocrit, ferritin
Notes The dose was administered by either of the parents who were advised to mix the supplement with water, orange juice, or 
lemonade if the child refused to take the supplement on an empty stomach. Families also counselled on nutritional causes 
of IDA, consequences if not treated, iron rich foods, enhancers and inhibitors. Families also received home check up visits 
every two weeks
In Jordan, malaria, hookworm, and schistosoma do not constitute a problem
Risk of bias





Low risk Participants were allocated randomly to one of three groups 










High risk Participants: Not reported
Personnel: Not reported





High risk 71 of 134 children (53%) did not complete the study. Children lost 
because 1) refused to take the iron, 2) parents did not administer iron 
for 3 months, 3) parents did not return to clinic for follow up visits. 




High risk Only 34 children had ferritin values.
Other bias High risk Very large age range and small sample size for the outcomes, age is 
important for risk of anaemia and iron deficiency. Baseline 
haemoglobin higher in group 2 than in group 1
Hall 2002 (C)
Methods Cluster-randomised trial. 2-arm design with randomisation at school level (60 schools, 30 per arm)
Participants Children (1201 randomised, 1113 followed up), both sexes (613 female (51%)), aged 6–19 years (mean of 11.4 years), 
attending rural informal community schools in the Kolondieba district of Mali. Approximately 20 randomly children (10 
boys and 10 females) attending 2nd or 4th grade were selected from each school. Any child with severe anaemia (Hb ≤80 
g/L) were excluded. Baseline prevalence of anaemia: approximately 55%. Socioeconomic status not reported
Interventions Schools were allocated to one of the following groups:
Group 1 (n = 551 at follow up, number randomised not clear): children received 65 mg elemental iron (as 200 mg of 
ferrous sulphate) and 250 μg (0.25 mg) of folic acid once a week;
Group 2 (n = 562 at follow up, number randomised not clear): No intervention
Length of the intervention: 10 weeks
Outcomes Anaemia, haemoglobin. Results by sex are included in the corresponding subgroup analysis
Notes All children in every school were treated for parasitic infections at baseline using albendazole, and vitamin A to treat night 
blindness. Supplements were given by the teachers and 83% of children were given all 10 tablets and 91% received at least 
nine tablets
Malaria is endemic in Mali, although the study was done in the dry season when transmission is less intense than in the wet 
season
Authors provided the ICC (0.0698) and design effect (2.22) to adjust data by the effect of clustering; the estimated effective 
sample size was used in the analyses.
Risk of bias
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Low risk 60 schools were randomly assigned to either a treatment or a 
comparison group by using a computer-generated random number 




Low risk Not reported. Since the intervention was allocated at health care unit 






High risk Participants: Not reported
Personnel: Not reported





Low risk 1201 children at baseline, 1113 followed up at 14–16 weeks. (93% 
followed up). 88 children who did not provide second samples had 





Unclear risk There is insufficient information to permit judgement.
Other bias Low risk The study appears to be free of other bias.
Khademloo 2009
Methods Randomised controlled trial. 2-arm design with individual randomisation
Participants 100 Infants, both sexes (sex distribution not reported), aged 6–24 months referred to the public health care centre in Sari, 
Iran. Urban area. Inclusion and exclusion criteria were not adequately described. Baseline prevalence of anaemia not 
reported. Socioecomic status: although information on sex and mothers’ educational level were collected this information 
was not reported
Interventions Children were allocated to one of the following groups:
Group 1 (n = 50): infants received fifteen drops containing elemental iron (as ferrous sulphate) given daily
Group 2 (n = 50): infants received thirty drops of iron once a week
Length of the intervention: 12 weeks
Outcomes Ferritin, haemoglobin.
Notes Trial not included in the subgroup analysis by dose
Malaria endemicity not reported.
The total dose of iron per week is unknown.
Risk of bias





Unclear risk Babies “randomly divided in two equal groups”. Method of 










High risk Participants: Not reported
Personnel: Not reported









Unclear risk Groups were described as similar at baseline, but information on 
methods and results was scarce
Other bias Low risk The study appears to be free of other sources of bias.
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Liu 1995 (C)
Methods Randomised clinical trial. 3 arm design with randomisation at classroom level
Participants 246 healthy children, both sexes (131 females (57%)), aged 3 to 6 years, attending Kindergarten in Changxi, China, an 
autonomous region of China. Kindergarten has 9 large classrooms and two meals and two snacks are provided daily. 
Exclusion criteria were chronic infectious diseases, cardiopathies, or respiratory diseases, and intake during the previous 
month of supplements or drugs containing iron or specially prescribed iron-rich and absorption-promoting foods for the 
month prior to entering the study. Approximately 29 % of the children were anaemic at baseline. Socioeconomic status not 
reported
Interventions Classrooms were allocated to one of the following groups:
Group 1 (n = 89): children received 5–6 mg of elemental iron per kilogram (as ferrous sulphate) daily;
Group 2 (n = 74): children received 5–6 mg of elemental iron per kilogram (as ferrous sulphate) twice a week 
(approximately 170–204 mg of iron per week);
Group 3 (n=83): children received 5–6 mg of elemental iron per kilogram (as ferrous sulphate) tablet once a week 
(approximately 75–120 mg of iron per week);
Iron tablets were administered by teachers under direct supervision 1 hour after breakfast, making sure that the child 
swallowed it
Length of the intervention: 3 months
Group 2 and 3 were combined and compared with group 1; their individual results are presented in the subgroup analyses 
by regimen and by anaemia status
Outcomes Haemoglobin and ferritin.
Notes We adjusted the results of this study to account for the effect of clustering in data; the estimated effective sample size was 
used in the analyses.
Malaria endemicity not reported.
Risk of bias





Unclear risk Children were randomly allocated to the classroom according to 
their age and then classrooms were randomised to each of the three 




Low risk Not reported. Since randomisation occurred at classroom level, it is 






High risk Participants: Not reported
Personnel: Not reported
Outcome assessors: Results were tabulated, without knowledge of 
the children’s supplementation regimen, by two nurses in charge of 






Low risk 238 children completed the study. 5 left the kindergarten during the 
study and 3 children from daily group discontinued supplementation 




Unclear risk There is insufficient information to permit judgement.
Other bias High risk Data not adjusted by the effect of clustering in data
Nguyen 2002
Methods Randomised trial. 4 arm design with individual randomisation
Participants 280 children, both sexes (133 females (47.5%), aged 5 to 12 months, living in one of four communes in the rural district of 
Bac Ninh, Vietnam. Inclusion criteria: Hb< 70 g/L, no pathologies after a clinical examination and not receiving any iron 
supplements. Baseline prevalence of anaemia: ~60%. Socioeconomic status: ~95% dedicated to agriculture
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Interventions Two communes were allocated to one of the following groups:
Group 1 (n = 70): children received a placebo (2.5 ml of syrup without iron) every day;
Group 2 (n = 70): children received a daily dose of 15 mg elemental iron (2.0 ± 0.3 mg iron/day/kg body weight) (as 
ferrous sulphate)
Participants from other two communes were randomly allocated to one of the following groups:
Group 3 (n = 70): children received a daily dose of 15 mg elemental iron (2.0 ± 0.3 mg iron/day/kg body weight) (as 
ferrous sulphate);
Group 4 (n = 70): children received a weekly dose of 15 mg elemental iron (as ferrous sulphate)
Length of the intervention: 3 months (groups 1 and 2) and 6 months (groups 3 and 4)
For the purposes of this review only groups 3 and 4 were compared
Outcomes Haemoglobin, anthropometric measurements (height for age, weight, age and weight for height were Z-scores)
Notes Article translated from French.
The supplements were administered between 8 and 10 am by local auxiliaries, under regular supervision of a member of 
the research team. 98% and 95% of the infants in group 3 and 4, respectively, received more than 90% of the expected total 
dose of iron
Malaria endemicity not reported.
Risk of bias





Unclear risk Only children from groups 3 and 4 were randomly allocated to either 












Low risk Participants: the nature of the treatment was unknown to the family 
of the infant; all the infants received identical looking syrups (with 
or without iron)
Personnel: community auxiliaries were not aware of the treatments
Outcome assessors: Neither the people in charge of measurements 





Low risk 10 children did not complete the study, 4 because parents refused to 
continue, 3 due to address change and 4 because of low compliance 




High risk Results on growth not reported.
Other bias Low risk The study appears to be free of other sources of bias.
Olsen 2000
Methods Randomised, placebo-controlled, double-blind study. 2-arm design with individual randomisation
Participants 231 children, both sexes (99 females (43%)), aged 4–15 years (8.6 years in average), living in Luo villages of Asino, 
Ohala, and Pith-Kodhiambo in Kisumu district of Nyanza Province in western Kenya. Participants had moderately low 
blood haemoglobin concentrations (80–130 g/L for children 4–14 years of age or non-pregnant female >14 years of age and 
80–135 g/Lif male and >14 years of age). Exclusion criteria: severe anaemia (Hb <80 g/L) or pregnant. Baseline prevalence 
of anaemia: 47.5%. Socioeconomic status not reported
Interventions Participants were allocated to one of the following groups:
Group 1 (n = 121): children received treatment twice weekly with a 60 mg of elemental iron (total of 120 mg of iron per 
week, as 200 mg of ferrous dextran);
Group 2 (n = 110): children received a placebo.
Length of the intervention: 12 months.
Outcomes Haemoglobin, serum ferritin (median and interquartile range, could not be extracted), reinfection rates and intensities of 
hookworm, Ascaris lumbricoides, Trichuris trichiura, and Schistosoma mansoni, compliance (“reasonable”)
Notes At baseline, any individual infected with any intestinal helminth. S. mansoni, and malaria were treated (only abstract says 
treated with malaria)
After baseline examination, each subject was given a container (labelled with the subject’s name, study number and 
identification sticker) containing 50 tablets. At the end of each 4-month period, the number of tablets taken was registered, 
based on the number of remaining tablets. In order to encourage intake, field assistants visited every participant at least 
once a month. Tablet intake for the whole study period was 98.9% of the scheduled value, and 90.1% of the children each 
appeared to take between 80% and 120% of the scheduled number of tablets
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Iron supplementation had no effect on either reinfection rates or intensities in children. Multiple logistic regression analyses 
controlling for baseline infection status confirmed the effect in adults of
Malaria endemic area.
Risk of bias









Low risk The tablets were coded by the manufacturer and sealed envelopes 






Low risk Participants: received identical pills and instructions
Personnel: envelopes revealing randomizations code not opened 
until analysis was complete
Outcome assessors: envelopes revealing randomizations code not 





Low risk Of 231 randomised, one became pregnant and 30 lost to follow up. 




Unclear risk There is insufficient information to permit judgement.
Other bias Unclear risk Baseline intensity of A. Lumbricoides infection was higher in the 
placebo group than in the iron group. HIV not assessed at baseline, 
but at 4 months, and assumed to reflect baseline status; it is unclear 
what treatment was available for participants
Palupi 1997
Methods Double-masked, randomised controlled field trial. 3-arm design with individual randomisation
Participants 299 children, both sexes (sex distribution not reported), aged 2–5 years, who were registered at the West Javanese village 
of Setia Asih. Of 344 potential subjects, parental permission was obtained for 299 children. No further inclusion or 
exclusion criteria mentioned. Baseline prevalence of anaemia: 36.7%. Socioeconomic status not reported
Interventions Participants were allocated to one of the following groups:
Group 1 (n = 98): children received 30 mg elemental iron (as ferrous sulphate) once per week and anthelminthic treatment;
Group 2 (n = 96): children received 30 mg elemental iron (as ferrous sulphate) once per week and placebo for 
anthelminthic treatment;
Group 3 (n = 98): children received placebos for both iron supplements and antihelminthic treatment. The placebo syrup 
did not contain ferrous sulphate, but was similar in taste and appearance to the iron-containing syrup
Length of the intervention: 9 weeks
For the purpose of this review only groups 2 and 3 were compared
Outcomes Haemoglobin, haemoglobin mean change, anaemia, anthropometric measurements (Height-for-age Z-score, Weight-for-age 
Z-score, Weight-for-height Z-score change), helminthic infection
Notes The anthelminthic tablets as well as the placebos were ingested under supervision of the researcher one week before iron 
supplementation started. The supplements were given to the children by their mothers and intake was not supervised by 
health centre staff or the researchers, but compliance was controlled by checking the iron content in the stool Z-scores used 
the National Center for Health Statistics data as a reference
Malaria endemicity not reported.
Risk of bias





Unclear risk Children were randomly divided into three, equal-sized treatment 




Low risk Mothers received a bottle with 100 mL glucose syrup. Although the 
concealment is not clearly described, this is a double-blind trial and 
its unlikely that there was a selection bias
Blinding 
(performance 
Low risk Reported as double-masked trial.
Participants: were not aware of the treatment

















Personnel: all mothers received a bottle with 100 mL glucose syrup 
containing or not iron





Low risk 289 (out of 299) children remained; 10 (3%) dropped out because 




Unclear risk There is insufficient information to permit judgement.
Other bias Low risk The study appears to be free of other sources of bias.
Roschnik 2003 (C)
Methods Cluster-randomised trial. 2-arm design with randomisation at school level and stratified by sponsorship status
Participants 1,160 children (752 followed up), both sexes (371 females (49.5%)), aged 7–8 years and 12–14 y. The study included 40 
primary schools in the Mangochi District, Malawi. Baseline prevalence of anaemia: around 54%. Socioeconomic status not 
reported
Interventions Schools were randomly allocated to one of the following treatments:
Group 1 (20 schools, n = 640): children received 65 mg of elemental iron (as 200 mg ferrous sulphate) and 250 μg (0.25 
mg) of folic acid once a week
Group 2 (20 schools, n = 640): children received no intervention
Length of the intervention: 15 weeks
Outcomes Haemoglobin concentration, bilharzia infection, school attendance, test scores and drop-out rate and repetition rate (at the 
school level).
Notes Results were stratified by age (<10 y, 10–14 y and 15+). For the purposes of this review we only included those data from 
children <10 years of age (192 in the intervention group and 190 in the control group), until we can obtain the data for all 
children <12 years
A famine occurred in the region at the time of the study.
Each study group included 10 sponsorship schools and 10 non-sponsorship schools, 10 coastal and 10 upland schools. All 
children in Coastal intervention and comparison schools, where the prevalence of bilharzia was over 50%, were dewormed 
with Praziquantel (600mg) just after the baseline survey
A vitamin A capsule (200,000 IU) was given to all children in standard 2 and below 63% of children took 10 iron tablets or 
more.
Analysis originally not adjusted by the effect of clustering. The effective sample was calculated by imputing the ICC from 
Roschnik 2004 (C), which has a similar study design; the estimated effective sample size was used in the analyses.
Malaria endemicity not reported.
Risk of bias





Unclear risk 40 primary schools in the Mangochi District were randomly divided 
into the intervention (1st iron group) and comparison group (2nd iron 
group). Each group includes 10 sponsorship schools and 10 non-




Low risk Not reported. Since the intervention was allocated at school level, it 






High risk Participants: not reported.
Personnel: not reported





High risk 1280 were randomised, 1160 had haemoglobin levels at baseline and 




Unclear risk There is insufficient information to permit judgement.
Other bias Unclear risk Children attending sponsored schools responded better to the 
treatment
Roschnik 2004 (C)
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Methods Cluster-randomised trial. 2-arm design with randomisation at school level
Participants 1785 children (1510 followed up), both sexes (747 females (49.5%), aged 7–12 years. The study included 51 primary 
schools: 20 in Iloilo and 31 in Guimaras, Philippines. Baseline prevalence of anaemia: ~15%. Socioeconomic status not 
reported
Interventions Schools were randomly allocated to one of the following treatments:
Group 1 (25 schools, unclear the number of children randomised): children received 108 mg of elemental iron (as 325 mg 
ferrous sulphate);
Group 2 (26 schools, unclear the number of children randomised): children received no intervention
Length of the intervention: 10 weeks
Outcomes Anaemia, haemoglobin, haemoglobin change.
Notes Supplementation started between 1 and 7 weeks after the baseline survey and the second survey took place between 5 and 
18 weeks after the end of the iron supplementation
The consumption of each tablet was recorded by the teachers. Side effects were not recorded. All 10 iron tablets were taken 
by 93.4% of children
67% of children were infected with one or more intestinal worms
Malaria endemicity not reported.
Authors provided the ICC (0.1123) and design effect (4.35) to adjust data by the effect of clustering; the estimated effective 
sample size was used in the analyses.
Risk of bias










Low risk Not reported. Since the intervention was allocated at school level, it 






High risk Participants: not reported.
Personnel: not reported





Unclear risk 15.4% of attrition. Losses presumably higher among the control 
group as two schools were dropped out because they were unable to 




Unclear risk There is insufficient information to permit judgement.
Other bias High risk The second blood sample was withdrawn between 5 and 18 weeks 
after the end of the iron supplementation
Fourteen of the 49 schools in the study had participated for about 2 
months in the fortified rice programme: six in the intervention group 
and eight in the control group. The mean haemoglobin concentration 
of children in the 14 schools that had participated in the programme 
was slightly but significantly higher than that of children in the other 
25 schools (126.4 g/L versus 125.0 g/L, P ¼ 0.031)
Analysis was not adjusted by the effect of clustering in data
Schultink 1995
Methods Randomised clinical trial. 2-arm design with individual randomisation
Participants 87 children, both sexes, aged 2–5 years, from Subdistrict Kelurahan Tenga of East Jakarta, Indonesia. The initial selection 
criterion was a haemoglobin concentration < 110 g/L.
96 children were invited to receive anthelmintic treatment before starting iron supplementation; only 87 accepted and were 
randomised
Interventions Participants were allocated to one of the following groups:
Group 1 (n = 44): children were supplemented daily with 30 mg elemental iron (as ferrous sulphate dissolved in 5 mL 
syrup);
Group 2 (n = 43): children were supplemented twice a week with 30 mg elemental iron (as ferrous sulphate dissolved in 5 
mL syrup) (total 60 mg of iron per week)
Length of the intervention: 8 weeks.
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Outcomes Haemoglobin, ferritin, zinc protoporphyrin, mean changes of haematological variables (anaemia prevalence taken from 
Beaton 1999).
Notes Parents and supervising health staff were instructed that each child should take 5 mL from the small bottle on Mondays and 
Fridays and 5 mL from the large bottle on the remaining days of the week using a standardized spoon for 8 wk. Bottles had 
similar appearance
Malaria endemicity not reported.
Risk of bias





Unclear risk Subjects were assigned at random to two groups. Method of 










Low risk Participants: were not aware of the treatment
Personnel: all mothers received two small bottles (each 80 mL) and 
two large bottles (each 170 mL), each containing a syrup of similar 
appearance






High risk A complete set of data was obtained for 33 subjects in the group 
supplemented twice weekly (group 1) (75%) and for 32 subjects in 




Unclear risk There is insufficient information to permit judgement.
Other bias High risk Baseline haemoglobin concentrations were different between 
groups.
The results include 25 children with Hb> 110 g/L and the initial 
description only mentions 16
Sen 2009 (C)
Methods Cluster-randomised controlled trial. 4-arm design with randomisation at school level
Participants 240 school age females, aged 9–13 years, attending four schools in Vadodara area of India. Females were excluded from 
the analysis if menstruation commenced. None of the Females were involved in athletic sports on a regular basis. Baseline 
prevalence of anaemia: 68.3%. Socioeconomic status not described in detail but participants were described as 
“underprivileged”
Interventions Schools were allocated to one of the following groups:
Group 1 (n = 65): females received 100 mg elemental iron (as ferrous gluconate) and 500 μg (0.5 mg) folic acid folic acid 
oral once weekly;
Group 2 (n = 89): females received the same supplement twice weekly (200 mg of elemental iron per week);
Group 3 (n = 59): females received 100 mg elemental iron (as ferrous gluconate) daily;
Group 4 (n = 41): females received no supplement.
Length of the intervention: 1 year.
Groups 1 and 2 were combined and compared with groups 3 and 4 as appropriate
Outcomes Physical work capacity, haemoglobin change and adherence.
Notes Malaria endemicity not reported.
Analyses in this review include the estimated effective sample size only, after adjusting the data to account for the 
clustering effect
Risk of bias





Low risk Of 17 schools meeting the inclusion criteria, 4 schools were selected 
randomly using a random numbers table. Once the four schools were 
selected, the chit system (chits representing school 1, 2, 3, 4) was 
used. The order of placing a school in a category was: the first 
school that is picked up (from the four) goes to daily; the chit is then 
put back; the next chit picked up goes to twice weekly; the next to 
once weekly and the one left over, to control so that all schools have 
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an equal probability of being allocated to any of the four groups 




Low risk Not reported. Since allocation was at school level it is unlikely that 






Unclear risk Participants, personnel and outcome assessors: Each school received 






High risk 4 schools. In these schools a random sample of 240 children was 
selected. 163 had pre and postintervention data for work capacity 
(68% followed up). Females who started their periods were 
excluded from the analysis. For cognitive tests results relate to a 




Unclear risk There is insufficient information to permit judgement.
Other bias High risk The design effect was not taken into account in the analysis
Siddiqui 2004
Methods Randomised controlled trial with. 2-arm design with individual randomisation
Participants 60 children, both sexes (30 females (50%)), aged 5–10 years, attending a private school, blue collar workers, in Karachi 
Pakistan. Inclusion: anaemia (haemoglobin <110 g/L). Exclusion criteria: acute disease (diarrhoea, fever, cough, running 
nose) or history of chronic disease (joint pain, bleeding disorders). Socioeconomic status not described
Interventions Participants were allocated to one of the following groups:
Group 1 (n = 30): Children took supplements containing 60 mg of elemental iron (as 200 mg ferrous sulphate) once a week 
for 2 months (8 doses total);
Group 2 (n = 30): Children took 60 mg of elemental iron supplements (as 200 mg ferrous sulphate) daily for 56 days
Length of the intervention: ~ 2 months (weekly dosing was 8 weeks but daily dosing only 56 days)
Outcomes Haemoglobin, hematocrit, serum iron, total iron binding capacity, serum ferritin
Notes Both groups de-wormed prior to start of study (mebendazole).
Malaria endemicity not reported.
Risk of bias





Unclear risk Children were randomly assigned to one of the groups. Method of 










High risk Participants: not reported.
Personnel: not reported.









Unclear risk There is insufficient information to permit judgement.
Other bias Unclear risk Unclear whether 60 participants reflected all anaemic children in the 
school or whether (and if so how) the 30 males and 30 females were 
selected out of all eligible students in the school. Age in weekly 
group significantly different than those in daily group. Did not 
assess or adjust/exclude iron status indicators for inflammation
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Sinisterra 1997 (C)
Methods Cluster-randomised trial. 2-arm design with randomisation at school level (5 schools)
Participants Children (909 randomised, 842 followed up), both sexes (408 female (48%)), aged 6–13 years, attending rural schools in 
the district of Anton, Cocle, Panama. Exclusion criterion: severe anaemia (Hb ≤90 g/L) and clinical conditions that could 
affect iron status. Baseline prevalence of anaemia: approximately 42.4%. Socioeconomic status not explicitly reported
Interventions Schools received one of the following interventions:
Group 1 (n = 176 at follow up, number randomised not clear): children received daily 60 mg of elemental iron (as ferrous 
sulphate) and “nutricrema”;
Group 2 (n = 210 at follow up, number randomised not clear): “nutricrema”
Group 3 (n = 225 at follow up, number randomised not clear): children received daily 60 mg of elemental iron (as ferrous 
sulphate) and “nutricrema” once a week;
Group 4 (composed by two schools n=195 at follow up, number randomised not clear): Milk plus a fortified cookie plus 
folic acid
Length of the intervention: 6 months
Only groups 1 and 3 were randomised and thus included in our analysis
Outcomes Anaemia (Hg < 120 g/L), haemoglobin, attitudes, beliefs, growth
Notes Malaria endemicity not reported.
We adjusted the results of this study to account for the effect of clustering in data; the estimated effective sample size was 
used in the analyses.
Risk of bias









Low risk Not described. Since the intervention was allocated at school level, 






High risk Participants: Not reported
Personnel: Not reported










Unclear risk There is insufficient information to permit judgement.
Other bias High risk The prevalence of anaemia among those receiving weekly 
supplementation was 20 percentage points higher than those 
receiving daily supplementation (54.7% vs 34.7%)
Soemantri 1997
Methods Randomised controlled trial. 2-arm design with individual randomisation
Participants 97 children, both sexes (sex distribution not reported), aged 7–11 years, attending the primary school Batang, in Indonesia. 
Inclusion criteria: anaemia (Hb below 120 g/L); not taking iron supplements during the last six months; no evidence of 
hepatosplenomegaly, haemoglobinopathy, acute or chronic disease, severe anaemia. Baseline prevalence of anaemia: 
67.36%. Socioeconomic status not reported
Interventions Children were divided into 2 groups and randomly assigned
Group 1 (n = 52): children received daily 3 mg of iron per kilogram (as ferrous sulphate);
Group 2 (n = 45): children received once a week 3 mg of elemental iron per kilogram (as ferrous sulphate) (approximately 
85 mg of iron per week)
Length of the intervention: 3 months.
Outcomes Anthropometric measurements (weight for age Z-score, height for age Z-score) and haemoglobin
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Notes The solutions were given by the school teachers on school days with careful supervision
All children with intestinal parasites were treated prior to supplementation
Z-scores used the National Center for Health Statistics data as a reference
Malaria endemicity not reported.
Risk of bias





Unclear risk Children were randomly assigned to the study groups. Method of 










High risk Participants: not reported.
Personnel: not reported.










Unclear risk There is insufficient information to permit judgement.
Other bias Low risk The study appears to be free of other sources of bias.
Sungthong 2002
Methods Double-blind, randomised, placebo-controlled trial. 3-arm design with individual randomisation
Participants Of 50 government schools located outside the municipality, selected schools had to met the following criteria: 1) high 
prevalence of underweight according to school-records (no # or prevalence given to define “high”); 2) a least 150 students 
in school; 3) not >1 h away by car from research centre; 4) teachers willing to cooperate in study; 5) no previous iron 
supplementation programme implemented. Subsequently 2 schools selected 397 school age children in grades 1–6 (9.7 
years of age in average), both sexes (212 females (53%)) only those with written parental consent included. Excluded those 
with severe Iron deficiency anaemia (Hb equal or lower than 80 g/L and serum ferritin equal or lower than 20 μg/L) severe 
malnutrition weight-for-height <3rd percentile of Thai reference, chronic illness such as thalassaemia, haemolytic disease 
and physical handicaps. Participants assigned to group stratified by anaemia status. Baseline prevalence of anaemia:~ 35%. 
This study took place in a socioeconomically disadvantaged community
Interventions Participants were allocated to one of the following groups:
Group1 (n = 134): each child received 2 bottles with tablets, the first was to be taken on Monday only while the second was 
to be taken for the remaining days of the week (60 mg of elemental iron (as ferrous sulphate) weekly;
Group 2 (n = 140): each child received 2 bottles with tablets, the first was to be taken on Monday only while the second 
was to be taken for the remaining days of the week. Both bottles had 60 mg of elemental iron (as ferrous sulphate) daily);
Group 3 (n = 123): Same procedure as groups 1 and 2 but children received placebo. The tablets were similar in colour, 
shape, size, and taste as the iron tablets
Length of the intervention: 16 weeks
Outcomes Haemoglobin, serum ferritin, mean changes of both, height, weight
Notes This area is free from malaria
Risk of bias





Low risk Children were stratified by anaemic status to balance the proportion 
of anaemic and non anaemic children across the intervention groups. 
The children were then assigned by simple random allocation within 
each stratum using a computer random number generator

















Low risk Tablets placed in packages labelled only with participants’ name, 
content not known to any of the project personnel. 2 supplement 
packages similar in appearance: On Mondays received one packages 
which contained iron for daily and weekly group, but placebo for 
control group. Rest of week consumed tablets from other package, 







Low risk Participants: neither parents nor participants knew the content of 
supplement packages
Personnel: researchers did not know the content of supplement 









Unclear risk There is insufficient information to permit judgement.
Other bias Unclear risk Baseline prevalence of anaemia was different among study arms 
(39, 40 & 28%, for daily, weekly and placebo, respectively), but 
haemoglobin concentrations were not statistically different
Tavil 2003
Methods Randomised clinical trial. 2-arm design with randomisation at individual level
Participants 94 children aged 5 months to 6 years (median age was 18 months of age), both sexes (35 females (37.2%)), attending Dr 
Sami Ulus Children’s Hospital in Ankara, Turkey, from December 1999 to December 2000. Inclusion criteria: iron 
deficiency anaemia (defined as haemoglobin (Hb) levels below 100 g/L, transferrin saturation levels below 12%, and 
ferritin levels below 12 ng/mL) and negative supplement intake during the past 3–4 weeks. Exclusion criteria: chronic, 
metabolic, and genetic diseases. Socioeconomic status not described
Interventions Participants were randomly allocated to one of the following groups:
Group 1 (n = 48): children received daily 6 mg/kg of elemental iron as ferrous sulphate;
Group 2 (n = 46): children received 6 mg/kg of elemental iron as ferrous sulphate 2 days a week (Tuesday and Friday) (120 
mg of iron per week).
Twenty-three healthy children whose age and gender distribution were compatible with the other groups were included in 
the study as the control group. This group was not included in the analyses
Length of the intervention: 2 months
Outcomes Haemoglobin, hematocrit; red blood cell count, mean corpuscular volume, mean corpuscular haemoglobin, mean 
corpuscular haemoglobin concentration, iron deficiency anaemia, serum iron, serum iron binding capacity, transferrin 
saturation, transferrin
Notes Malaria endemicity not reported.
Risk of bias





Unclear risk Participants were randomly divided into two groups. Method of 










High risk Participants: not reported.
Personnel: not reported.





Unclear risk It is unclear the final number of participants per group. The report 
mentions that ’thirty three patients who had not been regularly 
conforming to the iron deficiency treatment as recommended or who 
were intolerant to the medication due to the side effects were 
excluded from the study. The patients presenting no increase in the 
Hb levels despite the iron treatment were reevaluated at the end of 
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the first month, and those who were detected as thalassaemia traits 




Unclear risk There is insufficient information to permit judgement.
Other bias Unclear risk It is unclear the failure rate of the intervention and whether the 
results are biased because of the exclusions
Taylor 2001
Methods Double-blind randomised controlled trial. Factorial design (6 arms) with individual randomisation
Participants 425 children, both sexes (50% females), aged 6–15 years (mean age 11.2 years), attending three rural primary schools in 
Kwa-Zulu Natal, South Africa. The sample was stratified by school, age and sex. Four children with anaemia were 
included in the study (Hb < 80 g/L) - all of these children were allocated to receive iron. Females over 12 years of age were 
excluded as the safety of albendazole in pregnancy has not been established. Socioeconomic status not reported although it 
was stated that the study was carried out in the third poorest province in South Africa. Anaemia at baseline was 35%
Interventions Children were allocated to 1 of the following groups:
Group 1 (n = 56): children received 400 mg of albendazole weekly, 40 mg/kg of praziquantel weekly, and 65 mg of 
elemental iron (as 200 mg ferrous fumarate) plus 100 μg (0.1 mg) of folic acid weekly;
Group 2 (n = 60): children received 400 mg of albendazole weekly, 40 mg/kg of praziquantel weekly, and placebo for iron 
and folic acid weekly;
Group 3 (n = 60): children received 400 mg of albendazole for three days, 40 mg/kg of praziquantel weekly, and 65 mg of 
elemental iron (as 200 mg ferrous fumarate) plus 100 μg (0.1 mg) of folic acid weekly;
Group 4 (n = 57): children received 400 mg of albendazole for three days, 40 mg/kg of praziquantel weekly, and placebo 
for iron and folic acid weekly;
Group 5 (n = 101): children received placebo for albendazole, placebo for praziquantel and 65 mg of elemental iron (as 200 
mg ferrous fumarate) plus 100 μg (0.1 mg) of folic acid weekly;
Group 6 (n = 91): children received only placebos.
For the purposes of this review only groups 5 and 6 were analysed
Length of the intervention: 10 weeks, children were followed up for a year with measures at baseline, 6 months and 12 
months
Outcomes Height, weight, full blood count, anaemia (could not be extracted), presence of malarial parasites, presence of hookworm 
infection, urine infection or presence of blood in urine
Notes All groups received interventions under supervision by teachers
It was reported that the area is endemic for malaria, schistosomiasis and hookworm
Risk of bias





Unclear risk Randomised controlled trial, with individual randomisation. 6-arm 
trial (factorial design). Sample stratified by school, age and sex. 




Low risk Each pupil’s treatment was individually packaged at each phase of 







Low risk Participants: all pupils were blinded to the type of supplement used
Personnel: field team were blinded to the type of supplement used





High risk 428 children entered the study. 4 children who were anaemic at 
baseline were all allocated to receive iron treatment. It was stated 
that intention to treat analysis was not carried out as data was 
missing for children who were absent from school on the day 
specimens were collected. It was stated that the sample sizes varied 
at each phase of the study. There was considerable variation in the 
size of treatment groups - it was not clear why. The numbers 
available at each assessment point and missing data were not stated. 
The number with data on Hb at both 6 and 12 months follow up was 




Unclear risk There is insufficient information to permit judgement.
Other bias High risk It was stated that groups were similar at baseline for prevalence of 
anaemia and other variables. Although the figure suggests there was 
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considerable variation in mean Hb levels at baseline - although the 
differences between groups were not significant. Children with 
anaemia all received iron. The lack on information on attrition and 
missing data mean that results are difficult to interpret
Thu 1999
Methods Double-blind, placebo-controlled trial. 2-arm design with randomisation at individual level
Participants 68 children, both sexes (88 females (54%)) 6–24 months of age, living in the Chi Lang Bac commune, Thanh Mien district, 
Hai Duong province in Vietnam. Exclusion criteria: infectious disease at the time of enrolment and a birth weight < 2.5 kg 
according to the birth record. Baseline prevalence of anaemia: ~50%. Socioeconomic status not reported
Interventions Participants were allocated to one of the following groups:
Group 1 (n = 55): children received daily 8 mg elemental iron (as ferrous sulphate), 5 mg elemental zinc(as zinc sulphate), 
333 mg retinol, and 20 mg vitamin C 5 d/wk for 3 mo;
Group 2 (n = 54): children received 20 mg elemental iron (as ferrous sulphate), 17 mg zinc, 1700 mg retinol, and 20 mg 
vitamin C once a week (Thursdays); the rest of the week were given a placebo;
Group 3 (n = 54): children received a placebo Monday to Friday that was similar in colour and appearance to the 
supplement
Length of the intervention: 12 weeks.
Outcomes Haemoglobin, serum retinol, zinc. weight and length (score z, measured 3 mo after the intervention ceased)
Notes The syrup was put into the children’s mouth by syringe by a research staff member who visited the children daily between 
0700 and 1000
Before the start of the study, the acceptability of the syrup was tested in 12 children. Mothers of these children reported 
good acceptance and no side effects. Acceptability throughout the study remained good, and the children took all of the 
supplements as intended
Z-scores used the National Center for Health Statistics data as a reference
Malaria endemicity not reported.
Risk of bias










Low risk Blind supplementation was guaranteed by coding the 3 treatment 
groups as A, B, and C and by putting the syrups to be used for each 
group in bottles having a corresponding code. Neither the main 
researcher and his assistants nor the mothers knew which 






Low risk Blind supplementation was guaranteed by coding the 3 treatment 
groups as A, B, and C and by putting the syrups to be used for each 
group in bottles having a corresponding code
Participants: children received a placebo similar in colour and 
appearance to the supplement
Personnel: Neither the main researcher and his assistants nor the 
mothers knew which supplement was represented by which code
Outcome assessors: Neither the main researcher and his assistants 






Low risk Of the 168 children enrolled at baseline, complete data sets were 
available for 163 children for anthropometric data and for 160 
children for biochemical data. Reasons for attrition included 
families’ moving to other places (n=3), mothers’ refusing further 





Unclear risk There is insufficient information to permit judgement.
Other bias Low risk The study appears to be free of other sources of bias.
Verhoef 2002
Methods Double-blind, placebo-controlled trial. 2×2 factorial design with randomisation at individual level
Participants 328 children, both sexes (148 females (45%)), aged 2–36 months. The study was done during rainy seasons in the period 
1998–2000 in Mtito Andei Division, Eastern Province, Kenya
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Children were randomly sampled. At screening, children were judged eligible for the study when they met the following 
criteria: the haemoglobin concentration was 60–110 g/L (anaemic); the axillary temperature was below 37·5C; there were 
no symptoms suggestive of malaria or anaemia, or any systemic illness occurring in combination with a blood dipstick test 
result indicating current or recent malarial infection; the parents intended to stay in the study area during the intervention 
period and gave their consent; no allergy to sulfa drugs was reported; and no sulfa drugs had been used in the previous 3 
weeks. Children with a positive malaria dipstick test result but without symptoms of systemic illness were included
Interventions Participants were randomly assigned to one of four groups
Group 1 (n = 82): children received intermittently sulphadoxine-pyrimethamine and iron supplement of 6 mg elemental 
iron (as ferrous fumarate) per kg body weight weekly (approximately 65 mg of elemental iron per week);
Group 2 (n = 82): children received intermittently sulphadoxine-pyrimethamine and iron placebo;
Group 3 (n = 82): children received intermittently sulphadoxine-pyrimethamine placebo and iron supplement of 6 mg 
elemental iron (as ferrous fumarate) per kg body weight weekly (approximately 65 mg of elemental iron per week);
Group 4 (n = 82): children received intermittently sulphadoxine-pyrimethamine placebo and iron placebo
Iron was administered twice per week as ferrous fumarate in a suspension at a target dose of
Length of the intervention: 12 weeks
For the purposes of this review, groups 1 and 3 were combined (iron) and compared with the combination of groups 2 and 
4 (no iron)
Outcomes Malaria attacks, adverse drug reactions, anaemia, iron deficiency, serum ferritin (could not be extracted) and difference in 
mean haemoglobin change from that of placebo (we calculated final haemoglobin concentrations)
Notes Sulphadoxine-pyrimethamine was administered by the clinical officer employed by the project once every 4 weeks at 
therapeutic doses. Iron was administered by community health-workers
Children in all groups were under intense health surveillance throughout the intervention period
Malaria transmission is highly seasonal in this area
Risk of bias





Low risk Balanced block randomisation (41 blocks). The allocation schedule 
was generated by one of the researchers for each block, by means of 
tables with randomised permutations, and only after acceptance of 




Low risk The order of the children listed in each block was concealed from 
the person generating the allocation schedule. Both placebos and 
active compounds were administered as suspensions that were 
indistinguishable in taste and appearance. Bottles were colour-
coded, but none of the field investigators was aware of the code until 











Low risk Of 328 children undergoing randomisation, 307 (94%) completed 
the trial and 21 (6%) did not (migrated or moved temporarily from 
the study area, 13; parents withdrew consent, three; developed 
severe anaemia, one; died, one; developed malaria but treated 





Unclear risk There is insufficient information to permit judgement.
Other bias Low risk The study appears to be free of other sources of bias.
Yang 2004 (C)
Methods Cluster-randomised trial. 3-arm trial with randomisation at classroom level
Participants 353 preschool children, both sexes 58 females (44.7%), aged 3–6 years, attending a kindergarten in Baotou City. Inclusion 
criterion: absence of major diseases, haemoglobin 90–140g/L
Interventions Classrooms were allocated to one of the following groups:
Group 1 (n = 120): children received tablets containing 30 mg elemental iron: 5 mg zinc, 300 μg vitamin A, 50 mg vitamin 
C: 7.5 μg vitamin D3, 150 μg (0.15 mg) folic acid five times every week (Monday to Friday);
Group 2 (n = 120): children received the same tablets as group 1 only once a week;
Group 3 (n = 113): children received a placebo similar in colour and appearance to the iron supplement tablets. Placebo 
was given daily
Length of the intervention: 14 weeks
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Outcomes Haemoglobin, serum ferritin, erythrocyte protoporphyrin, iron deficiency (serum ferritin <30 μg/L), height-for-age Z-
scores, weight-for-age Z-scores)
Notes Study translated from Chinese. We attempted to contact the author to validate the extraction
Teachers and nurses received iron supplement tablets from kindergarten doctors and helped children to take the tablets with 
semi-liquid food. All groups have the same food in the kindergarten except for the tablets
We adjusted the results of this study to account for the effect of clustering in data; the estimated effective sample size was 
used in the analyses.
Malaria endemicity not reported.
Risk of bias





Unclear risk Children were randomly assigned to the treatment or the control 





Low risk Every week, teachers and nurses received iron supplement tablets 
from kindergarten doctors and helped children to take the tablets. 
Since the intervention was allocated at classroom level, it is unlikely 






Low risk Participants: children received a placebo similar in colour and 
appearance to the supplement
Personnel: Every week, teachers and nurses received iron 










Unclear risk There is insufficient information to permit judgement.
Other bias Unclear risk The data was not adjusted by the effect of clustering.
Young 2001
Methods Randomised controlled trial. 2-arm with individual randomisation after stratifying children by anaemia status
Participants 577 Malawian children, both sexes (sex distribution not reported), 15 and 60 months of age, were enrolled as they attended 
the mobile child health clinic in their area. Exclusion criteria:children with severe anaemia (Hb < 70 g/L). Baseline 
prevalence of anaemia: 83%. Socioeconomic status not reported
Interventions Children were allocated to one of the following groups:
Group 1 (n = 73 at follow up): children received 60 mg of iron once a week;
Group 2 (n = 73 at follow up) children received 60 mg of elemental iron (as ferrous
sulphate) plus 7500 IU vitamin A, 45 mg vitamin C, 600 IU vitamin D3, 3 mg vitamin B1, 1.5 mg B2 and 22.5 mg vitamin 
B3 once a week;
Group 3 (n = 85 at follow up): children received 60 mg of elemental iron (as ferrous sulphate) daily
Groups 1 and 2 were combined and reported independently for the relevant subgroup analysis
Length of the intervention: 12 weeks
Outcomes Haemoglobin concentration.
Notes All children received treatment for hookworm at baseline with albendazole
Adherence to the treatment, as reported by guardians along with a monthly tablet count, was similar in each group, 
approximately 52%. Reported adverse effects ranged from 2.7% to 9.4%, with the weekly iron/vitamin group reporting the 
least adverse effects and the daily iron group the most
Malaria endemicity not reported.
Risk of bias





Unclear risk The children were stratified according to haemoglobin (Hb) levels 
(using the HemoCue) and then randomised. Method of sequence 
generation not described

















Unclear risk Supplements were administered by guardian but unclear whether 






High risk Participants: Not reported.
Personnel: Not reported.





High risk Attrition of 60% (n=346). No description of why more than half of 




Unclear risk There is insufficient information to permit judgement.
Other bias Low risk The study appears to be free of other sources of bias.
Yurdakok 2004
Methods Randomised control trial. 3 arm design with individual randomisation
Participants 79 infants, both sexes (sex distribution not reported), 4 months of age at baseline, identified for potential enrolment at 
Hacettepe University Ihsan Dogramaci Children’s Hospital Well Baby Clinic, Ankara Turkey. Inclusion criteria: 1) 
gestational age more than 37 weeks, 2) birthweight >2500g, 3) singleton birth, 4) no congential malformation, 5) no 
perinatal disease, 6) breast milk as the only source of food on admission, 7) no history of iron supplementation or therapy, 
8) no known hematologic disorder of mother-infant pairs, 9) mother intended to breasted exclusively until 6 months of age 
and to continue breastfeeding with introduction of complementary foods no earlier than 7 months of age. Infants or mothers 
with iron deficiency or iron deficiency anaemia identified at baseline were excluded from the study. Baseline prevalence of 
anaemia: unknown. Socioeconomic status not reported
Interventions Infants were randomised to one of the following groups:
Group 1 (n = 27): infants received daily 1 mg/kg/d iron (as ferrous sulphate);
Group 2 (n = 27): infants received 7 mg of iron/kg/week (as ferrous sulphate) every Tuesday. The whole dose was divided 
into three, but all iron was provided only once a week (approximately 45 mg of elemental iron per week);
Group 3 (n = 25): infants received no supplementation.
The dose was adjusted monthly according to infant’s weight.
Length of the intervention: 3 months
Outcomes Haemoglobin, mean corpuscular volume, red cell distribution width, transferrin saturation, serum ferritin and adverse 
effects; Iron Deficiency or Iron Deficiency Anaemia are reported together
Notes Mothers gave supplement at home in morning one hour before breastfeeding (this seems difficult to control/estimate, as it 
seems to assume there is no night nursing or on demand feeding)
Malaria endemicity not reported.
Risk of bias















High risk Participants: Not reported.
Personnel: Not reported.





Low risk 12 of 79 (15%) did not finish the study. 3 mothers withdrew from 
the study. Mothers that introduced complementary foods early or 
gave other milks (not breast milk) were removed from study (n=5), 
non-compliance for iron supplementation were removed from the 
study (n=2). Infants who contracted infectious disease were 
removed (n=2). Withdrawns did not significantly differ across three 
groups. No differences at baseline between those who completed the 
study and those who did not

















Unclear risk There is insufficient information to permit judgement.
Other bias Low risk The study appears to be free of other bias.
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Table 4
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agarwal 2003 Prospective study conducted in government schools in Northeast Delhi. 2088 adolescent females participated in the 
study, with 702 females receiving daily iron-folate supplementation, 695 females on weekly iron-folate 
supplementation and 691 females serving as controls. The authors concluded that though the weekly regimen took 
longer, it was as effective and practical as daily regimens in raising haemoglobin levels This study was excluded 
because the authors looked only at adolescent females, which is out of the scope of this review
Ahmed 2001 Randomised, double-blind, placebo-controlled study in a 2×2 factorial design conducted in urban Bangladesh. Female 
postmenarchal adolescent subjects were randomised to a placebo (for vitamin A and for iron/folic acid), vitamin A 
only, iron and folic acid only, and iron, folic acid and vitamin A weekly for 12 weeks. Haemoglobin concentrations 
were raised significantly more in response to iron and folic acid and iron, folic acid, and vitamin A when compared to 
vitamin A alone or to placebo
This study was excluded because the study evaluated post-menarchal females specifically, which is out of the scope of 
this review
Ahmed 2005 Randomised double-blind clinical trial conducted in Bangladesh. Anemic (haemoglobin < 120 g/L) females (n=197) 
aged 14–18 y from rural schools in Dhaka District were entered into a randomised double-blind trial and received 
twice-weekly supplements of iron and folic acid or multiple micronutrients (15 micronutrients, including iron and 
folic acid) for 12 wk. In conclusion, twice-weekly MMN supplementation for 12 wk significantly improved the status 
of the micronutrients assessed but was not more efficacious than was supplementation with iron and folic acid alone in 
improving the hematologic status of anaemic adolescent females
The study was excluded because the authors did not compare intermittent iron supplementation versus daily/placebo 
and hence the study is out of the scope of this review
Avila-Jimenez 2011 Randomised trial conducted in Mexico City, Mexico. The trial included 1,699 healthy, at term, singleton babies 
during their first year of life and excluded those with low weight at birth, unknown gestational age, bleeding disorder 
or any other medical conditions that may be associated with anaemia (i.e., malabsorption)
Children were randomly assigned to receive a daily, weekly (7 mg/dose) or monthly dose of supplements containing 
30 mg elemental iron (as either ferrous sulphate or aminochelate iron), for one year
The study was excluded because the authors compared two intermittent iron supplementation regimens and such 
comparison is out of the scope of this review
Azeredo 2010 A prospective population study performed in the city of Viçosa, Southeastern Brazil, in 2007–8. A total of 103 non-
anaemic children, aged between six and 18 months of age, were included and divided into two supplementation 
groups: daily dosage (group 1, n=34) and weekly dosage (group 2, n=69). After six months of supplementation, the 
daily dosage was found to be more effective than the weekly scheme to prevent anaemia in infants
The study was excluded because it was not randomised.
Beasley 2000 Single-blind randomised trial performed in three rural villages of the Muheza district of Tanzania. Females between 
the ages of 12–18 were randomised to a treatment 12 doses of ferrous sulphate or a control of 12 doses of vitamin B12 
over the 16 weeks following anti-helminthic treatment. The use of a strict placebo was not allowed due to ethical 
reasons. The authors found a significantly greater improvement in serum ferritin in the iron supplemented group but 
no significant differences in haemoglobin when compared to the control group
This study was excluded because the study evaluated adolescent females which is out of the scope of this review
Briars 2003 Randomised clinical trial performed in Dunedin, New Zealand. Free-living healthy adult women of childbearing age 
(n=138) were randomised to receive a 2,800 μg (2.8 mg) folic acid weekly, a daily 400 μg (0.4 mg) folic acid 
supplement, or placebo. Authors found that a weekly high-dose folic acid supplement was as effective as a daily 
supplement in lowering homocysteine concentrations
The study was excluded because vitamin and minerals were given as foodlets and they are out of the scope of this 
review
Februhartanty 2002 Single-blind experimental community study carried out in Kupang, East Nusa Tenggara, Indonesia. Post-menarchal 
adolescent females (n=150) were randomised to weekly iron supplementation, placebo, or supplementation during 4 
consecutive days of their menstrual cycle. The authors found that weekly iron supplementation for 16 weeks led to a 
greater improvement in haemoglobin concentration, compared with supplementation during four consecutive days of 
menstruation
This study was excluded because supplementation was administered to only postmenarchal adolescent females which 
is out of the scope of this review
Hafeez 1998 Randomised trial conducted at Combined Military Hospital (CMH), Lahore, Pakistan, from January 1996 to June 
1996. 130 children aged 1–6 years (average 27 months), both sexes, with iron deficiency anaemia (Hb 110 g/L) were 
divided into 2 subgroups, group A in which children received daily oral dosage of 6 mg/kg of elemental iron as 
ferrous gluconate and group B, in which children received the same dosage of iron on three consecutive days per 
week. The intervention lasted 2 months. Haemoglobin and ferritin concentrations increased in both groups with no 
differences between them
The study was excluded because the intermittent supplements were given on consecutive days
Hop 2005 Randomised, double-blind, placebo-controlled trial conducted in Vietnam. Infants aged 6–12 mo (n=138) were 
allocated to one of the following groups: daily multiple micronutrient, daily placebo, weekly multiple micronutrient, 
or daily iron supplements. All were supplemented for 6 mo, 7 d/wk, under supervision. DMM supplementation had 
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Study Reason for exclusion
the best overall performance of the micronutrient supplements tested; it reduced the rate of length-growth faltering 
and had the best hematinic effect
The study was excluded because vitamin and minerals were given as foodLETs and they are out of the scope of this 
review
Jackson 2003 The objectives of this study were to ascertain whether, short-term supplementation with iron and folic acid could 
reduce anaemia and iron deficiency, and be well tolerated by adolescent females over an 8-week period. It included 
608 postmenarchal adolescent schoolgirls with mild to moderate anaemia. The females were randomly assigned to 
three groups (iron alone, folic acid alone, and iron with folic acid) and given weekly supplements for eight weeks. 
Iron and folic acid tablets contained 60 mg elemental iron (as ferrous sulphate) and 3500 μg (3.5 mg) folic acid, 
respectively. A fourth group of females who had normal Hb concentrations and received no treatment was also 
included at baseline and after eight weeks. Authors found that the females receiving iron (alone or in combination) 
had greater mean rise in Hb than females who received folic acid alone. Eight weeks of supplements given on a 
weekly basis were well tolerated, causing few symptoms and was effective in reducing anaemia by 30–40%
The study was excluded because the control group was not randomised. Also the control group had normal Hb values 
while the females receiving the intervention were anaemic
Jaleel 2004 Prospective study that included 90 apparently healthy individuals. They were divided into 3 groups of 30 subjects 
each. First group comprised of male subjects of age between 25–45 years, second group was of postmenopausal 
women of age between 46–65 years and third group of reproductive age group that is between 15–45 years. Each 
group was further divided into 3 subgroups of 10 male subjects, 10 postmenopausal and 10 women of reproductive 
age groups. The first subgroup was given iron supplements (as ferrous sulphate 300 mg) daily. The second subgroup 
received supplementation (as ferrous sulphate 300 mg) on weekly basis that is 6 times for 36 days and third subgroup 
received iron supplements in double dose (ferrous sulphate 600 mg) on weekly basis that is 6 times for 36 days. It was 
concluded, that 600mg of iron given on a weekly gave similar results as that of subjects receiving 300 mg on a daily 
basis
This study was excluded because the populations assessed are out of the scope of this review
Jayatissa 1999 In Sri Lanka 36% of all adolescents have inadequate iron intakes. Daily and weekly iron supplementation of 659 
adolescent schoolgirls, divided into three groups, was studied in an eight-week double-blind trial. One group received 
60 mg of elemental iron, 250 μg (0.25 mg) of folic acid, and 100 mg of vitamin C daily. The second group was given 
the same doses on a weekly basis. The third group was given a placebo. All of the participants were de-wormed at the 
beginning of the study. Anaemia was more common among older adolescents. Haemoglobin levels increased 
significantly at the end of the study. The prevalence of anaemia was reduced from 25% to 9.5% by weekly 
supplementation and from 18.5% to 8.6% by daily supplementation. The difference in haemoglobin levels between 
the two groups receiving supplementation was not significant
The study was excluded because it is not clear whether is randomised or not. Based on the methods the selection of 
participants was at random but not the allocation of the intervention
Kanal 2005 This was a community trial in which social marketing and community mobilization approaches were applied to 
introduce weekly iron-folic acid supplementation to prevent anaemia in Cambodian women of reproductive age. The 
programme was implemented in three very different environments: secondary schoolgirls, women working in garment 
factories in the vicinity of Phnom Penh, and women in rural villages. All three groups of women showed substantial 
improvements in knowledge about the causes, consequences, and prevention of anaemia, and the large majority 
reported interest in continuing to take the supplements
The study was excluded because it was not randomised.
Kapur 2003 A community-based trial that compared the effect of nutrition education and/or iron supplementation (weekly) on iron 
status of 400 children, 9–36 months, living in an urban slum in Delhi
Children and care takers were selected by using a random number table. Children were assigned to one of the 
following groups. Group 1, received nutrition education. Group 2, received supplements with 20 mg elemental iron. 
Group 3, received nutrition education with supplementation with 20 mg elemental iron and Group 4, control given 
placebo
To ensure objectivity and to avoid spill over effect, specifically with respect to nutrition education, caution was 
maintained in forming groups and allocation of subjects therein. Subjects from the Anganwadis in Block A (A1, A2, 
A3 and A4) and Block B (including B1, B2, B3, B4, B5 and B6) (which were more or less adjoining) were allocated 
to experimental groups 3 (NE+ S) and 4 (NE), where nutrition education was a component. Control and Experimental 
group 2 (supplementation group), on the other hand, included subjects from Block C (including C1, C2 and C3), 
Block D (including D1, D2 and D3) and Block E (including E1, E2, E3, E4 and E5) which are situated at a distance of 
about 1 – 2 Km from the Experimental groups 3 and 4 (information provided by the author)
The intervention program was of four months duration, with a treatment phase of 8 wk followed by 8 wk of no 
treatment. There was no significant effect of any of the intervention at 8 weeks. At 16 wk, there was significant 
positive effect of nutrition education group (p less than 0.05)
This study was excluded because the allocation was not at random
Kianfar 2000 A randomised trial comparing the effects of daily and intermittent iron supplementation regimens in adolescent 
schoolgirls in the areas of Zahedan and Rasht, Iran. 1853 subjects were selected by stepwise random sampling and 
randomised to a daily group, supplemented with 50 mg elemental iron per day, a once weekly group supplemented 
with 50 mg elemental iron and a twice weekly group, also supplemented with 50 mg elemental iron. The authors 
concluded that the once and twice weekly regimens were effective in treating anaemia but that the daily schedule was 
more effective at increasing iron stores than a weekly dose in the short-term
This study was excluded because it evaluated adolescent females which is out of the scope of this review
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Study Reason for exclusion
Lechtig 2006 This paper is one of a series of papers that describes the experiences of a multiple micronutrient intervention 
programme implemented in poor urban mothers and their young children of Chiclayo, Peru. It summarizes the lessons 
learned for consideration of future programming
The study was excluded because the authors gave foodlets and that intervention is out of the scope of this review
Leenstra 2009 A double-blind, randomised controlled study using a factorial design carried out in primary schools in Kisumu, 
Western Kenya. The study aimed to evaluate the effect of weekly iron and vitamin A supplementation on 
haemoglobin, iron status, and malaria and non-malaria morbidity in adolescent schoolgirls. Weekly iron 
supplementation was found to greatly increase haemoglobin levels in menstruating and iron-deficient females but not 
in iron-replete and non menstruating females
This study was excluded because it looked only at adolescent school females between the ages of 12–18 years which 
is out of the scope of this review
Lima 2006 A controlled, community-based intervention was carried out with 378 infant to evaluate the impact of weekly 
treatment with ferrous sulphate on haemoglobin level, morbidity and nutritional status in a sample of anaemic infants 
from Zona da Mata Meridional in the state of Pernambuco, Brazil. Participating infants were divided into three 
groups: two received 45 mg of elemental iron weekly, from 12 to 18 months of life (69 children with moderate/severe 
anaemia, and 111 with mild anaemia); the third group was composed of 65 non-anaemic children, who received no 
intervention. The remaining 133 children constituted the control group. Less than half the children receiving ferrous 
sulphate recovered from anaemia at the end of follow-up while 40.3% of the children without anaemia at baseline, 
who did not receive treatment, developed anaemia
The study was excluded because it was not randomised.
Lin 2001 270 rural preschool children aged 3–7 years with low levels of vitamin A and iron living in Beijing, China. 
Participants were divided into four groups based on their determinations: control, lower serum vitamin A, lower iron, 
and both lower iron and serum vitamin A. Forty-one subjects who had lower iron and lower serum vitamin A (< 1.12 
mumol/L) were divided into two groups: one of them supplemented with 30 mg elemental iron (as ferrous sulphate 
0.15 g) once a day for 8 weeks, and the other group supplemented with iron and 12,500 IU vitamin A twice a week for 
8 weeks. Authors concluded that supplementation with vitamin A and iron was helpful to improve body iron 
nutritional status and immunological function obviously in preschool children with iron-deficiency and sub-clinical 
deficiency of vitamin A
The study was excluded because the daily and weekly groups did not receive the same nutrients
López de Romaña 
2005
Randomised, double-blind, masked, controlled trial conducted in Peru. Infants aged 6 to 12 mo (n=313) were assigned 
to receive either a daily dose of iron, a daily dose of multiple micronutrients, a weekly dose of multiple 
micronutrients, or a placebo for 6 mo. None of the supplements tested prevented growth faltering or the morbidities 
common during infancy. The daily multiple micronutrient intervention was the most efficacious for preventing 
anaemia, iron, and zinc deficiencies, 15%, 20%, and 50% of this group still remained anaemic, zinc deficient, and iron 
deficient, respectively, at the end of the study
The study was excluded because vitamin and minerals were given as foodLETs and they are out of the scope of this 
review
López de Romaña 
2006
Randomised community trial undertook in 26 Peruvian communities with stunting rates above the average. 
Households were selected if they had at least one child under 5 years of age and at least one woman or adolescent 
females of childbearing age (12 through 44 years). A total of 866 households (448 in the intervention group and 418 
in the comparison group-unclear) were selected. Women received Nutrivit capsules while children received Foodlets. 
Authors concluded that weekly supplementation with multi-micronutrients had a protective effect on the haemoglobin 
levels of both women and adolescent females of childbearing age and children under 5 years of age
The study was excluded because vitamin and minerals were given as foodlets and they are out of the scope of this 
review
Menendez 1997 Randomized clinical trial in Tanzania. Newborns (n=832) were randomly assigned to group DI, receiving daily oral 
iron (2 mg/kg daily) plus weekly Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone); group IP, receiving iron 
plus weekly placebo; group DP, receiving daily placebo plus weekly Deltaprim; or group PP. supplementation was 
given from 8 to 24 weeks of age, and the weekly chemoprophylaxis from 8 to 48 weeks. The groups that received iron 
supplementation had a lower frequency of severe anaemia
The study was excluded because only the malaria prophylaxis was given on a weekly basis
Mwanakasale 2009 Placebo-controlled intervention trial conducted in Nchelenge district in Luapula province of Zambia. Children 
between 9 and 15 years of age received once a week either 200 mg of ferrous sulphate or 100 mg of vitamin C. Both 
study groups received a single dose of praziquantel at baseline and the follow-up lasted 9 months
The study was excluded because it was not randomised.
Perrin 2002 It is a commentary paper on Shah 2002.
Risonar 2008 242 Filipino schoolchildren aged 6–12 years with haemoglobin (Hb) concentration <120g/L and enrolled for school 
year 2003–2004. UNICEF iron-folate tablets containing 60mg elemental iron and 400 μg (0.40mg) folic acid were 
given weekly through directly observed supplementation by the teachers for 27 weeks. The intervention reduced 
anaemia prevalence among anaemic schoolchildren and resulted in high compliance to and coverage of iron 
supplementation
The study was excluded because it does not have a control group
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Study Reason for exclusion
Rivera 1998 Report that presents the results of a regional program providing weekly iron supplements to school-age children 
attending 30 schools, between 1995 and 1997, in Chiriqui, Panama,
This study was excluded because the study design (pre-post without a control group) is out of the scope of this review
Schümann 2009 Randomised doubly-masked, placebo-controlled trial undertook in Cambodia. Children aged 6–24 months (n= 250) 
received twice-weekly administration of 3 RDAs of iron and folic acid, with and without a complement of 2 RDAs of 
11, and 1 RDA of 3 additional essential micronutrients as compared to a placebo control (PlbCON) given as 
foodLETs. Supplementation of micronutrients along with iron and folic acid mitigates the excess morbidity of iron-
folate alone, without reducing its efficacy in correcting anaemia and building iron stores
The study was excluded because vitamin and minerals were given as foodLETs and they are out of the scope of this 
review
Shah 2002 Randomised-controlled trial of healthy adolescent females in government female schools of Dharan, Nepal. The study 
aimed to compare the effectiveness of weekly versus daily iron folate supplementation. Females (n=209) were 
randomised to either a daily iron-folate group, a weekly iron-folate group, or a placebo group which did not receive 
any tablets. The authors concluded that once weekly iron folate supplementation was an effective alternative to daily 
regimens
The study was excluded because it evaluated only adolescent females which is not in the scope of this review
Sharma 2000 Randomised experimental trial of adolescent females in poor communities in urban areas of Delhi and rural parts of 
Rajasthan. Subjects were randomised to either daily iron folate supplementation, weekly iron folate supplementation 
or weekly iron folate with vitamin C. The authors concluded that the response of haemoglobin levels was greater 
following daily iron folate supplementation when compared to weekly iron supplementation, but that the addition of 
vitamin C led to greater increases in haemoglobin than administration of iron and folate alone
This study was excluded because it evaluated only adolescent females which is out of the scope of this review
Shobha 2003 Randomised trial of 244 adolescent females at an Andhra Pradesh residential social welfare school in the Ranga 
Reddy district of India. Females were stratified by anaemia status and then randomly assigned to either a daily or 
twice weekly supplementation regimen. Supervised administration of iron twice weekly was found to be similarly 
advantageous as daily supplementation in this population
This study was excluded because it evaluated only adolescent females which is out of the scope of this review
Smuts 2005 Randomised trial undertook in South Africa. Infants aged 6–12 mo (n=265) were individually randomised to 1 of 4 
intervention groups a daily multiple micronutrient supplement, a daily placebo supplement; a multiple micronutrient 
supplement 1 d of the week and placebo supplement on the other days of the week, and a daily iron supplement. For 6 
mo, the blinded supplements were provided to mothers at monthly health clinic sessions, and consumption was 
verified during weekly household visits by community health workers, when morbidity was also checked. The DMM 
was the most effective intervention tested, not only for improving anaemia but also for improving iron, zinc, 
riboflavin, and tocopherol status
The study was excluded because vitamin and minerals were given as foodlets and they are out of the scope of this 
review
Soekarjo 2004 A school-based grade-randomised intervention was conducted in rural and urban, East Java, Indonesia among 
adolescents. 1757 females and 1859 males were randomised to weekly supplementation (650 mg iron, 250 μg (0.25 
mg) folic acid), weekly vitamin A supplementation (10,000 IU), or both, were compared to a group not receiving any 
supplements. Weekly iron supplementation was not effective at raising haemoglobin levels, likely due to poor 
compliance and side effects
This study was excluded because it evaluated an exclusively adolescent population, which is out of the scope of this 
review
Sotelo-Cruz 2002 20 anaemic children aged 2 to 5 years living in Hermosillo, Mexico. Group A received oral ferrous sulphate twice a 
day whereas group B received the some dose per kilogram of weight like that of group A once a week for three 
months. Haemoglobin concentrations improved in both groups
The study was excluded because it is not randomised.
Tee 1999 Study that investigated whether long-term, weekly iron folate supplements administered at school would improve 
haemoglobin and ferritin concentrations in adolescent females, including those with mild-to-moderate anaemia and 
haemoglobin concentrations indicating borderline anaemia. 266 females with haemoglobin concentrations of 80–
119.9 g/L (group A) and 358 females with haemoglobin concentrations of 120–130 g/L (group B) who were otherwise 
healthy. Two hundred sixty-six females in group A and 268 females in group B were randomly assigned to receive 
either 60 or 120 mg iron plus 3500 μg (3.5 mg) folic acid weekly for 22 wk. Ninety of the females in group B were 
randomly assigned to receive only 5000 μg (5 mg) folic acid weekly. Authors concluded that long-term, weekly iron-
folate supplementation was found to be a practical, safe, effective, and inexpensive method for improving iron 
nutrition in adolescent schoolgirls
Study was excluded because children in both arms were given iron on a weekly basis. Group C did not receive 
supplements but was not followed up
Tomashek 2001 Randomised double-blind study, in which 215 anaemic children, initially treated for malaria and helminth infection, 
received 12 weeks of thrice-weekly oral iron and folic acid. Group I received placebo and chloroquine treatment for 
symptomatic malaria infection (i.e., no presumptive anti-malarial treatment given). Group II received placebo and 
monthly presumptive treatment with sulphamethoxazole-pyrimethamine (SP). Group III also received monthly SP and 
thrice-weekly vitamins A and C (VAC). Mean haemoglobin concentration increased from 66 to 102 g/L, with no 
significant differences among groups
Study was excluded because all the participants were given iron and folic acid on a weekly basis













De-Regil et al. Page 228
Study Reason for exclusion
UNICEF 2006 Report that presents the results of a National program providing weekly iron supplements (ferrous fumarate) to infants 
and pregnant women living in priority districts in the Republic of Panama
This study was excluded because the study design (pre-post without a control group) is out of the scope of this review
Vir 2008 Study performed in school and non-school females aged 11 to 18 years that aimed to assess the effectiveness of 
weekly iron-folic acid supplementation in reducing the prevalence of anaemia in adolescent females. The project 
provided weekly iron-folic acid tablets, family life education, and deworming tablets every 6 months to 150,700 
adolescent school females and non-school females of a total district population of 3,647,834. Groups were not 
evaluated simultaneously. In 4 years, the overall prevalence of anaemia was reduced from 73.3% to 25.4%. 
Hemoglobin levels and anaemia prevalence were influenced significantly at 6 months. No difference in the impact on 
haemoglobin or anaemia prevalence was observed between supervised and unsupervised females
The study was excluded because it was not randomised.
Wijaya-Erhardt 2007 A double-blind, randomised, placebo-controlled trial. Indonesian infants.
aged 6–12 mo were randomly allocated to 1 of 4 groups: daily multiple-micronutrients food like tablets (foodlets), 
weekly multiple-micronutrient foodlets, daily iron foodlets, or daily placebo Data were obtained at baseline and 23 
wk. DI and daily multiple-micronutrients foodlets are efficacious in improving and weekly multiple-micronutrient is 
efficacious in maintaining iron stores
The study was excluded because vitamin and minerals were given as foodlets and they are out of the scope of this 
review
Zavaleta 2000 A randomised, double-blind, placebo-controlled study conducted among adolescent school females in Lima, Peru. 312 
adolescents females were randomly assigned to either 60mg ferrous sulphate Mon–Friday (daily), 60 mg of ferrous 
sulphate twice weekly with placebo 3 times per week, or a placebo five days per week. Both iron supplementation 
regimens were found to be effective at reducing iron deficiency and the daily supplementation schedule was found to 
be more effective at raising haemoglobin concentration and reducing anaemia
This study was excluded because it evaluated adolescent females which is out of the scope of this review
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Table 5
Characteristics of studies awaiting assessment [ordered by study ID]
Husseini 1999
Methods Cluster-randomised trial. 2-arm design with randomisation at village level
Participants 822 children, both sexes, 5 to 26 months (average age 17.5 months). Inclusion criterion: haemoglobin <90 g/L
Interventions Villages were allocated to one of the following groups>
Group 1: children received 20 mg of iron daily;
Group 2: children received 25 mg of iron once a week;
Length of the intervention: 18 months with visits every 4 weeks
Intervention supervised and unsupervised.
Outcomes Anaemia, haemoglobin, ferritin
Notes Information obtained from Beaton 1999
Kargarnovin 2010
Methods Randomised trial. 2-arm design with individual randomisation
Participants 160 anaemic infants, both sexes, 6–24 months living in the South of Tehrna, Iran
Interventions Children were allocated to one of the following groups:
Group 1 (n=80): children were given daily containing 40 mg of elemental iron (as ferrous sulphate);
Group 1 (n=80): children were given 40 mg of elemental iron (as ferrous sulphate) once a week on Friday mornings
Length of the intervention: 6 months.
Outcomes Haemoglobin, erythrocyte volume, total iron binding capacity, transferrin saturation, serum transferrin
Notes Article written in Farsi. The author was contacted to obtain the information
Figure 2 is not available in PDF and the author has been contacted to obtain this information
The article concludes that weekly administration of iron compared with daily consumption seems superior due to similar 
effects, better compliance of mothers and lower costs for the treatment of anaemia in infants between 6 and 24 months
Reid 2001
Methods Double-blind randomised trial. 3 arm study with randomisation at individual level
Participants 125 Mexican preschoolers with low Hb, age 12–40 months of age
Interventions Participants were allocated to one of the following treatments:
Group 1: placebo
Group 2: iron (Fe),
Group 3: iron + B-12 (Fe+B-12), or
Group 4: multiple micronutrients (MM = iron, vitamin B12, vitamin B2, vitamin B6, vitamin A, vitamin E, folic acid zinc, 
cooper). Doses were 2 x RDA, 3 times/wk, under supervision
Length of the intervention: 3 months
Outcomes Anaemia, haematocrit, ferritin, retinol, serum B12
Notes This study has not been published. If the data is made available to us, we will include it in future updates of the review
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Table 6
Characteristics of ongoing studies [ordered by study ID]
Zeeba Zaka-ur-Rab 2010
Trial name or title A clinical trial to compare the effects of daily versus intermittent iron supplementation on markers of oxidative stress 
and anti-oxidant status in children with iron deficiency anaemia
Methods Randomised, controlled trial.
Method of generating randomisation sequence: random number table
Method of allocation concealment: sequentially numbered, sealed, opaque envelopes
Blinding and masking:Outcome Assessor Blinded
Participants 150 children between 1–15 years of age with iron deficiency anaemia. Exclusion criteria: children with history of fever 
within last 4 weeks, acute or chronic medical disorders, hemolytic anaemia, haemoglobin <6gm%, patients receiving 
iron/vitamin/mineral supplements (including herbal drugs), blood transfusion within 8 weeks
Interventions Intervention: sodium feredetate: 6 mg/kg daily;
Control: sodium feredetate: 6 mg/kg on day 1 and day 4.
Length of the intervention: 8 weeks.
Outcomes Changes in malonyl dialdehyde, oxidized glutathione, superoxide dismutase, glutathione peroxidase, catalase, changes 
in hemo globin, serum ferritin, total iron binding capacity and serum iron
Timepoint: 8 weeks
Starting date Date of first enrolment: 02-03-2009
Contact information Dr. Zeeba Zaka-ur-Rab
Deptt. of Pediatrics, J.N. Med. College, A.M.U.
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